{ "disease": "breast-cancer", "label": "Breast cancer", "url": "https://usebiotransfer.org/disease/breast-cancer/", "built": "2026-09-12", "facts_hash": { "answers": "d065565a3335", "targets": "ffdf0003c6c4" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-11", "trials": "2026-09-11" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "ESR1", "ensembl": "ENSG00000091831", "n_drug_entries": 51, "n_distinct_drugs": 43, "drugs": { "ACOLBIFENE": "PHASE_3", "AFIMOXIFENE": "PHASE_2", "AMCENESTRANT": "PHASE_3", "ARZOXIFENE": "APPROVAL", "BAZEDOXIFENE": "APPROVAL", "BRILANESTRANT": "PHASE_2", "CAMIZESTRANT": "PREAPPROVAL", "CHF4227": "PHASE_1", "CLOMIPHENE": "APPROVAL", "CYCLOFENIL": "APPROVAL", "DIENESTROL": "APPROVAL", "DIETHYLSTILBESTROL": "APPROVAL", "DIETHYLSTILBESTROL DIPHOSPHATE": "APPROVAL", "DROLOXIFENE": "PHASE_2", "ELACESTRANT": "APPROVAL", "ENCLOMIPHENE": "PHASE_2", "ESTETROL": "APPROVAL", "ESTRADIOL": "APPROVAL", "ESTRADIOL CYPIONATE": "APPROVAL", "ESTRADIOL VALERATE": "APPROVAL", "ESTRIOL": "APPROVAL", "ESTROGENS, CONJUGATED": "APPROVAL", "ESTROGENS, CONJUGATED SYNTHETIC A": "APPROVAL", "ESTROGENS, ESTERIFIED": "APPROVAL", "ESTRONE": "APPROVAL", "ESTROPIPATE": "APPROVAL", "ETHINYL ESTRADIOL": "APPROVAL", "FISPEMIFENE": "PHASE_2", "FULVESTRANT": "APPROVAL", "GIREDESTRANT": "PHASE_3", "GTX-758": "PHASE_2", "IDOXIFENE": "PHASE_3", "LASOFOXIFENE": "APPROVAL", "MESTRANOL": "APPROVAL", "MK-6913": "PHASE_2", "OSPEMIFENE": "APPROVAL", "POLYESTRADIOL": "APPROVAL", "QUINESTROL": "APPROVAL", "RALOXIFENE": "APPROVAL", "SYNTHETIC CONJUGATED ESTROGENS, B": "APPROVAL", "TAMOXIFEN": "APPROVAL", "TAS-108": "PHASE_2", "TOREMIFENE": "APPROVAL" }, "approved": [ "ARZOXIFENE", "BAZEDOXIFENE", "CLOMIPHENE", "CYCLOFENIL", "DIENESTROL", "DIETHYLSTILBESTROL", "DIETHYLSTILBESTROL DIPHOSPHATE", "ELACESTRANT", "ESTETROL", "ESTRADIOL", "ESTRADIOL CYPIONATE", "ESTRADIOL VALERATE", "ESTRIOL", "ESTROGENS, CONJUGATED", "ESTROGENS, CONJUGATED SYNTHETIC A", "ESTROGENS, ESTERIFIED", "ESTRONE", "ESTROPIPATE", "ETHINYL ESTRADIOL", "FULVESTRANT", "LASOFOXIFENE", "MESTRANOL", "OSPEMIFENE", "POLYESTRADIOL", "QUINESTROL", "RALOXIFENE", "SYNTHETIC CONJUGATED ESTROGENS, B", "TAMOXIFEN", "TOREMIFENE" ], "n_approved": 29, "approved_for": { "ARZOXIFENE": [ "breast cancer" ], "BAZEDOXIFENE": [ "osteopetrosis", "postmenopausal osteoporosis", "osteoporosis" ], "CLOMIPHENE": [ "female infertility", "infertility disorder", "hemorrhage", "polycystic ovary syndrome" ], "CYCLOFENIL": [ "Infertility" ], "DIENESTROL": [ "Atrophic Vaginitis" ], "DIETHYLSTILBESTROL": [], "DIETHYLSTILBESTROL DIPHOSPHATE": [], "ELACESTRANT": [ "breast cancer", "breast neoplasm", "male breast carcinoma" ], "ESTETROL": [ "menopause", "pregnancy" ], "ESTRADIOL": [ "menopause", "Atrophy", "hypogonadism", "Premature ovarian insufficiency", "osteoporosis", "Dyspareunia", "breast cancer", "primary ovarian failure", "postmenopausal atrophic vaginitis", "postmenopausal osteoporosis", "contraception", "leiomyoma" ], "ESTRADIOL CYPIONATE": [], "ESTRADIOL VALERATE": [ "Menorrhagia", "hypogonadism", "Premature ovarian insufficiency", "menopause", "Atrophy", "primary ovarian failure" ], "ESTRIOL": [], "ESTROGENS, CONJUGATED": [ "menopause", "Atrophy", "hypogonadism", "breast cancer", "primary ovarian failure", "osteoporosis", "Dyspareunia", "postmenopausal atrophic vaginitis", "postmenopausal osteoporosis" ], "ESTROGENS, CONJUGATED SYNTHETIC A": [ "menopause", "Atrophy", "osteoporosis" ], "ESTROGENS, ESTERIFIED": [ "breast cancer", "menopause", "Atrophy", "hypogonadism", "primary ovarian failure" ], "ESTRONE": [], "ESTROPIPATE": [ "Atrophy", "hypogonadism", "menopause", "primary ovarian failure", "osteoporosis" ], "ETHINYL ESTRADIOL": [ "acne", "endometriosis", "Dysmenorrhea", "contraception" ], "FULVESTRANT": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "LASOFOXIFENE": [ "postmenopausal osteoporosis", "osteoporosis" ], "MESTRANOL": [ "contraception" ], "OSPEMIFENE": [ "menopause", "Dyspareunia", "Atrophy", "postmenopausal atrophic vaginitis", "Atrophic Vaginitis" ], "POLYESTRADIOL": [ "prostate cancer" ], "QUINESTROL": [ "breast cancer" ], "RALOXIFENE": [ "osteoporosis", "postmenopausal osteoporosis" ], "SYNTHETIC CONJUGATED ESTROGENS, B": [ "Atrophy", "menopause" ], "TAMOXIFEN": [ "breast cancer" ], "TOREMIFENE": [ "breast cancer", "breast carcinoma", "breast neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "PR", "bucket": "Advanced Clinical" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "PGR", "ensembl": "ENSG00000082175", "n_drug_entries": 31, "n_distinct_drugs": 28, "drugs": { "ASOPRISNIL": "PHASE_3", "CHLORMADINONE": "UNKNOWN", "CYPROTERONE": "PHASE_3", "DANAZOL": "APPROVAL", "DESOGESTREL": "APPROVAL", "DROSPIRENONE": "APPROVAL", "DYDROGESTERONE": "APPROVAL", "ETHYNODIOL DIACETATE": "APPROVAL", "ETONOGESTREL": "APPROVAL", "GESTODENE": "PHASE_3", "HYDROXYPROGESTERONE CAPROATE": "APPROVAL", "LEVONORGESTREL": "APPROVAL", "LONAPRISAN": "PHASE_2", "MEDROXYPROGESTERONE": "APPROVAL", "MEGESTROL": "APPROVAL", "MIFEPRISTONE": "APPROVAL", "NOMEGESTROL": "APPROVAL", "NORELGESTROMIN": "APPROVAL", "NORETHINDRONE": "APPROVAL", "NORGESTIMATE": "APPROVAL", "NORGESTREL": "APPROVAL", "ONAPRISTONE": "PHASE_2", "PROGESTERONE": "APPROVAL", "SEGESTERONE": "APPROVAL", "TELAPRISTONE": "PHASE_3", "TRIMEGESTONE": "APPROVAL", "ULIPRISTAL": "APPROVAL", "VILAPRISAN": "PHASE_3" }, "approved": [ "DANAZOL", "DESOGESTREL", "DROSPIRENONE", "DYDROGESTERONE", "ETHYNODIOL DIACETATE", "ETONOGESTREL", "HYDROXYPROGESTERONE CAPROATE", "LEVONORGESTREL", "MEDROXYPROGESTERONE", "MEGESTROL", "MIFEPRISTONE", "NOMEGESTROL", "NORELGESTROMIN", "NORETHINDRONE", "NORGESTIMATE", "NORGESTREL", "PROGESTERONE", "SEGESTERONE", "TRIMEGESTONE", "ULIPRISTAL" ], "n_approved": 20, "approved_for": { "DANAZOL": [ "breast fibrocystic disease", "endometriosis", "Menorrhagia" ], "DESOGESTREL": [ "contraception" ], "DROSPIRENONE": [ "acne", "Pain", "Dysmenorrhea", "endometriosis", "contraception" ], "DYDROGESTERONE": [ "Menstrual disorder" ], "ETHYNODIOL DIACETATE": [ "contraception" ], "ETONOGESTREL": [ "contraception" ], "HYDROXYPROGESTERONE CAPROATE": [ "premature birth" ], "LEVONORGESTREL": [ "Menorrhagia", "osteoporosis", "contraception", "Dysmenorrhea", "hemorrhage" ], "MEDROXYPROGESTERONE": [ "renal carcinoma", "endometriosis", "hemorrhage", "hyperplasia" ], "MEGESTROL": [ "inborn error of immunity", "Anorexia", "Cachexia", "AIDS", "breast cancer" ], "MIFEPRISTONE": [ "Cushing syndrome" ], "NOMEGESTROL": [ "breast cancer", "contraception" ], "NORELGESTROMIN": [ "contraception" ], "NORETHINDRONE": [ "endometriosis", "Dysmenorrhea", "acne", "hypogonadism", "leiomyoma" ], "NORGESTIMATE": [ "acne", "contraception" ], "NORGESTREL": [ "Menorrhagia", "hemorrhage" ], "PROGESTERONE": [ "amenorrhea", "atypical endometrial hyperplasia", "hemorrhage", "Infertility" ], "SEGESTERONE": [ "contraception" ], "TRIMEGESTONE": [], "ULIPRISTAL": [ "contraception", "Uterine leiomyoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "ERBB2", "ensembl": "ENSG00000141736", "n_drug_entries": 48, "n_distinct_drugs": 45, "drugs": { "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "ANVATABART OPADOTIN": "PHASE_2_3", "AV-412": "PHASE_1", "BMS-690514": "PHASE_2", "CANERTINIB": "PHASE_2", "CP-724714": "PHASE_2", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DISITAMAB VEDOTIN": "PHASE_3", "ERTUMAXOMAB": "PHASE_2", "GANCOTAMAB": "PHASE_2_3", "HEMAY-022": "PHASE_3", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "KN-026": "PHASE_3", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "MARGETUXIMAB": "APPROVAL", "MASOPROCOL": "APPROVAL", "MM-111": "PHASE_2", "MUBRITINIB": "PHASE_1", "NERATINIB": "APPROVAL", "PERTUZUMAB": "APPROVAL", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "TRASTUZUMAB": "APPROVAL", "TRASTUZUMAB BOTIDOTIN": "PHASE_3", "TRASTUZUMAB DERUXTECAN": "APPROVAL", "TRASTUZUMAB DUOCARMAZINE": "APPROVAL", "TRASTUZUMAB EMTANSINE": "APPROVAL", "TUCATINIB": "APPROVAL", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZANIDATAMAB": "APPROVAL", "ZENOCUTUZUMAB": "APPROVAL" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "DACOMITINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "MARGETUXIMAB", "MASOPROCOL", "NERATINIB", "PERTUZUMAB", "TRASTUZUMAB", "TRASTUZUMAB DERUXTECAN", "TRASTUZUMAB DUOCARMAZINE", "TRASTUZUMAB EMTANSINE", "TUCATINIB", "VANDETANIB", "ZANIDATAMAB", "ZENOCUTUZUMAB" ], "n_approved": 17, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "MARGETUXIMAB": [ "HER2 positive breast carcinoma", "breast cancer" ], "MASOPROCOL": [ "prostate cancer" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "PERTUZUMAB": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB": [ "breast cancer", "breast carcinoma", "gastric cancer", "gastric neoplasm", "breast neoplasm" ], "TRASTUZUMAB DERUXTECAN": [ "breast cancer", "HER2 positive breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB DUOCARMAZINE": [], "TRASTUZUMAB EMTANSINE": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TUCATINIB": [ "HER2 positive breast carcinoma", "metastasis", "breast neoplasm", "breast cancer", "colorectal carcinoma", "breast carcinoma" ], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ], "ZANIDATAMAB": [ "biliary tract neoplasm" ], "ZENOCUTUZUMAB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "PIK3CA", "ensembl": "ENSG00000121879", "n_drug_entries": 32, "n_distinct_drugs": 31, "drugs": { "ALPELISIB": "APPROVAL", "APITOLISIB": "PHASE_2", "AZD-6482": "UNKNOWN", "BAY-1082439": "PHASE_1", "BGT-226": "PHASE_1_2", "BUPARLISIB": "PHASE_3", "COPANLISIB": "APPROVAL", "DACTOLISIB": "PHASE_3", "DS-7423": "PHASE_1", "FIMEPINOSTAT": "PHASE_2", "GEDATOLISIB": "PHASE_3", "GSK-1059615": "PHASE_1", "INAVOLISIB": "APPROVAL", "IZORLISIB": "PHASE_1_2", "OMIPALISIB": "PHASE_1", "PANULISIB": "PHASE_1", "PAXALISIB": "PHASE_2_3", "PF-04691502": "PHASE_2", "PICTILISIB": "PHASE_2", "PILARALISIB": "PHASE_2", "PKI-179": "PHASE_1", "RECILISIB": "PHASE_1", "SAMOTOLISIB": "PHASE_2", "SERABELISIB": "PHASE_2", "SF-1126": "PHASE_2", "SONOLISIB": "PHASE_2", "TASELISIB": "PHASE_3", "VOXTALISIB": "PHASE_2", "VS-5584": "PHASE_1", "WX-037": "PHASE_1", "ZSTK-474": "PHASE_1" }, "approved": [ "ALPELISIB", "COPANLISIB", "INAVOLISIB" ], "n_approved": 3, "approved_for": { "ALPELISIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "COPANLISIB": [ "follicular lymphoma", "non-Hodgkin lymphoma", "neoplasm of mature B-cells" ], "INAVOLISIB": [ "breast neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "AKT1", "ensembl": "ENSG00000142208", "n_drug_entries": 15, "n_distinct_drugs": 15, "drugs": { "AFURESERTIB": "PHASE_3", "BAY-1125976": "PHASE_1", "CAPIVASERTIB": "APPROVAL", "GSK-690693": "PHASE_1", "IPATASERTIB": "PHASE_3", "LY-2780301": "PHASE_1_2", "MIRANSERTIB": "PHASE_2", "MK-2206": "PHASE_2", "PIFUSERTIB": "PHASE_2", "RUPITASERTIB": "PHASE_1", "SR-13668": "PHASE_1", "TAS0612": "PHASE_1", "TRICIRIBINE": "PHASE_1_2", "UPROSERTIB": "PHASE_2", "XL-418": "PHASE_1" }, "approved": [ "CAPIVASERTIB" ], "n_approved": 1, "approved_for": { "CAPIVASERTIB": [ "breast cancer", "breast neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "PTEN", "ensembl": "ENSG00000171862", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "CDK4", "ensembl": "ENSG00000135446", "n_drug_entries": 17, "n_distinct_drugs": 15, "drugs": { "ABEMACICLIB": "APPROVAL", "AG-24322": "PHASE_1", "ALVOCIDIB": "PHASE_3", "AT-7519": "PHASE_2", "AZD-5438": "PHASE_1", "MILCICLIB": "PHASE_2", "PALBOCICLIB": "APPROVAL", "PHA-793887": "PHASE_1", "RG-547": "PHASE_1", "RGB-286638": "PHASE_1", "RIBOCICLIB": "APPROVAL", "RONICICLIB": "PHASE_2", "TRILACICLIB": "APPROVAL", "UCN-01": "PHASE_2", "VORUCICLIB": "PHASE_1" }, "approved": [ "ABEMACICLIB", "PALBOCICLIB", "RIBOCICLIB", "TRILACICLIB" ], "n_approved": 4, "approved_for": { "ABEMACICLIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "PALBOCICLIB": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "RIBOCICLIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "TRILACICLIB": [ "small cell lung carcinoma", "myelosuppression" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "CDK6", "ensembl": "ENSG00000105810", "n_drug_entries": 12, "n_distinct_drugs": 10, "drugs": { "ABEMACICLIB": "APPROVAL", "ALVOCIDIB": "PHASE_3", "AT-7519": "PHASE_2", "AZD-5438": "PHASE_1", "PALBOCICLIB": "APPROVAL", "PHA-793887": "PHASE_1", "RIBOCICLIB": "APPROVAL", "RONICICLIB": "PHASE_2", "TRILACICLIB": "APPROVAL", "UCN-01": "PHASE_2" }, "approved": [ "ABEMACICLIB", "PALBOCICLIB", "RIBOCICLIB", "TRILACICLIB" ], "n_approved": 4, "approved_for": { "ABEMACICLIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "PALBOCICLIB": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "RIBOCICLIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "TRILACICLIB": [ "small cell lung carcinoma", "myelosuppression" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "BRCA1", "ensembl": "ENSG00000012048", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "BRCA2", "ensembl": "ENSG00000139618", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "TACSTD2", "ensembl": "ENSG00000184292", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "DATOPOTAMAB DERUXTECAN": "APPROVAL", "SACITUZUMAB GOVITECAN": "APPROVAL" }, "approved": [ "DATOPOTAMAB DERUXTECAN", "SACITUZUMAB GOVITECAN" ], "n_approved": 2, "approved_for": { "DATOPOTAMAB DERUXTECAN": [ "breast cancer", "breast neoplasm", "non-small cell lung carcinoma" ], "SACITUZUMAB GOVITECAN": [ "breast cancer", "urothelial carcinoma", "triple-negative breast carcinoma", "breast neoplasm" ] }, "tractability": [ { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "OC", "bucket": "Approved Drug" } ] } ], "trials": { "by_antigen": { "HER2": { "n": 589, "n_observational": 100, "n_active": 285, "n_withdrawn": 25, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03723928", "title": "S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04254263", "title": "Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04281641", "title": "Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2020-05-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04329065", "title": "Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04547907", "title": "A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2024-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04553770", "title": "Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04680442", "title": "Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction", "status": "RECRUITING", "last_update": "2025-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04750122", "title": "Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients", "status": "RECRUITING", "last_update": "2021-04-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802759", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04893109", "title": "ATEMPT 2.0: Adjuvant T-DM1 vs TH", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04986579", "title": "Scalp Cooling in MBC", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04993014", "title": "Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2021-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020860", "title": "Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer", "status": "RECRUITING", "last_update": "2025-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05159193", "title": "Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2024-02-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05232916", "title": "Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05256745", "title": "RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05288777", "title": "Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05292742", "title": "Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2022-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05304962", "title": "FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05325632", "title": "Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab", "status": "RECRUITING", "last_update": "2026-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05345860", "title": "Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer", "status": "RECRUITING", "last_update": "2022-04-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05376878", "title": "An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05388149", "title": "Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease", "status": "RECRUITING", "last_update": "2025-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05417594", "title": "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05420467", "title": "A Study for the Adjuvant Treatment of Breast Cancer", "status": "RECRUITING", "last_update": "2022-07-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05559164", "title": "Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted", "status": "RECRUITING", "last_update": "2025-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582499", "title": "Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05704829", "title": "NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05760612", "title": "Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab", "status": "RECRUITING", "last_update": "2025-09-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05766410", "title": "A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC", "status": "RECRUITING", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05795101", "title": "TRUDI: TDXD+Durva in HER2+/Low IBC", "status": "RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05816655", "title": "Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05824975", "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)", "status": "RECRUITING", "last_update": "2024-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05834764", "title": "Pyrotinib in Women With High-risk in Early Stage Breast Cancer", "status": "RECRUITING", "last_update": "2023-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05838066", "title": "Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.", "status": "RECRUITING", "last_update": "2025-05-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05868226", "title": "PRE-ISPY Phase I/II Oncology Platform Program", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05891561", "title": "Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2024-11-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05900206", "title": "Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05950945", "title": "Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05982678", "title": "Basket Study for Oligo-metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05989347", "title": "Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06035679", "title": "Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06102824", "title": "Organoid-based Functional Precision Therapy for Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06106477", "title": "Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06162559", "title": "Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study", "status": "RECRUITING", "last_update": "2024-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06217185", "title": "The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).", "status": "RECRUITING", "last_update": "2024-02-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06278870", "title": "Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial", "status": "RECRUITING", "last_update": "2024-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06299202", "title": "Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy", "status": "RECRUITING", "last_update": "2024-09-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313086", "title": "DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-05-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06331169", "title": "Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-08-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06348134", "title": "Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery", "status": "RECRUITING", "last_update": "2026-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06409390", "title": "Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06414733", "title": "HER-2 B Cell Peptide Vaccine", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06418594", "title": "Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis", "status": "RECRUITING", "last_update": "2024-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06435429", "title": "A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06439693", "title": "The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06441890", "title": "BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06446882", "title": "Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06450314", "title": "Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06486883", "title": "Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06500208", "title": "Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC", "status": "RECRUITING", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06517212", "title": "Tirzepatide Weight Loss for MRD+ Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06533826", "title": "TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06643585", "title": "A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse", "status": "RECRUITING", "last_update": "2025-05-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06665178", "title": "Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06686394", "title": "Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06750484", "title": "Trial of Trastuzumab Deruxtecan in Previously Treated HER2", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06830889", "title": "A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06832202", "title": "A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients", "status": "RECRUITING", "last_update": "2025-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06837792", "title": "Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06846437", "title": "JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06927180", "title": "SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC", "status": "RECRUITING", "last_update": "2025-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06949410", "title": "HER2 Vaccine for Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06992882", "title": "A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)", "status": "RECRUITING", "last_update": "2025-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07003074", "title": "A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07007559", "title": "ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07008976", "title": "Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07014410", "title": "Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07043725", "title": "A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07053085", "title": "A Study of Surgery and Radiotherapy in People With Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07057427", "title": "Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07060807", "title": "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07065435", "title": "RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study", "status": "RECRUITING", "last_update": "2025-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07095023", "title": "Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07134153", "title": "Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases", "status": "RECRUITING", "last_update": "2025-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07136428", "title": "Asciminib in HER2+ Breast Cancer Brain Metastases", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07137416", "title": "Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07182721", "title": "SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07195344", "title": "Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07198724", "title": "ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07203378", "title": "Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07216105", "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07220135", "title": "Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07257809", "title": "Herombopag Treated T-DM1 Induced Platelet Reduction", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07263425", "title": "Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis", "status": "RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07281001", "title": "A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07294508", "title": "A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07299825", "title": "A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07335081", "title": "ctDNA in HER2+ EBC Neoadjuvant Treatment", "status": "RECRUITING", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340398", "title": "Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07371585", "title": "Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07383818", "title": "Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)", "status": "RECRUITING", "last_update": "2026-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07393425", "title": "Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07394218", "title": "ctDNA-guided Treatment Decision-making", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07418125", "title": "Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07441460", "title": "A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07446452", "title": "Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07459673", "title": "HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07497386", "title": "A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07498478", "title": "Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07520760", "title": "A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07537673", "title": "Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan", "status": "RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07543536", "title": "Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07593976", "title": "Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07600164", "title": "Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07612215", "title": "Elacestrant in Advanced Triple Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07616427", "title": "Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07630402", "title": "Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07647016", "title": "Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07657130", "title": "Optimal Application Timing of ADC Drugs for Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07673029", "title": "A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07694986", "title": "Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07695259", "title": "Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07716189", "title": "Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005970", "title": "Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2020-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00038402", "title": "Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer", "status": "COMPLETED", "last_update": "2012-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00068757", "title": "Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer", "status": "COMPLETED", "last_update": "2012-09-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00070564", "title": "S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00103233", "title": "Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00129896", "title": "Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients", "status": "COMPLETED", "last_update": "2023-03-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00134680", "title": "Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC", "status": "COMPLETED", "last_update": "2014-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00146042", "title": "UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2012-10-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00194714", "title": "Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab", "status": "COMPLETED", "last_update": "2024-06-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00206492", "title": "Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients", "status": "TERMINATED", "last_update": "2017-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00243503", "title": "Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2011-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00258349", "title": "Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer", "status": "COMPLETED", "last_update": "2014-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00301730", "title": "Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung", "status": "COMPLETED", "last_update": "2015-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00301899", "title": "Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab", "status": "COMPLETED", "last_update": "2012-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00381901", "title": "Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery", "status": "COMPLETED", "last_update": "2011-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00404066", "title": "Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer", "status": "COMPLETED", "last_update": "2017-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00433407", "title": "T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2012-10-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00434031", "title": "CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2012-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00436254", "title": "Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer", "status": "COMPLETED", "last_update": "2025-04-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00440622", "title": "Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients", "status": "TERMINATED", "last_update": "2013-02-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00470704", "title": "Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00493870", "title": "TAC Versus TC for Adjuvant Breast Cancer", "status": "COMPLETED", "last_update": "2023-03-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509769", "title": "A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00513058", "title": "Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00542191", "title": "Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer", "status": "TERMINATED", "last_update": "2021-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00545688", "title": "A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.", "status": "COMPLETED", "last_update": "2017-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00567554", "title": "Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer", "status": "COMPLETED", "last_update": "2016-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00580112", "title": "An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00605397", "title": "PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00625898", "title": "BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab", "status": "TERMINATED", "last_update": "2020-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00629616", "title": "Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer", "status": "COMPLETED", "last_update": "2021-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00630032", "title": "Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer", "status": "COMPLETED", "last_update": "2024-02-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00679211", "title": "A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00679341", "title": "A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin\u00ae) and Docetaxel (Taxotere\u00ae) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease", "status": "COMPLETED", "last_update": "2014-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00687648", "title": "Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2009-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00741260", "title": "Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00768859", "title": "Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study", "status": "COMPLETED", "last_update": "2012-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00770809", "title": "Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00796978", "title": "Trastuzumab in Treating Older Women With Early-Stage Breast Cancer", "status": "COMPLETED", "last_update": "2024-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00803556", "title": "Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy", "status": "COMPLETED", "last_update": "2011-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820222", "title": "Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2019-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00829166", "title": "A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00841828", "title": "Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients", "status": "COMPLETED", "last_update": "2023-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00842998", "title": "Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer", "status": "UNKNOWN", "last_update": "2009-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00875979", "title": "A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab", "status": "COMPLETED", "last_update": "2013-12-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00892567", "title": "Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2016-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00928330", "title": "Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00932373", "title": "A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen", "status": "COMPLETED", "last_update": "2015-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00934856", "title": "A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2017-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00943670", "title": "Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression", "status": "COMPLETED", "last_update": "2013-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00944047", "title": "Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression", "status": "COMPLETED", "last_update": "2018-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00949247", "title": "Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases", "status": "COMPLETED", "last_update": "2020-07-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00951665", "title": "A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00963547", "title": "A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)", "status": "TERMINATED", "last_update": "2024-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00971737", "title": "Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2019-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00976989", "title": "A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01026142", "title": "A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)", "status": "COMPLETED", "last_update": "2018-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01038804", "title": "A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01048099", "title": "Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-01-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01049425", "title": "Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer", "status": "COMPLETED", "last_update": "2019-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01120184", "title": "A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)", "status": "COMPLETED", "last_update": "2024-03-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01137994", "title": "A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01142778", "title": "A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2018-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01196052", "title": "A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2014-10-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01205217", "title": "Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer", "status": "WITHDRAWN", "last_update": "2017-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01242449", "title": "Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01271920", "title": "Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01272037", "title": "Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01276041", "title": "Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01288092", "title": "BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2012-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01321775", "title": "Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer", "status": "UNKNOWN", "last_update": "2011-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01340430", "title": "Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2024-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01373710", "title": "Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis", "status": "COMPLETED", "last_update": "2025-11-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01376505", "title": "Vaccine Therapy in Treating Patients With Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01387373", "title": "Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer", "status": "COMPLETED", "last_update": "2020-10-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01401166", "title": "Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer", "status": "COMPLETED", "last_update": "2017-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01419197", "title": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy", "status": "COMPLETED", "last_update": "2016-10-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01436604", "title": "Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin \u00ae) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging", "status": "TERMINATED", "last_update": "2017-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01479179", "title": "Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab", "status": "WITHDRAWN", "last_update": "2016-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01494662", "title": "HKI-272 for HER2-Positive Breast Cancer and Brain Metastases", "status": "COMPLETED", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01495884", "title": "The Myocet/Lapatinib Study. ICORG 10-03, V5", "status": "TERMINATED", "last_update": "2015-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01501487", "title": "MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I", "status": "COMPLETED", "last_update": "2018-06-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01513083", "title": "A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01528345", "title": "Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer", "status": "TERMINATED", "last_update": "2016-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01557764", "title": "Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-07-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01564368", "title": "DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy", "status": "COMPLETED", "last_update": "2024-04-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01565083", "title": "A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2016-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01565200", "title": "HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1", "status": "COMPLETED", "last_update": "2025-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01583426", "title": "Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)", "status": "COMPLETED", "last_update": "2020-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01596530", "title": "Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment", "status": "TERMINATED", "last_update": "2012-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597414", "title": "Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1", "status": "COMPLETED", "last_update": "2022-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01622868", "title": "Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01632332", "title": "Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2018-10-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01669239", "title": "Study of Neoadjuvant Myocet\u00ae, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01688609", "title": "Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2017-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01702558", "title": "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)", "status": "TERMINATED", "last_update": "2021-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01702571", "title": "A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01730677", "title": "Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab", "status": "UNKNOWN", "last_update": "2014-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01745965", "title": "A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.", "status": "COMPLETED", "last_update": "2025-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772472", "title": "A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)", "status": "COMPLETED", "last_update": "2025-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01816035", "title": "Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2017-05-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01827163", "title": "Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2019-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01828021", "title": "Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01835236", "title": "Trastuzumab & Pertuzumab Followed by T-DM1 in MBC", "status": "COMPLETED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01853748", "title": "T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)", "status": "COMPLETED", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01875666", "title": "Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib", "status": "COMPLETED", "last_update": "2020-09-04", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01904903", "title": "Cardiac Safety Study in Patients With HER2 + Breast Cancer", "status": "COMPLETED", "last_update": "2022-05-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01921335", "title": "ARRY-380 + Trastuzuamab for Breast w/ Brain Mets", "status": "COMPLETED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01937117", "title": "Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01950182", "title": "Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01959490", "title": "Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer", "status": "COMPLETED", "last_update": "2019-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01966471", "title": "A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer", "status": "COMPLETED", "last_update": "2022-06-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01975142", "title": "Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.", "status": "COMPLETED", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01976169", "title": "Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01983501", "title": "A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2020-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01985841", "title": "Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer", "status": "TERMINATED", "last_update": "2015-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01996410", "title": "The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients", "status": "TERMINATED", "last_update": "2016-11-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02000596", "title": "1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.", "status": "TERMINATED", "last_update": "2022-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02019277", "title": "A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02038010", "title": "BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx", "status": "COMPLETED", "last_update": "2020-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02059876", "title": "Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer", "status": "UNKNOWN", "last_update": "2014-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02061085", "title": "Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02073487", "title": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel", "status": "COMPLETED", "last_update": "2021-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02073916", "title": "T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2019-04-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02089854", "title": "Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer", "status": "UNKNOWN", "last_update": "2016-12-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02095210", "title": "HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025", "status": "TERMINATED", "last_update": "2020-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02102438", "title": "Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2016-08-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02126449", "title": "DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2019-10-24", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02131064", "title": "A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2019-07-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02132949", "title": "A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer", "status": "COMPLETED", "last_update": "2021-09-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02135159", "title": "Patients With Brain Metastases From HER2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02139358", "title": "Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2021-02-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02144012", "title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer", "status": "TERMINATED", "last_update": "2017-03-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213744", "title": "MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients", "status": "TERMINATED", "last_update": "2017-01-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02226276", "title": "Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02236000", "title": "A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-01-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02238509", "title": "Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies", "status": "UNKNOWN", "last_update": "2016-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02297230", "title": "Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics", "status": "TERMINATED", "last_update": "2018-10-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02297698", "title": "Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients", "status": "COMPLETED", "last_update": "2023-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02326974", "title": "T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02336984", "title": "A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS", "status": "WITHDRAWN", "last_update": "2021-01-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02344472", "title": "Detect V / CHEVENDO (Chemo vs. Endo)", "status": "UNKNOWN", "last_update": "2024-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02365805", "title": "Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2017-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02390427", "title": "Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02402712", "title": "Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2019-09-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02422199", "title": "A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab", "status": "UNKNOWN", "last_update": "2018-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02433067", "title": "Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer", "status": "TERMINATED", "last_update": "2020-10-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02445586", "title": "Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer", "status": "COMPLETED", "last_update": "2019-10-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02448420", "title": "Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530424", "title": "\"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment \"", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02562378", "title": "T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2022-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02563925", "title": "Brain Irradiation and Tremelimumab in Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2022-08-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02568839", "title": "Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2020-08-13", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02586025", "title": "Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel", "status": "COMPLETED", "last_update": "2023-05-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02586675", "title": "TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer", "status": "COMPLETED", "last_update": "2022-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02598427", "title": "Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer", "status": "TERMINATED", "last_update": "2018-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02605915", "title": "Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2020-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02624973", "title": "PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625441", "title": "Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02627274", "title": "A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)", "status": "COMPLETED", "last_update": "2022-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02648477", "title": "Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02651610", "title": "Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2017-07-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02654119", "title": "Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery", "status": "COMPLETED", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657343", "title": "An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.", "status": "COMPLETED", "last_update": "2022-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658084", "title": "Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2019-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658734", "title": "A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane", "status": "COMPLETED", "last_update": "2021-04-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02682693", "title": "Denosumab as an add-on Neoadjuvant Treatment (GeparX)", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02696707", "title": "An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2025-12-18", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02725541", "title": "Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer", "status": "WITHDRAWN", "last_update": "2016-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02738970", "title": "A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)", "status": "COMPLETED", "last_update": "2018-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02789332", "title": "Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency", "status": "COMPLETED", "last_update": "2020-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02789657", "title": "Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.", "status": "COMPLETED", "last_update": "2022-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02843126", "title": "Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer", "status": "COMPLETED", "last_update": "2019-09-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02894398", "title": "Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02896855", "title": "A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02909751", "title": "Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer", "status": "COMPLETED", "last_update": "2021-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02924883", "title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy", "status": "COMPLETED", "last_update": "2021-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02953860", "title": "Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2021-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02980965", "title": "Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983604", "title": "GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer", "status": "TERMINATED", "last_update": "2019-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02993198", "title": "A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging", "status": "UNKNOWN", "last_update": "2024-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02997995", "title": "Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure", "status": "COMPLETED", "last_update": "2020-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03032107", "title": "A Study Of Pembrolizumab In Combination With Trastuzumab-DM1", "status": "COMPLETED", "last_update": "2025-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03058939", "title": "Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer", "status": "WITHDRAWN", "last_update": "2019-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03078751", "title": "Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer", "status": "COMPLETED", "last_update": "2021-10-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03084939", "title": "Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03112590", "title": "Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-04-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03140553", "title": "TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2020-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03153163", "title": "Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2018-11-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03190967", "title": "T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery", "status": "TERMINATED", "last_update": "2023-10-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03199885", "title": "Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03203616", "title": "Kadcyla In pAtients With bRAin Metastasis", "status": "WITHDRAWN", "last_update": "2018-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03213925", "title": "Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer", "status": "UNKNOWN", "last_update": "2017-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03238495", "title": "Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer", "status": "UNKNOWN", "last_update": "2021-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03248492", "title": "A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)", "status": "TERMINATED", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03264547", "title": "A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab", "status": "COMPLETED", "last_update": "2025-09-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03304080", "title": "Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03329378", "title": "Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer", "status": "TERMINATED", "last_update": "2023-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03364348", "title": "4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2022-10-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03366428", "title": "Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer", "status": "COMPLETED", "last_update": "2022-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03368196", "title": "DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein", "status": "COMPLETED", "last_update": "2022-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03387553", "title": "HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer", "status": "COMPLETED", "last_update": "2026-05-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03414658", "title": "The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03425656", "title": "Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin\u00ae in Breast Cancer", "status": "COMPLETED", "last_update": "2024-06-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03429101", "title": "A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2021-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03455270", "title": "G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2022-12-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03460067", "title": "Omission of Radiation in Patients With Her-2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03481998", "title": "A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03523572", "title": "Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer", "status": "COMPLETED", "last_update": "2025-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03523585", "title": "DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03529110", "title": "DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03530696", "title": "T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer", "status": "COMPLETED", "last_update": "2024-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03587740", "title": "ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03619044", "title": "The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-\u03b1 Status in Patients With Metastatic Breast Cancer HER2 + and ER\u03b1 Neg Treated With Trastuzumab + Pertuzumab + Taxane.", "status": "TERMINATED", "last_update": "2022-02-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03644186", "title": "To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)", "status": "COMPLETED", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03701334", "title": "A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03709082", "title": "Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03716180", "title": "DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03725059", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03726879", "title": "A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03734029", "title": "Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03742102", "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03747120", "title": "Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03765983", "title": "GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases", "status": "TERMINATED", "last_update": "2026-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03789110", "title": "NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811418", "title": "A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2019-11-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03820063", "title": "Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03894007", "title": "Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer", "status": "TERMINATED", "last_update": "2021-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03907098", "title": "Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03913234", "title": "Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients", "status": "UNKNOWN", "last_update": "2022-05-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924466", "title": "Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients", "status": "UNKNOWN", "last_update": "2024-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03964142", "title": "Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity", "status": "COMPLETED", "last_update": "2023-05-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03975647", "title": "A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04001621", "title": "Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-12-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04001829", "title": "Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04031885", "title": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-08-24", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042051", "title": "Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer", "status": "TERMINATED", "last_update": "2025-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042701", "title": "DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04047758", "title": "Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer", "status": "UNKNOWN", "last_update": "2021-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04066790", "title": "Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer", "status": "TERMINATED", "last_update": "2020-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04094896", "title": "TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2019-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04132960", "title": "Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04158947", "title": "A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone", "status": "UNKNOWN", "last_update": "2020-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04185649", "title": "The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-12-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04188548", "title": "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04193059", "title": "Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04197687", "title": "TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery", "status": "UNKNOWN", "last_update": "2023-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04208178", "title": "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04215003", "title": "A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC", "status": "UNKNOWN", "last_update": "2024-06-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04246502", "title": "Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04249622", "title": "Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer", "status": "TERMINATED", "last_update": "2025-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04266249", "title": "CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04296942", "title": "BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)", "status": "TERMINATED", "last_update": "2022-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04298918", "title": "A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04301375", "title": "Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2020-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04351230", "title": "T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398914", "title": "Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419181", "title": "Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04420598", "title": "DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease", "status": "COMPLETED", "last_update": "2025-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04425018", "title": "MARGetuximab Or Trastuzumab (MARGOT)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439110", "title": "Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04457596", "title": "T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04494425", "title": "Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04504331", "title": "Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2026-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508803", "title": "Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04509596", "title": "DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2025-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04514419", "title": "Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04538742", "title": "A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04539938", "title": "A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04540692", "title": "Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04569747", "title": "A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04578106", "title": "Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy", "status": "TERMINATED", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04582968", "title": "Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases", "status": "UNKNOWN", "last_update": "2023-01-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04588545", "title": "Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04622319", "title": "A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04629846", "title": "Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.", "status": "COMPLETED", "last_update": "2024-04-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639219", "title": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04655183", "title": "Study of M4344 in Combination With Niraparib", "status": "WITHDRAWN", "last_update": "2021-06-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665986", "title": "Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2020-12-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04675827", "title": "De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade", "status": "TERMINATED", "last_update": "2024-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04733118", "title": "Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04739761", "title": "A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04740918", "title": "A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)", "status": "TERMINATED", "last_update": "2025-08-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752059", "title": "Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases", "status": "COMPLETED", "last_update": "2023-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04760431", "title": "TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)", "status": "UNKNOWN", "last_update": "2021-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04784715", "title": "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04856475", "title": "Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04858529", "title": "Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)", "status": "UNKNOWN", "last_update": "2023-11-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04873362", "title": "A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04900311", "title": "Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-05-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04917900", "title": "Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04924699", "title": "A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-03-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04957212", "title": "Comparing Efficacy and Safety Between Pertuzumab\u00ae and Perjeta\u00ae in Neoadjuvant Treatment of HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04963595", "title": "Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964934", "title": "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04975308", "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04993430", "title": "A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05041842", "title": "Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05054374", "title": "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05081609", "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05085626", "title": "Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05101096", "title": "Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05113251", "title": "Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05130840", "title": "Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05132582", "title": "A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05165225", "title": "Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05172518", "title": "Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2021-12-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05177432", "title": "Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05180006", "title": "Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy", "status": "TERMINATED", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05194072", "title": "A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05205200", "title": "Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02", "status": "UNKNOWN", "last_update": "2024-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05227131", "title": "Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05255523", "title": "Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2022-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05257395", "title": "A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05296798", "title": "A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05323955", "title": "Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05346224", "title": "A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta\u00ae in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05353361", "title": "A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer", "status": "UNKNOWN", "last_update": "2023-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05378464", "title": "Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer", "status": "SUSPENDED", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05385705", "title": "A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020", "status": "TERMINATED", "last_update": "2025-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05388500", "title": "Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)", "status": "NOT_YET_RECRUITING", "last_update": "2022-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05415215", "title": "A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2026-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05426486", "title": "A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429684", "title": "Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-06-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05439499", "title": "This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole \u00b1 Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.", "status": "UNKNOWN", "last_update": "2022-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05463952", "title": "A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05474690", "title": "A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2024-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05503108", "title": "Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer", "status": "SUSPENDED", "last_update": "2023-11-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05529862", "title": "Trans-RosaLEE Study: a Biomarker-directed, Translational Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05560308", "title": "Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy", "status": "UNKNOWN", "last_update": "2022-10-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05574881", "title": "Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05576077", "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05577442", "title": "Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05593094", "title": "A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05596409", "title": "ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633979", "title": "Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650879", "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05656079", "title": "To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study", "status": "UNKNOWN", "last_update": "2022-12-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05678205", "title": "A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors", "status": "WITHDRAWN", "last_update": "2025-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05705401", "title": "Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05710328", "title": "Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05710666", "title": "Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05721248", "title": "STOP-HER2: Stopping Trastuzumab in HER2+ MBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05735392", "title": "Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)", "status": "COMPLETED", "last_update": "2023-02-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05744375", "title": "Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab", "status": "TERMINATED", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05755048", "title": "FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05774886", "title": "Implantable Microdevice for TNBC - Pilot Study", "status": "WITHDRAWN", "last_update": "2023-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05802225", "title": "Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta\u00ae as Neoadjuvant Therapy of HER2-Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806047", "title": "Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05840211", "title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05845138", "title": "A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.", "status": "UNKNOWN", "last_update": "2023-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05885776", "title": "Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research", "status": "UNKNOWN", "last_update": "2023-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05919212", "title": "Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05953168", "title": "T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients", "status": "UNKNOWN", "last_update": "2023-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05954143", "title": "Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05985187", "title": "Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta\u00ae Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.", "status": "UNKNOWN", "last_update": "2023-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06038539", "title": "Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta\u00ae Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy na\u00efve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer", "status": "TERMINATED", "last_update": "2026-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06048718", "title": "T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06057610", "title": "A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06068985", "title": "Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06080620", "title": "The Choice of Treatment Methods and Efficacy of LABC", "status": "UNKNOWN", "last_update": "2023-10-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06100874", "title": "A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06125834", "title": "Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy", "status": "UNKNOWN", "last_update": "2024-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06126640", "title": "A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06136897", "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06172127", "title": "PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06245824", "title": "Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-07", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06265428", "title": "A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06271837", "title": "A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06299852", "title": "Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06308939", "title": "Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial", "status": "UNKNOWN", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06316531", "title": "A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06328387", "title": "HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06429761", "title": "Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06435104", "title": "Aromatherapy in the Treatment of Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06465368", "title": "A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause", "status": "COMPLETED", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06470633", "title": "To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06481956", "title": "T-DM1 Combined With CDK4/6 Inhibitor Ribociclib", "status": "ENROLLING_BY_INVITATION", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06510465", "title": "Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06548178", "title": "T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06578299", "title": "Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585969", "title": "A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06595563", "title": "HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer", "status": "TERMINATED", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06625515", "title": "First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers", "status": "TERMINATED", "last_update": "2026-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06635447", "title": "Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680596", "title": "Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06718335", "title": "Pyrotinib in HER2-positive Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06797622", "title": "Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06882499", "title": "Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06884254", "title": "Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta\u00ae (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.", "status": "WITHDRAWN", "last_update": "2025-10-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06907082", "title": "Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma\u00ae) in Early HER2-positive Breast Cancer in Routine Clinical Practice", "status": "COMPLETED", "last_update": "2025-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06968585", "title": "A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06973525", "title": "This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07093931", "title": "Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07116824", "title": "HB1801 Combined Treatment of HER2-positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07129187", "title": "SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130344", "title": "PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07136974", "title": "Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07150208", "title": "T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07150767", "title": "A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2025-12-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07151586", "title": "Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07152782", "title": "T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07162051", "title": "A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07187752", "title": "Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07197697", "title": "A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07198672", "title": "Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07239271", "title": "A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07245797", "title": "A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07246317", "title": "Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07294430", "title": "Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07294534", "title": "A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07300215", "title": "An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07333937", "title": "Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07368543", "title": "Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07371910", "title": "Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07386938", "title": "A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta\u00ae in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07416253", "title": "Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07421141", "title": "De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07454668", "title": "Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07465172", "title": "GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07466303", "title": "Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07527806", "title": "Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07528898", "title": "Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07533526", "title": "Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07553390", "title": "Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07565324", "title": "Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07578116", "title": "Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07589972", "title": "Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07619365", "title": "Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07630103", "title": "Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07630948", "title": "Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07678957", "title": "A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07679269", "title": "Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07683754", "title": "T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07687225", "title": "Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07701941", "title": "A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07726342", "title": "SMP-656 for HER2-Positive Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07748260", "title": "De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07772245", "title": "Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07774624", "title": "Study of SKB103 in HER2-negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07782086", "title": "A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07782840", "title": "QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07785856", "title": "Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00301730", "title": "Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung", "status": "COMPLETED", "last_update": "2015-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03747120", "title": "Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05378464", "title": "Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer", "status": "SUSPENDED", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "HER2", "ERBB2", "trastuzumab", "pertuzumab", "trastuzumab deruxtecan", "Enhertu", "trastuzumab emtansine" ] }, "TROP2": { "n": 140, "n_observational": 18, "n_active": 120, "n_withdrawn": 4, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03606967", "title": "Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230109", "title": "Sacituzumab Govitecan In TNBC", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04434040", "title": "Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04468061", "title": "Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04986579", "title": "Scalp Cooling in MBC", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332561", "title": "Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05417594", "title": "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582499", "title": "Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05594095", "title": "SNF Platform Study of HR+/ HER2-advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05601440", "title": "Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05627960", "title": "First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2022-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633654", "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05749588", "title": "FUSCC Refractory TNBC Platform Study (FUTURE2.0)", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05770531", "title": "Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05866432", "title": "Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases", "status": "RECRUITING", "last_update": "2025-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941507", "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05969041", "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06081244", "title": "NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06102824", "title": "Organoid-based Functional Precision Therapy for Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06103864", "title": "A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06104085", "title": "99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer", "status": "RECRUITING", "last_update": "2023-10-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06176261", "title": "DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06230055", "title": "Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06236269", "title": "HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan", "status": "RECRUITING", "last_update": "2024-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06238921", "title": "Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases", "status": "RECRUITING", "last_update": "2025-12-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06263543", "title": "Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06312176", "title": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06393374", "title": "Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06409390", "title": "Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06439771", "title": "A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06462092", "title": "Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer", "status": "RECRUITING", "last_update": "2025-09-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06508216", "title": "A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer", "status": "RECRUITING", "last_update": "2024-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06533826", "title": "TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06616987", "title": "Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer", "status": "RECRUITING", "last_update": "2025-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06649331", "title": "Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06665178", "title": "Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06715020", "title": "Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06715826", "title": "Target-specific immunoPET Imaging of Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06793332", "title": "BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC", "status": "RECRUITING", "last_update": "2025-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06827613", "title": "A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06841354", "title": "A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06851299", "title": "The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.", "status": "RECRUITING", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06878625", "title": "A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06889610", "title": "A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06926920", "title": "A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06954480", "title": "Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06963905", "title": "Saci Nivo Rela for TNBC", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06966700", "title": "A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06974604", "title": "Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM", "status": "RECRUITING", "last_update": "2025-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07011654", "title": "Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07046455", "title": "Trop-2 Targeted PET Probes in Advanced TNBC", "status": "RECRUITING", "last_update": "2025-07-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07069595", "title": "PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07258108", "title": "Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07357597", "title": "An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07371208", "title": "Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07394218", "title": "ctDNA-guided Treatment Decision-making", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07401537", "title": "Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07461454", "title": "YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07471776", "title": "Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07533123", "title": "A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07591090", "title": "A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07623577", "title": "Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases", "status": "RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07657130", "title": "Optimal Application Timing of ADC Drugs for Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01631552", "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer", "status": "COMPLETED", "last_update": "2021-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02161679", "title": "Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer", "status": "WITHDRAWN", "last_update": "2021-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02574455", "title": "Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)", "status": "COMPLETED", "last_update": "2022-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03401385", "title": "First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03742102", "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03901339", "title": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03901469", "title": "A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03971409", "title": "Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03992131", "title": "A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)", "status": "TERMINATED", "last_update": "2024-01-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03995706", "title": "Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0", "status": "COMPLETED", "last_update": "2024-09-04", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04039230", "title": "Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04143711", "title": "Study of DF1001 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152499", "title": "Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04448886", "title": "Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04454437", "title": "Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04595565", "title": "Sacituzumab Govitecan in Primary HER2-negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639986", "title": "Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04647916", "title": "Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04927884", "title": "A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies", "status": "TERMINATED", "last_update": "2024-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04958785", "title": "Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05008510", "title": "P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .", "status": "WITHDRAWN", "last_update": "2022-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05101096", "title": "Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05104866", "title": "A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05113966", "title": "Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05143229", "title": "Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05374512", "title": "A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05382286", "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05382299", "title": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05460273", "title": "A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05520723", "title": "Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05552001", "title": "Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05629585", "title": "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05675579", "title": "A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05708144", "title": "NIR Fluorescent Molecular Probe for the Identification of Breast Tissue", "status": "COMPLETED", "last_update": "2024-01-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05774886", "title": "Implantable Microdevice for TNBC - Pilot Study", "status": "WITHDRAWN", "last_update": "2023-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05824325", "title": "Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer\uff08GALAXY\uff09", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-06-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05840211", "title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05928780", "title": "An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)", "status": "UNKNOWN", "last_update": "2023-07-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06100874", "title": "A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06112379", "title": "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06328387", "title": "HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06462079", "title": "Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06470672", "title": "Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06612203", "title": "Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06849492", "title": "HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06934733", "title": "The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07007780", "title": "Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07040644", "title": "A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07054242", "title": "A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07109284", "title": "SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07134556", "title": "Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC", "status": "WITHDRAWN", "last_update": "2026-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07139470", "title": "Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07151586", "title": "Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153965", "title": "Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07163481", "title": "A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07178730", "title": "NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07244874", "title": "Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07271992", "title": "TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07299409", "title": "First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07359404", "title": "Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07367178", "title": "Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07368543", "title": "Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07371910", "title": "Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07419867", "title": "A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07458113", "title": "Sac-TMT for Active TNBC Brain Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07466927", "title": "Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07509515", "title": "QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07553390", "title": "Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07628504", "title": "Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07738341", "title": "GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/\u2161)", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07788222", "title": "Sacituzumab Govitecan and Q901 in Advanced TNBC", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06827613", "title": "A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "TROP2", "TROP-2", "TACSTD2", "sacituzumab", "Trodelvy", "datopotamab", "Datroway" ] }, "HER3": { "n": 38, "n_observational": 3, "n_active": 21, "n_withdrawn": 0, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04348747", "title": "Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04965766", "title": "Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05504707", "title": "DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05594095", "title": "SNF Platform Study of HR+/ HER2-advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06172478", "title": "A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06298084", "title": "Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06649331", "title": "Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06686394", "title": "Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06797635", "title": "Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06956690", "title": "A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07060807", "title": "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07193394", "title": "Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07597629", "title": "A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07694986", "title": "Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00911898", "title": "A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers", "status": "COMPLETED", "last_update": "2015-01-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01097460", "title": "MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer", "status": "COMPLETED", "last_update": "2015-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01451632", "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers", "status": "COMPLETED", "last_update": "2016-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01512199", "title": "Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)", "status": "TERMINATED", "last_update": "2017-10-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01918254", "title": "A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein", "status": "COMPLETED", "last_update": "2017-09-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953926", "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations", "status": "TERMINATED", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02980341", "title": "Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-10-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241810", "title": "Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2020-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03321981", "title": "MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.", "status": "COMPLETED", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03552406", "title": "Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2021-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03832855", "title": "Assessing the Immunogenicity of pING-hHER3FL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209465", "title": "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.", "status": "TERMINATED", "last_update": "2025-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04383210", "title": "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04610528", "title": "A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression", "status": "UNKNOWN", "last_update": "2023-06-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04699630", "title": "A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05057013", "title": "A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05569811", "title": "NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05809752", "title": "A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05865990", "title": "HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05954143", "title": "Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06038539", "title": "Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta\u00ae Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy na\u00efve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer", "status": "TERMINATED", "last_update": "2026-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07701941", "title": "A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "HER3", "ERBB3", "patritumab" ] }, "PD-L1": { "n": 283, "n_observational": 22, "n_active": 116, "n_withdrawn": 14, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03606967", "title": "Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740893", "title": "PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer", "status": "RECRUITING", "last_update": "2025-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04273061", "title": "Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity", "status": "RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04434040", "title": "Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04468061", "title": "Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585750", "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04683679", "title": "A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802759", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04819243", "title": "PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study", "status": "RECRUITING", "last_update": "2025-01-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04954599", "title": "Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05000294", "title": "Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05092373", "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187338", "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332561", "title": "Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582499", "title": "Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582538", "title": "Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel", "status": "RECRUITING", "last_update": "2025-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05720260", "title": "Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC", "status": "RECRUITING", "last_update": "2024-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05795101", "title": "TRUDI: TDXD+Durva in HER2+/Low IBC", "status": "RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022029", "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06058377", "title": "Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06103864", "title": "A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06135714", "title": "Metastasis-directed Therapy for Oligometastases of Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06197581", "title": "Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer", "status": "RECRUITING", "last_update": "2024-08-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06305962", "title": "177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06312176", "title": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06340230", "title": "SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer", "status": "RECRUITING", "last_update": "2024-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06342037", "title": "NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06371274", "title": "A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.", "status": "RECRUITING", "last_update": "2025-08-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06508216", "title": "A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer", "status": "RECRUITING", "last_update": "2024-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06690840", "title": "Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06771609", "title": "Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06793553", "title": "Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC", "status": "RECRUITING", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06827236", "title": "A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06839560", "title": "Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06841354", "title": "A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06926868", "title": "A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06954480", "title": "Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06963905", "title": "Saci Nivo Rela for TNBC", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06966700", "title": "A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07078604", "title": "A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07111832", "title": "A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07173751", "title": "ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07258108", "title": "Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07260591", "title": "VSV-02 Compassionate Use in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-12-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07309770", "title": "Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07321015", "title": "A Single-Arm Phase \u2161 Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340541", "title": "Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01898117", "title": "Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01975831", "title": "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab", "status": "COMPLETED", "last_update": "2022-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02129556", "title": "Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2019-02-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264678", "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02299999", "title": "SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02322814", "title": "A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread", "status": "TERMINATED", "last_update": "2023-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02403271", "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors", "status": "COMPLETED", "last_update": "2019-01-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02404441", "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2022-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02425891", "title": "A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)", "status": "COMPLETED", "last_update": "2022-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02447003", "title": "Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)", "status": "COMPLETED", "last_update": "2020-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02460224", "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.", "status": "COMPLETED", "last_update": "2022-02-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02484404", "title": "Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02489448", "title": "Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2022-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02527434", "title": "Study of Tremelimumab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530489", "title": "Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2026-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02536794", "title": "MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2022-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02543645", "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2018-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "status": "TERMINATED", "last_update": "2024-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02563925", "title": "Brain Irradiation and Tremelimumab in Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2022-08-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02586987", "title": "A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2019-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02605915", "title": "Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2020-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02620280", "title": "Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1", "status": "COMPLETED", "last_update": "2024-03-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02622074", "title": "Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)", "status": "COMPLETED", "last_update": "2020-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02628132", "title": "Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients", "status": "COMPLETED", "last_update": "2020-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639026", "title": "Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers", "status": "COMPLETED", "last_update": "2025-11-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02643303", "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers", "status": "COMPLETED", "last_update": "2022-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02644369", "title": "Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02649686", "title": "Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658214", "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02669914", "title": "MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors", "status": "TERMINATED", "last_update": "2018-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02685059", "title": "Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2021-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02708680", "title": "Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In", "status": "COMPLETED", "last_update": "2024-12-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02725489", "title": "Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers", "status": "COMPLETED", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02734004", "title": "A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02779751", "title": "A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02791334", "title": "A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors", "status": "COMPLETED", "last_update": "2024-09-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02802098", "title": "Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2020-06-19", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02811497", "title": "Study of Azacitidine and Durvalumab in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2021-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02819518", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02826434", "title": "Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02838823", "title": "Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2019-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02849496", "title": "Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02883062", "title": "Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02890368", "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides", "status": "TERMINATED", "last_update": "2023-04-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02914470", "title": "Carboplatin-cyclophosphamide Combined With Atezolizumab", "status": "COMPLETED", "last_update": "2021-10-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02924883", "title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy", "status": "COMPLETED", "last_update": "2021-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02926196", "title": "Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab", "status": "COMPLETED", "last_update": "2025-12-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02936102", "title": "A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.", "status": "TERMINATED", "last_update": "2025-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2019-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02997995", "title": "Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure", "status": "COMPLETED", "last_update": "2020-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02999477", "title": "A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03036488", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)", "status": "COMPLETED", "last_update": "2025-10-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03051672", "title": "Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC", "status": "TERMINATED", "last_update": "2021-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03101280", "title": "A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2020-10-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03125902", "title": "A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)", "status": "COMPLETED", "last_update": "2024-03-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03125928", "title": "Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03132467", "title": "Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer", "status": "COMPLETED", "last_update": "2024-06-05", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03147040", "title": "AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer", "status": "TERMINATED", "last_update": "2022-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164993", "title": "Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03167619", "title": "Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)", "status": "COMPLETED", "last_update": "2022-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03175666", "title": "QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03197389", "title": "Effect of Pembrolizumab (Keytruda\u00ae) on Biomarkers in Early Breast Cancer.", "status": "COMPLETED", "last_update": "2021-05-19", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03197935", "title": "A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2023-10-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03199040", "title": "Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy", "status": "TERMINATED", "last_update": "2024-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03199885", "title": "Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03202316", "title": "Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03206203", "title": "Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03256344", "title": "Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases", "status": "COMPLETED", "last_update": "2024-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280563", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03281954", "title": "Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289962", "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors", "status": "COMPLETED", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03292172", "title": "A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2020-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03330405", "title": "Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356860", "title": "Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.", "status": "COMPLETED", "last_update": "2024-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03371017", "title": "A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-11-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03387085", "title": "QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.", "status": "TERMINATED", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03395899", "title": "Pre-operative Immunotherapy Combination Strategies in Breast Cancer", "status": "COMPLETED", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03396445", "title": "Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)", "status": "COMPLETED", "last_update": "2025-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409198", "title": "Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer", "status": "COMPLETED", "last_update": "2024-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03414658", "title": "The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03414684", "title": "Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03417544", "title": "Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC", "status": "COMPLETED", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430466", "title": "Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2020-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430518", "title": "Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer", "status": "COMPLETED", "last_update": "2020-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03464942", "title": "Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2023-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03483012", "title": "Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis", "status": "COMPLETED", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03498716", "title": "A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer", "status": "TERMINATED", "last_update": "2024-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03518606", "title": "Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2025-01-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03524170", "title": "Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2022-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544125", "title": "Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2020-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03549000", "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.", "status": "TERMINATED", "last_update": "2024-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03566485", "title": "Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer", "status": "TERMINATED", "last_update": "2021-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03568656", "title": "Study to Evaluate CCS1477 in Advanced Tumours", "status": "COMPLETED", "last_update": "2025-08-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03579472", "title": "M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2022-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03594396", "title": "Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03595592", "title": "Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-03-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03608865", "title": "Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing", "status": "COMPLETED", "last_update": "2022-01-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03616886", "title": "Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03620201", "title": "M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2024-10-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03650348", "title": "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03665285", "title": "A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2024-03-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03725059", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03726879", "title": "A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03739931", "title": "Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies", "status": "COMPLETED", "last_update": "2025-08-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03742102", "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03756298", "title": "Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03797326", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03800836", "title": "A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03801369", "title": "AMTEC IIT: Phase 2 Multiarm Study in TNBC", "status": "TERMINATED", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03802604", "title": "Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03820141", "title": "Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03821935", "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829501", "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03845166", "title": "A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03853707", "title": "Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-02-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03872505", "title": "Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer", "status": "WITHDRAWN", "last_update": "2021-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03874325", "title": "Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer", "status": "TERMINATED", "last_update": "2022-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03875573", "title": "Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03881878", "title": "TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery", "status": "UNKNOWN", "last_update": "2019-03-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03891953", "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03894007", "title": "Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer", "status": "TERMINATED", "last_update": "2021-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03911453", "title": "Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors", "status": "COMPLETED", "last_update": "2024-10-03", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915678", "title": "Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03952325", "title": "Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC", "status": "TERMINATED", "last_update": "2021-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03961698", "title": "Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03964532", "title": "TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03982173", "title": "Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors", "status": "WITHDRAWN", "last_update": "2023-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03983954", "title": "Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03988036", "title": "A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)", "status": "COMPLETED", "last_update": "2023-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04034823", "title": "KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2019-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042701", "title": "DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04053322", "title": "Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04088032", "title": "Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer", "status": "WITHDRAWN", "last_update": "2020-07-16", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04102618", "title": "A Window-of-opportunity Study of Pelareorep in Early Breast Cancer", "status": "TERMINATED", "last_update": "2022-08-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04148911", "title": "A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-12-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04176848", "title": "CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04177108", "title": "A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04191135", "title": "Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)", "status": "COMPLETED", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04215146", "title": "A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04222426", "title": "89Zr-atezolizumab PET Scan and Lobular Breast Cancer", "status": "TERMINATED", "last_update": "2022-07-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04244552", "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies", "status": "TERMINATED", "last_update": "2023-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04249167", "title": "Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-01-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260802", "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04296942", "title": "BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)", "status": "TERMINATED", "last_update": "2022-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04405505", "title": "A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)", "status": "UNKNOWN", "last_update": "2020-05-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04408118", "title": "First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin\u00ae) in mTNBC", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04442126", "title": "A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04489940", "title": "Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04504669", "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04521686", "title": "Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04538742", "title": "A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04551885", "title": "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04584112", "title": "A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2023-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04596150", "title": "Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04630210", "title": "Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity", "status": "WITHDRAWN", "last_update": "2022-06-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04634747", "title": "Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer", "status": "UNKNOWN", "last_update": "2022-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639245", "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04690855", "title": "A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2023-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04711824", "title": "Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04732598", "title": "A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04739670", "title": "Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04740918", "title": "A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)", "status": "TERMINATED", "last_update": "2025-08-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04756505", "title": "Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial", "status": "WITHDRAWN", "last_update": "2023-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04759248", "title": "Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04770272", "title": "Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04789096", "title": "Tucatinib Together With Pembrolizumab and Trastuzumab", "status": "TERMINATED", "last_update": "2025-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04789668", "title": "Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04799249", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)", "status": "COMPLETED", "last_update": "2024-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04873362", "title": "A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04927884", "title": "A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies", "status": "TERMINATED", "last_update": "2024-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05001347", "title": "A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ\u00ae) in Patients With Ovarian Cancer and Selected Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05081492", "title": "CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05082259", "title": "ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05082610", "title": "A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05180006", "title": "Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy", "status": "TERMINATED", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05205200", "title": "Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02", "status": "UNKNOWN", "last_update": "2024-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05209529", "title": "Chemo-free BRCA-targeted Neoadjuvant Strategy", "status": "WITHDRAWN", "last_update": "2024-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215106", "title": "Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05234606", "title": "A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2022-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05253053", "title": "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05266937", "title": "Atezolizumab Plus CArboplatin Plus Nab-paclitaxel", "status": "UNKNOWN", "last_update": "2024-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05374512", "title": "A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05382286", "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429684", "title": "Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-06-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05498155", "title": "Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05498896", "title": "Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05539365", "title": "Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer", "status": "WITHDRAWN", "last_update": "2025-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05576077", "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05603013", "title": "Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)", "status": "UNKNOWN", "last_update": "2022-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05629585", "title": "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05774886", "title": "Implantable Microdevice for TNBC - Pilot Study", "status": "WITHDRAWN", "last_update": "2023-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05780307", "title": "IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2023-06-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05787587", "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05809895", "title": "Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05812326", "title": "PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06067061", "title": "\"neoBREASTIM\": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06112379", "title": "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06175390", "title": "Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06229067", "title": "Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06470672", "title": "Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06724263", "title": "A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06842472", "title": "PD-L1 Inhibitor + RT \u00b1 Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07011823", "title": "Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07040644", "title": "A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07041437", "title": "Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07134556", "title": "Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC", "status": "WITHDRAWN", "last_update": "2026-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07161791", "title": "Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191405", "title": "Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07244874", "title": "Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07317778", "title": "Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07459738", "title": "A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07466927", "title": "Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07487519", "title": "Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07681297", "title": "Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07729956", "title": "A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07762703", "title": "Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639245", "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05812326", "title": "PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-L1", "PDL1", "CD274", "atezolizumab", "durvalumab" ] }, "B7-H4": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06774963", "title": "A Phase 1 Study of LNCB74 in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03514121", "title": "FPA150 in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-11-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05067972", "title": "A Study of PF-07260437 in Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "B7-H4", "VTCN1" ] }, "ROR1": { "n": 10, "n_observational": 1, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486089", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07510802", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02706392", "title": "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies", "status": "TERMINATED", "last_update": "2022-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02776917", "title": "Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04441099", "title": "NBE-002 in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04504916", "title": "A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)", "status": "TERMINATED", "last_update": "2025-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05274451", "title": "A Study to Investigate LYL797 in Adults With Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05694364", "title": "Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06299163", "title": "NM32-2668 in Adult Patients With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 5, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486089", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07510802", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02706392", "title": "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies", "status": "TERMINATED", "last_update": "2022-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05694364", "title": "Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "ROR1", "zilovertamab" ] }, "LIV-1": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01969643", "title": "A Safety Study of SGN-LIV1A in Breast Cancer Patients", "status": "COMPLETED", "last_update": "2023-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03310957", "title": "Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-12-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "LIV-1", "SLC39A6", "ladiratuzumab" ] }, "mesothelin": { "n": 14, "n_observational": 0, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05403554", "title": "A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers", "status": "RECRUITING", "last_update": "2024-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06623396", "title": "A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486089", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07510802", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02414269", "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02485119", "title": "Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies", "status": "COMPLETED", "last_update": "2018-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02580747", "title": "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso", "status": "UNKNOWN", "last_update": "2015-10-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02792114", "title": "T-Cell Therapy for Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03102320", "title": "Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05451849", "title": "A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer", "status": "TERMINATED", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05623488", "title": "CAR T Cells in Mesothelin-Expressing Breast Cancer", "status": "TERMINATED", "last_update": "2025-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06256055", "title": "Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors", "status": "UNKNOWN", "last_update": "2024-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 9, "n_observational": 0, "n_active": 7, "n_withdrawn": 0, "trials": [ { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06623396", "title": "A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486089", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07510802", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02414269", "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02580747", "title": "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso", "status": "UNKNOWN", "last_update": "2015-10-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02792114", "title": "T-Cell Therapy for Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05623488", "title": "CAR T Cells in Mesothelin-Expressing Breast Cancer", "status": "TERMINATED", "last_update": "2025-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "mesothelin", "MSLN" ] }, "MUC1": { "n": 33, "n_observational": 7, "n_active": 9, "n_withdrawn": 4, "trials": [ { "nct": "NCT03723928", "title": "S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04020575", "title": "Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)", "status": "RECRUITING", "last_update": "2023-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06218303", "title": "Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486089", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07510802", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003761", "title": "Vaccine Therapy in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004156", "title": "Vaccine Therapy in Treating Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2013-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00071942", "title": "Vaccine Therapy in Treating Patients With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2013-12-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00088413", "title": "PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer", "status": "COMPLETED", "last_update": "2019-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00179309", "title": "Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer", "status": "COMPLETED", "last_update": "2014-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00549822", "title": "Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2017-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00640861", "title": "Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer", "status": "COMPLETED", "last_update": "2018-10-31", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00706615", "title": "Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2020-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00925548", "title": "STRIDE - STimulating Immune Response In aDvanced brEast Cancer", "status": "TERMINATED", "last_update": "2014-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00938756", "title": "Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome", "status": "UNKNOWN", "last_update": "2010-04-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00986609", "title": "MUC1 Vaccine for Triple-negative Breast Cancer", "status": "COMPLETED", "last_update": "2018-07-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01110174", "title": "Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms", "status": "COMPLETED", "last_update": "2019-11-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02140996", "title": "Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers", "status": "UNKNOWN", "last_update": "2016-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02261389", "title": "Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-12-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02270372", "title": "Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer", "status": "COMPLETED", "last_update": "2018-05-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02587689", "title": "Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor", "status": "UNKNOWN", "last_update": "2016-12-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02839954", "title": "CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor", "status": "UNKNOWN", "last_update": "2016-12-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03175666", "title": "QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03384316", "title": "Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer", "status": "COMPLETED", "last_update": "2020-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03387085", "title": "QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.", "status": "TERMINATED", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03524261", "title": "Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2020-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03554109", "title": "QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03652077", "title": "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies", "status": "COMPLETED", "last_update": "2021-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04328194", "title": "Autotaxin (ATX) as a Marker for Breast Cancer", "status": "UNKNOWN", "last_update": "2020-03-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05239143", "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05812326", "title": "PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 9, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT04020575", "title": "Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)", "status": "RECRUITING", "last_update": "2023-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486089", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07510802", "title": "Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02587689", "title": "Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor", "status": "UNKNOWN", "last_update": "2016-12-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02839954", "title": "CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor", "status": "UNKNOWN", "last_update": "2016-12-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05239143", "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05812326", "title": "PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "MUC1", "mucin-1", "mucin 1" ] }, "Nectin-4": { "n": 22, "n_observational": 1, "n_active": 20, "n_withdrawn": 1, "trials": [ { "nct": "NCT05582499", "title": "Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05594095", "title": "SNF Platform Study of HR+/ HER2-advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06465069", "title": "A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06649331", "title": "Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07020117", "title": "A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07287995", "title": "A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07309770", "title": "Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07545122", "title": "A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07558447", "title": "Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07591090", "title": "A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04561362", "title": "Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05234606", "title": "A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2022-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06036121", "title": "A Study of ADRX-0706 in Select Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06238479", "title": "A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06724835", "title": "Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)", "status": "UNKNOWN", "last_update": "2024-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06840483", "title": "Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06994078", "title": "Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07080619", "title": "SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218003", "title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07419867", "title": "A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT06724835", "title": "Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)", "status": "UNKNOWN", "last_update": "2024-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "Nectin-4", "NECTIN4", "enfortumab" ] } }, "by_drug": { "ABEMACICLIB": { "n": 144, "n_observational": 35, "n_active": 99, "n_withdrawn": 8, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305834", "title": "Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04523857", "title": "ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04614194", "title": "Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802759", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04923542", "title": "SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925856", "title": "Immunomonitoring of Breast Cancer Patients During Systemic Treatment", "status": "RECRUITING", "last_update": "2023-10-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05095207", "title": "Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05305924", "title": "Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05307705", "title": "A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05345860", "title": "Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer", "status": "RECRUITING", "last_update": "2022-04-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05362760", "title": "Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management", "status": "RECRUITING", "last_update": "2025-05-16", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05372640", "title": "Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05386108", "title": "Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05501704", "title": "ETHAN - ET for Male BC", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05524584", "title": "Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05573126", "title": "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05608252", "title": "VS-6766+Abema+Fulv in Met HR+/HER- BC", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05696626", "title": "Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05708235", "title": "A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05735080", "title": "Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer", "status": "RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05766410", "title": "A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC", "status": "RECRUITING", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05891093", "title": "Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)", "status": "RECRUITING", "last_update": "2024-02-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05933395", "title": "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06044623", "title": "Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients", "status": "RECRUITING", "last_update": "2024-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06062498", "title": "Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06065748", "title": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06139107", "title": "RADIANT: Pre-op Radiation With Abemaciclib and Letrozole", "status": "RECRUITING", "last_update": "2025-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06169371", "title": "Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06179303", "title": "Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06188520", "title": "A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06197581", "title": "Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer", "status": "RECRUITING", "last_update": "2024-08-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06207734", "title": "Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer", "status": "RECRUITING", "last_update": "2025-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259929", "title": "NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer", "status": "RECRUITING", "last_update": "2025-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06341621", "title": "Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib", "status": "RECRUITING", "last_update": "2024-04-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06365788", "title": "Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06380751", "title": "Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06409390", "title": "Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06486883", "title": "Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06678269", "title": "A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07002177", "title": "A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07037199", "title": "Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07100106", "title": "A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07112053", "title": "A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07114601", "title": "A Study of LY4257496 in Participants With Cancer (OMNIRAY)", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07174336", "title": "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07180160", "title": "Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07190443", "title": "Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)", "status": "RECRUITING", "last_update": "2025-09-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191717", "title": "Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07214532", "title": "Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340541", "title": "Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07491380", "title": "Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07492641", "title": "BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07605728", "title": "Probiotics for Abemaciclib-Induced Abdominal Discomfort.", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01655225", "title": "A Study of LY3023414 in Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2022-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02057133", "title": "A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02102490", "title": "A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread", "status": "COMPLETED", "last_update": "2020-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02107703", "title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02246621", "title": "A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02308020", "title": "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02441946", "title": "A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2020-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02675231", "title": "A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02747004", "title": "A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02763566", "title": "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02779751", "title": "A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02784795", "title": "A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02791334", "title": "A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors", "status": "COMPLETED", "last_update": "2024-09-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02831530", "title": "Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients", "status": "COMPLETED", "last_update": "2018-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03099174", "title": "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer", "status": "COMPLETED", "last_update": "2025-06-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03130439", "title": "Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03155997", "title": "Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03227328", "title": "CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280563", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03284957", "title": "Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03425838", "title": "Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03616587", "title": "Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03703466", "title": "A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03846583", "title": "Tucatinib + Abemaciclib + Herceptin for HER2+ MBC", "status": "WITHDRAWN", "last_update": "2020-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03939897", "title": "Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03979508", "title": "Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03988114", "title": "A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2019-09-06", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04031885", "title": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-08-24", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04088032", "title": "Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer", "status": "WITHDRAWN", "last_update": "2020-07-16", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04158362", "title": "Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04188548", "title": "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04227327", "title": "Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)", "status": "TERMINATED", "last_update": "2025-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04256941", "title": "Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study", "status": "TERMINATED", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04293393", "title": "Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305236", "title": "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer", "status": "TERMINATED", "last_update": "2023-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04316169", "title": "Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04351230", "title": "T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04352777", "title": "Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer", "status": "COMPLETED", "last_update": "2025-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432454", "title": "Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation", "status": "COMPLETED", "last_update": "2025-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04481113", "title": "Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04514159", "title": "A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer", "status": "COMPLETED", "last_update": "2023-02-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04565054", "title": "Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04584853", "title": "PreOperative Endocrine Therapy for Individualised Care With Abemaciclib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585724", "title": "Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases", "status": "WITHDRAWN", "last_update": "2021-10-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603183", "title": "ABemaciclib, ET \u00b1 paclItaxel in aGgressive HR+/HER2- MBC trIaL", "status": "COMPLETED", "last_update": "2025-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04707196", "title": "A Study of Abemaciclib in Indian Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-24", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752332", "title": "A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer", "status": "TERMINATED", "last_update": "2025-07-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04791384", "title": "Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer", "status": "TERMINATED", "last_update": "2026-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862663", "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04920708", "title": "Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964934", "title": "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04975308", "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05065411", "title": "Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05169567", "title": "Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05189717", "title": "A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults", "status": "UNKNOWN", "last_update": "2022-04-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05464173", "title": "Chidamide in Combination With Abemaciclib and Endocrinotherapy\uff08Doctor's Choice\uff09 in Breast Cancer Patients Previously Treated With Palbociclib", "status": "UNKNOWN", "last_update": "2024-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05548127", "title": "TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05563220", "title": "Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05759949", "title": "First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors", "status": "COMPLETED", "last_update": "2025-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05774886", "title": "Implantable Microdevice for TNBC - Pilot Study", "status": "WITHDRAWN", "last_update": "2023-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05952557", "title": "An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06001762", "title": "TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06152471", "title": "Effect of Salovum\u2122 and SPC-Flakes\u2122 on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer", "status": "UNKNOWN", "last_update": "2023-11-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561022", "title": "Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping", "status": "UNKNOWN", "last_update": "2024-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06570031", "title": "ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer", "status": "COMPLETED", "last_update": "2026-06-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585969", "title": "A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06630325", "title": "A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer", "status": "TERMINATED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760637", "title": "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06810492", "title": "The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07005557", "title": "Chemo-free in Older (\u226565) Node-Positive ER+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130643", "title": "Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07173556", "title": "A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07292207", "title": "Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07406594", "title": "Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07410559", "title": "Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07428018", "title": "Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07487129", "title": "Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt", "status": "COMPLETED", "last_update": "2026-03-23", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07490509", "title": "Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07521202", "title": "IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07553234", "title": "Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07599137", "title": "Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07706933", "title": "Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07717450", "title": "Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07767474", "title": "A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07782840", "title": "QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ACOLBIFENE": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05941520", "title": "Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00853996", "title": "Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer", "status": "COMPLETED", "last_update": "2018-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB": { "n": 18, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00425854", "title": "An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00431067", "title": "Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy", "status": "COMPLETED", "last_update": "2014-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00708214", "title": "BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00826267", "title": "6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab", "status": "COMPLETED", "last_update": "2013-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00950742", "title": "Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin\u00ae in Patients With HER2-positive Advanced Breast Cancer.", "status": "COMPLETED", "last_update": "2025-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01125566", "title": "LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment", "status": "COMPLETED", "last_update": "2019-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01271725", "title": "LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures", "status": "COMPLETED", "last_update": "2019-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01325428", "title": "Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01441596", "title": "Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases", "status": "COMPLETED", "last_update": "2015-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01531764", "title": "BIBW 2992 (Afatinib) and Vinorelbine", "status": "TERMINATED", "last_update": "2013-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01594177", "title": "Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy", "status": "COMPLETED", "last_update": "2014-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01649271", "title": "Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.", "status": "COMPLETED", "last_update": "2025-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02115048", "title": "Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone", "status": "TERMINATED", "last_update": "2019-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02511847", "title": "Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib", "status": "UNKNOWN", "last_update": "2016-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02768337", "title": "Cambridge Brain Mets Trial 1", "status": "TERMINATED", "last_update": "2024-01-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04158947", "title": "A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone", "status": "UNKNOWN", "last_update": "2020-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB DIMALEATE": { "n": 18, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00425854", "title": "An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00431067", "title": "Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy", "status": "COMPLETED", "last_update": "2014-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00708214", "title": "BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00826267", "title": "6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab", "status": "COMPLETED", "last_update": "2013-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00950742", "title": "Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin\u00ae in Patients With HER2-positive Advanced Breast Cancer.", "status": "COMPLETED", "last_update": "2025-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01125566", "title": "LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment", "status": "COMPLETED", "last_update": "2019-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01271725", "title": "LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures", "status": "COMPLETED", "last_update": "2019-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01325428", "title": "Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01441596", "title": "Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases", "status": "COMPLETED", "last_update": "2015-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01531764", "title": "BIBW 2992 (Afatinib) and Vinorelbine", "status": "TERMINATED", "last_update": "2013-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01594177", "title": "Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy", "status": "COMPLETED", "last_update": "2014-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01649271", "title": "Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.", "status": "COMPLETED", "last_update": "2025-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02115048", "title": "Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone", "status": "TERMINATED", "last_update": "2019-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02511847", "title": "Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib", "status": "UNKNOWN", "last_update": "2016-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02768337", "title": "Cambridge Brain Mets Trial 1", "status": "TERMINATED", "last_update": "2024-01-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04158947", "title": "A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone", "status": "UNKNOWN", "last_update": "2020-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AFIMOXIFENE": { "n": 8, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00084344", "title": "Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women", "status": "COMPLETED", "last_update": "2012-05-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00952731", "title": "4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ", "status": "COMPLETED", "last_update": "2015-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02067741", "title": "CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer", "status": "TERMINATED", "last_update": "2023-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02993159", "title": "Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast", "status": "COMPLETED", "last_update": "2024-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03063619", "title": "Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast", "status": "COMPLETED", "last_update": "2024-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04009044", "title": "Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04570956", "title": "Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk", "status": "TERMINATED", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05133674", "title": "Therapeutic Dose Monitoring (TDM) of Tamoxifen", "status": "UNKNOWN", "last_update": "2022-05-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AFURESERTIB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04851613", "title": "Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05390710", "title": "PhI to Solid Tumors and PhII to Locally Advanced or mTNBC", "status": "COMPLETED", "last_update": "2024-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ALPELISIB": { "n": 66, "n_observational": 13, "n_active": 28, "n_withdrawn": 2, "trials": [ { "nct": "NCT05508906", "title": "Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2025-10-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564377", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05627960", "title": "First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2022-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05646862", "title": "A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05660083", "title": "Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05753657", "title": "A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.", "status": "RECRUITING", "last_update": "2023-03-03", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05933395", "title": "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06545682", "title": "Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06837792", "title": "Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06993844", "title": "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01219699", "title": "A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene", "status": "COMPLETED", "last_update": "2020-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01300962", "title": "Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-12-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01623349", "title": "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer", "status": "COMPLETED", "last_update": "2021-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01708161", "title": "A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors", "status": "TERMINATED", "last_update": "2018-09-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01791478", "title": "BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01870505", "title": "BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01872260", "title": "Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01923168", "title": "Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women", "status": "COMPLETED", "last_update": "2018-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928459", "title": "Phase 1b Trial of BGJ398/BYL719 in Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02038010", "title": "BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx", "status": "COMPLETED", "last_update": "2020-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02051751", "title": "A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02058381", "title": "A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2020-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02077933", "title": "Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02088684", "title": "Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02167854", "title": "Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2021-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02379247", "title": "BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2022-06-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02437318", "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.", "status": "COMPLETED", "last_update": "2025-02-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02506556", "title": "Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2022-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02734615", "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers", "status": "TERMINATED", "last_update": "2022-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056755", "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments", "status": "COMPLETED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03207529", "title": "Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03284957", "title": "Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386162", "title": "SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03439046", "title": "Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant", "status": "TERMINATED", "last_update": "2026-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04188548", "title": "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04208178", "title": "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04216472", "title": "Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations", "status": "TERMINATED", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04251533", "title": "Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss", "status": "TERMINATED", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04300790", "title": "Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients", "status": "COMPLETED", "last_update": "2025-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04524000", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04544189", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04708860", "title": "Feasibility of Fasting & Exercise in Pts With HR+ MBC", "status": "COMPLETED", "last_update": "2024-08-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762979", "title": "Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862143", "title": "Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant", "status": "TERMINATED", "last_update": "2024-06-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04899349", "title": "Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant", "status": "TERMINATED", "last_update": "2024-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04965688", "title": "Biology Guided Therapy for Breast Cancer for ER Positive", "status": "TERMINATED", "last_update": "2025-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05025735", "title": "Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05038735", "title": "Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063786", "title": "Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05090358", "title": "Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05101564", "title": "Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer", "status": "COMPLETED", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05107388", "title": "Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer", "status": "UNKNOWN", "last_update": "2021-11-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05143229", "title": "Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05230810", "title": "Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05392608", "title": "SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05501886", "title": "Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05563220", "title": "Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05625087", "title": "Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05631795", "title": "Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment", "status": "COMPLETED", "last_update": "2026-07-09", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05966584", "title": "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer", "status": "TERMINATED", "last_update": "2024-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05967286", "title": "Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial", "status": "WITHDRAWN", "last_update": "2024-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07679269", "title": "Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ALVOCIDIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003690", "title": "Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2011-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00020332", "title": "Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00039455", "title": "Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2013-02-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AMCENESTRANT": { "n": 8, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03284957", "title": "Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03816839", "title": "Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)", "status": "TERMINATED", "last_update": "2025-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04059484", "title": "Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer", "status": "TERMINATED", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04191382", "title": "Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer", "status": "TERMINATED", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04478266", "title": "Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2025-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04940026", "title": "Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women", "status": "COMPLETED", "last_update": "2025-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05128773", "title": "Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity", "status": "TERMINATED", "last_update": "2025-09-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ANVATABART OPADOTIN": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06224673", "title": "ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ARZOXIFENE": { "n": 7, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003428", "title": "Hormone Therapy in Treating Women With Breast Cancer", "status": "COMPLETED", "last_update": "2013-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005879", "title": "LY353381 in Preventing Breast Cancer in Women With Hyperplasia", "status": "COMPLETED", "last_update": "2017-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005886", "title": "Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer", "status": "COMPLETED", "last_update": "2017-01-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00034125", "title": "Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.", "status": "COMPLETED", "last_update": "2006-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00088010", "title": "Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer", "status": "COMPLETED", "last_update": "2010-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00190697", "title": "A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment", "status": "COMPLETED", "last_update": "2007-05-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00253539", "title": "Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer", "status": "COMPLETED", "last_update": "2011-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BAZEDOXIFENE": { "n": 6, "n_observational": 1, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02448771", "title": "A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer", "status": "COMPLETED", "last_update": "2022-10-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02694809", "title": "The PROMISE Study: Duavee in Women With DCIS", "status": "COMPLETED", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02729701", "title": "Pilot Study of the Effect of Duavee\u00ae on Benign Breast Tissue Proliferation", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379024", "title": "Pilot Study of Effects of Duavee\u00ae on Imaging and Blood Biomarkers In Women With Menopausal Symptoms", "status": "TERMINATED", "last_update": "2021-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821141", "title": "Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821375", "title": "Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers", "status": "COMPLETED", "last_update": "2025-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BGT-226": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00600275", "title": "A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BMS-690514": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01068704", "title": "Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BUPARLISIB": { "n": 27, "n_observational": 0, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT01068483", "title": "Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01132664", "title": "Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer", "status": "TERMINATED", "last_update": "2016-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01155453", "title": "A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01248494", "title": "PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01285466", "title": "A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01300962", "title": "Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-12-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01339442", "title": "BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer", "status": "COMPLETED", "last_update": "2017-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01363232", "title": "Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients", "status": "COMPLETED", "last_update": "2020-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01501604", "title": "BKM120 in Cancers With PIK3CA Activating Mutations", "status": "WITHDRAWN", "last_update": "2015-09-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01513356", "title": "Pharmacodynamic Study of BKM120 in Breast Cancer", "status": "COMPLETED", "last_update": "2014-04-02", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01572727", "title": "A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation", "status": "COMPLETED", "last_update": "2017-03-09", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01576666", "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01589861", "title": "Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2026-04-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01610284", "title": "Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor", "status": "COMPLETED", "last_update": "2020-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01623349", "title": "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer", "status": "COMPLETED", "last_update": "2021-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01626209", "title": "A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01629615", "title": "A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2020-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01633060", "title": "A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi", "status": "TERMINATED", "last_update": "2019-01-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01790932", "title": "BKM120 For Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2019-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01816594", "title": "NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer", "status": "COMPLETED", "last_update": "2019-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01923168", "title": "Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women", "status": "COMPLETED", "last_update": "2018-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953445", "title": "Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer", "status": "WITHDRAWN", "last_update": "2014-12-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02000882", "title": "STAR Cape+BKM120 MBC With Brain Met", "status": "COMPLETED", "last_update": "2022-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02058381", "title": "A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2020-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02088684", "title": "Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02154776", "title": "Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02404844", "title": "Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer", "status": "COMPLETED", "last_update": "2018-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CAMIZESTRANT": { "n": 15, "n_observational": 0, "n_active": 13, "n_withdrawn": 0, "trials": [ { "nct": "NCT05774951", "title": "A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06188520", "title": "A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06380751", "title": "Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07195227", "title": "Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07427394", "title": "Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07647328", "title": "A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03616587", "title": "Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04214288", "title": "A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04711252", "title": "A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964934", "title": "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05551897", "title": "A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole", "status": "COMPLETED", "last_update": "2023-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05952557", "title": "An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06547164", "title": "A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants", "status": "COMPLETED", "last_update": "2025-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07717450", "title": "Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CANERTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00051051", "title": "A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer", "status": "COMPLETED", "last_update": "2007-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CAPIVASERTIB": { "n": 34, "n_observational": 2, "n_active": 25, "n_withdrawn": 1, "trials": [ { "nct": "NCT05455619", "title": "Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05720260", "title": "Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC", "status": "RECRUITING", "last_update": "2024-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06607757", "title": "Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06837792", "title": "Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06982521", "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07281833", "title": "Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07287917", "title": "Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07426822", "title": "Rash & Diarrhea Prophylaxis With Capivasertib", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07624617", "title": "Fast-Her: Fasting Effects on Breast Cancer Treatment", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01226316", "title": "Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules", "status": "COMPLETED", "last_update": "2025-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01992952", "title": "Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02077569", "title": "AKT Inhibitor in Oestrogen Positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02208375", "title": "mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02299999", "title": "SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423603", "title": "PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2025-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03182634", "title": "The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial", "status": "UNKNOWN", "last_update": "2019-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03310541", "title": "AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03616587", "title": "Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03742102", "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03801369", "title": "AMTEC IIT: Phase 2 Multiarm Study in TNBC", "status": "TERMINATED", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03997123", "title": "Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305496", "title": "Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04712396", "title": "A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body", "status": "COMPLETED", "last_update": "2021-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862663", "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05563220", "title": "Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06613516", "title": "Effect of Capivasertib on ctDNA in ER Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2025-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06635447", "title": "Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764186", "title": "A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07088913", "title": "A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants", "status": "COMPLETED", "last_update": "2026-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07802626", "title": "Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CLOMIPHENE": { "n": 0, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "CONTUSUGENE LADENOVEC": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00004038", "title": "Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2013-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00044993", "title": "Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer", "status": "COMPLETED", "last_update": "2013-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00082641", "title": "Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer", "status": "COMPLETED", "last_update": "2023-09-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01042535", "title": "Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-04-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01302821", "title": "C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer", "status": "WITHDRAWN", "last_update": "2017-02-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "COPANLISIB": { "n": 11, "n_observational": 0, "n_active": 3, "n_withdrawn": 2, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02705859", "title": "Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)", "status": "COMPLETED", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03128619", "title": "Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer", "status": "TERMINATED", "last_update": "2022-09-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03377101", "title": "Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer", "status": "WITHDRAWN", "last_update": "2018-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03432741", "title": "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer", "status": "TERMINATED", "last_update": "2025-05-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03803761", "title": "A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-09-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03939897", "title": "Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042051", "title": "Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer", "status": "TERMINATED", "last_update": "2025-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04108858", "title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer", "status": "TERMINATED", "last_update": "2025-10-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04345913", "title": "Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CP-724714": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00055926", "title": "CP-724,714 in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CUDC-101": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01171924", "title": "A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors", "status": "COMPLETED", "last_update": "2016-03-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DACOMITINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01920061", "title": "A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)", "status": "COMPLETED", "last_update": "2022-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DACTOLISIB": { "n": 8, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00620594", "title": "A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01248494", "title": "PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01285466", "title": "A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01288092", "title": "BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2012-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01337765", "title": "Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients", "status": "COMPLETED", "last_update": "2020-10-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01471847", "title": "A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01482156", "title": "Dose Finding Study of RAD001 (Everolimus, Afinitor\u00ae) in Combination With BEZ235 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01495247", "title": "Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2020-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DATOPOTAMAB DERUXTECAN": { "n": 21, "n_observational": 1, "n_active": 21, "n_withdrawn": 0, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05417594", "title": "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05866432", "title": "Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases", "status": "RECRUITING", "last_update": "2025-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06103864", "title": "A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06176261", "title": "DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06508216", "title": "A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer", "status": "RECRUITING", "last_update": "2024-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06533826", "title": "TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06954480", "title": "Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06974604", "title": "Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM", "status": "RECRUITING", "last_update": "2025-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07069595", "title": "PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07357597", "title": "An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07471776", "title": "Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03401385", "title": "First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03742102", "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05104866", "title": "A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05374512", "title": "A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05460273", "title": "A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05629585", "title": "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06112379", "title": "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07738341", "title": "GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/\u2161)", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DISITAMAB VEDOTIN": { "n": 21, "n_observational": 1, "n_active": 16, "n_withdrawn": 1, "trials": [ { "nct": "NCT05831878", "title": "RC48-ADC in HER2-low Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904964", "title": "Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)", "status": "RECRUITING", "last_update": "2023-06-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06178159", "title": "DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06227117", "title": "Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer", "status": "RECRUITING", "last_update": "2024-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06278870", "title": "Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial", "status": "RECRUITING", "last_update": "2024-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06389006", "title": "To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer", "status": "RECRUITING", "last_update": "2024-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561555", "title": "A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.", "status": "RECRUITING", "last_update": "2024-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06642545", "title": "Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone \u00b1 Toripalimab in HR-/HER2-low Breast Cancer", "status": "RECRUITING", "last_update": "2025-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06649331", "title": "Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07065435", "title": "RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study", "status": "RECRUITING", "last_update": "2025-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07309770", "title": "Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07446452", "title": "Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05726175", "title": "Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer", "status": "UNKNOWN", "last_update": "2023-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05861635", "title": "The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression", "status": "UNKNOWN", "last_update": "2023-05-17", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06000033", "title": "Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06015113", "title": "Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2023-08-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06105008", "title": "Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2024-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06157892", "title": "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06857747", "title": "Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.", "status": "UNKNOWN", "last_update": "2025-03-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06966453", "title": "A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07366840", "title": "RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "DROSPIRENONE": { "n": 0, "n_observational": 2, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "DYDROGESTERONE": { "n": 0, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "ELACESTRANT": { "n": 35, "n_observational": 2, "n_active": 26, "n_withdrawn": 1, "trials": [ { "nct": "NCT05386108", "title": "Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05512364", "title": "Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05573126", "title": "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05982093", "title": "Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06062498", "title": "Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06075953", "title": "DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06120283", "title": "BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06201234", "title": "Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06382948", "title": "Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06492616", "title": "A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06638307", "title": "A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06923527", "title": "Circulating Tumor DNA", "status": "RECRUITING", "last_update": "2026-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07159451", "title": "A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07198724", "title": "ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07222215", "title": "PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07242352", "title": "Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07395336", "title": "Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07612215", "title": "Elacestrant in Advanced Triple Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07766018", "title": "A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02338349", "title": "A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02650817", "title": "Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03778931", "title": "Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04791384", "title": "Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer", "status": "TERMINATED", "last_update": "2026-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04797728", "title": "Elacestrant in Preoperative Setting, a Window of Opportunity Study", "status": "COMPLETED", "last_update": "2022-10-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05563220", "title": "Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05596409", "title": "ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05618613", "title": "Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-07-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05963997", "title": "A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06126575", "title": "A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function", "status": "COMPLETED", "last_update": "2024-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06590857", "title": "Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06691035", "title": "Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06938711", "title": "A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2025-04-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07005882", "title": "Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07753954", "title": "Medical Imaging to Re-evaluate Elacestrant Clinical Usage", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENCLOMIPHENE": { "n": 0, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "ERTUMAXOMAB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00351858", "title": "Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2015-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00452140", "title": "Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment", "status": "TERMINATED", "last_update": "2009-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00522457", "title": "Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy", "status": "TERMINATED", "last_update": "2011-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ESTETROL": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00464516", "title": "Preoperative Estetrol in Breast Cancer", "status": "COMPLETED", "last_update": "2012-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02718144", "title": "Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer", "status": "COMPLETED", "last_update": "2021-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ESTRADIOL": { "n": 189, "n_observational": 11, "n_active": 71, "n_withdrawn": 5, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04263298", "title": "Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2022-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05181033", "title": "Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05307705", "title": "A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467891", "title": "Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05524584", "title": "Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05573126", "title": "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05594095", "title": "SNF Platform Study of HR+/ HER2-advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05601440", "title": "Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05608252", "title": "VS-6766+Abema+Fulv in Met HR+/HER- BC", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05683418", "title": "A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05816655", "title": "Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05933395", "title": "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06202261", "title": "A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2024-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06607757", "title": "Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06726148", "title": "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06756932", "title": "BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06954961", "title": "A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06982521", "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998407", "title": "ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024173", "title": "A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07062965", "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07117630", "title": "An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07207070", "title": "A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07405801", "title": "A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07498478", "title": "Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07540572", "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07558733", "title": "Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07604571", "title": "Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07666555", "title": "A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003066", "title": "Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2014-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012025", "title": "ICI 182780 in Treating Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00057941", "title": "Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00065325", "title": "The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2015-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00075764", "title": "S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00099437", "title": "Comparison of Fulvestrant (FASLODEX\u2122) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00146601", "title": "Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2007-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193726", "title": "Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer", "status": "TERMINATED", "last_update": "2018-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00206414", "title": "Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer", "status": "TERMINATED", "last_update": "2013-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00253422", "title": "Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors", "status": "COMPLETED", "last_update": "2025-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00256698", "title": "Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy", "status": "COMPLETED", "last_update": "2012-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313170", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg", "status": "COMPLETED", "last_update": "2020-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00324259", "title": "Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00327769", "title": "Faslodex Advanced Breast Cancer Local Chinese Study", "status": "COMPLETED", "last_update": "2011-01-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00357110", "title": "Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2010-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372996", "title": "Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2015-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00423917", "title": "Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00522262", "title": "Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial", "status": "COMPLETED", "last_update": "2015-01-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00570258", "title": "Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy", "status": "TERMINATED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00629616", "title": "Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer", "status": "COMPLETED", "last_update": "2021-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00661531", "title": "Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy", "status": "TERMINATED", "last_update": "2017-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00698035", "title": "Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients", "status": "COMPLETED", "last_update": "2014-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00728949", "title": "A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer", "status": "COMPLETED", "last_update": "2018-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00871858", "title": "Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01142401", "title": "Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01219699", "title": "A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene", "status": "COMPLETED", "last_update": "2020-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01296555", "title": "A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01344031", "title": "MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01528345", "title": "Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer", "status": "TERMINATED", "last_update": "2016-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01560416", "title": "Fulvestrant With or Without Ganetespib in HR+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597193", "title": "Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer", "status": "COMPLETED", "last_update": "2019-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597388", "title": "AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602380", "title": "A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01797120", "title": "Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI", "status": "COMPLETED", "last_update": "2018-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01923298", "title": "Estradiol Levels in Patients Treated With Estring", "status": "COMPLETED", "last_update": "2022-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01942135", "title": "Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01984138", "title": "REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02107703", "title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02115594", "title": "Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2014-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02137083", "title": "A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02188745", "title": "ER Reactivation Therapy for Breast Cancer", "status": "COMPLETED", "last_update": "2024-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02206984", "title": "Endocrine Response in Women With Invasive Lobular Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02238808", "title": "A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02291913", "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02447328", "title": "A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex\u00ae ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-09-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02455453", "title": "Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography", "status": "COMPLETED", "last_update": "2020-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530411", "title": "Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer", "status": "UNKNOWN", "last_update": "2015-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530424", "title": "\"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment \"", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02540330", "title": "A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant", "status": "TERMINATED", "last_update": "2024-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632045", "title": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02690480", "title": "Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02694809", "title": "The PROMISE Study: Duavee in Women With DCIS", "status": "COMPLETED", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02729701", "title": "Pilot Study of the Effect of Duavee\u00ae on Benign Breast Tissue Proliferation", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756364", "title": "Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02792465", "title": "A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02894398", "title": "Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02913430", "title": "Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib", "status": "COMPLETED", "last_update": "2024-09-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02922127", "title": "Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02953860", "title": "Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2021-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02955394", "title": "Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02958852", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02964507", "title": "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983071", "title": "G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-02-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983604", "title": "GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer", "status": "TERMINATED", "last_update": "2019-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056755", "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments", "status": "COMPLETED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03134638", "title": "A Study of SY-1365 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2021-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03147287", "title": "Palbociclib After CDK and Endocrine Therapy (PACE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03179904", "title": "TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03202862", "title": "The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2017-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280563", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289039", "title": "Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03355157", "title": "A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386162", "title": "SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03442504", "title": "Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03447132", "title": "Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03481998", "title": "A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544762", "title": "Correlation of 16\u03b1-[18F]Fluoro-17\u03b2-estradiol PET Imaging With ESR1 Mutation", "status": "UNKNOWN", "last_update": "2019-05-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03554044", "title": "T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03555877", "title": "Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03633331", "title": "Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685331", "title": "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03772353", "title": "Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2023-03-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03778931", "title": "Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809988", "title": "PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)", "status": "COMPLETED", "last_update": "2023-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854903", "title": "WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor", "status": "COMPLETED", "last_update": "2025-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03873428", "title": "Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES", "status": "UNKNOWN", "last_update": "2024-02-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04024436", "title": "A Study of TAS-120 in Patients With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04031885", "title": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-08-24", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04033172", "title": "Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )", "status": "UNKNOWN", "last_update": "2019-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04034589", "title": "Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive\uff0cHR-Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2020-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04053322", "title": "Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224272", "title": "A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04247126", "title": "A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305236", "title": "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer", "status": "TERMINATED", "last_update": "2023-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334330", "title": "Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China", "status": "UNKNOWN", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379024", "title": "Pilot Study of Effects of Duavee\u00ae on Imaging and Blood Biomarkers In Women With Menopausal Symptoms", "status": "TERMINATED", "last_update": "2021-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04524000", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04544189", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04567420", "title": "DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04726332", "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)", "status": "TERMINATED", "last_update": "2024-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04738292", "title": "Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)", "status": "TERMINATED", "last_update": "2024-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762979", "title": "Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796623", "title": "A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821375", "title": "Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers", "status": "COMPLETED", "last_update": "2025-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04856371", "title": "Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862663", "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04901299", "title": "Fulvestrant + Neratinib In Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04975308", "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05047848", "title": "Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-09-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05054374", "title": "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05075512", "title": "The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05076695", "title": "Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05191004", "title": "Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC", "status": "WITHDRAWN", "last_update": "2023-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05251714", "title": "CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05252416", "title": "(VELA) Study of BLU-222 in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05328440", "title": "Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)", "status": "UNKNOWN", "last_update": "2023-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05392608", "title": "SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05411380", "title": "Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.", "status": "UNKNOWN", "last_update": "2022-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05433480", "title": "A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554354", "title": "Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)", "status": "TERMINATED", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05574881", "title": "Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05625087", "title": "Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05654623", "title": "A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05792410", "title": "A Phase \u2160b/\u2161 Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.", "status": "UNKNOWN", "last_update": "2023-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806047", "title": "Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806671", "title": "Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05870579", "title": "[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05905341", "title": "Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.", "status": "WITHDRAWN", "last_update": "2023-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05932667", "title": "Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2023-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05966584", "title": "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer", "status": "TERMINATED", "last_update": "2024-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05986071", "title": "I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047184", "title": "Phase I Study of BEBT-209 in Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06074757", "title": "Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06375707", "title": "First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06506955", "title": "Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561022", "title": "Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping", "status": "UNKNOWN", "last_update": "2024-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06635447", "title": "Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680921", "title": "A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764186", "title": "A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06941142", "title": "A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957379", "title": "Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07038369", "title": "A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340619", "title": "Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07393321", "title": "A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07408089", "title": "Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07679269", "title": "Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07729046", "title": "Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07748208", "title": "A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07767474", "title": "A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07784036", "title": "JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07802626", "title": "Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ESTRADIOL CYPIONATE": { "n": 189, "n_observational": 11, "n_active": 71, "n_withdrawn": 5, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04263298", "title": "Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2022-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05181033", "title": "Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05307705", "title": "A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467891", "title": "Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05524584", "title": "Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05573126", "title": "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05594095", "title": "SNF Platform Study of HR+/ HER2-advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05601440", "title": "Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05608252", "title": "VS-6766+Abema+Fulv in Met HR+/HER- BC", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05683418", "title": "A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05816655", "title": "Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05933395", "title": "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06202261", "title": "A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2024-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06607757", "title": "Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06726148", "title": "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06756932", "title": "BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06954961", "title": "A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06982521", "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998407", "title": "ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024173", "title": "A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07062965", "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07117630", "title": "An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07207070", "title": "A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07405801", "title": "A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07498478", "title": "Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07540572", "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07558733", "title": "Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07604571", "title": "Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07666555", "title": "A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003066", "title": "Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2014-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012025", "title": "ICI 182780 in Treating Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00057941", "title": "Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00065325", "title": "The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2015-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00075764", "title": "S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00099437", "title": "Comparison of Fulvestrant (FASLODEX\u2122) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00146601", "title": "Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2007-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193726", "title": "Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer", "status": "TERMINATED", "last_update": "2018-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00206414", "title": "Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer", "status": "TERMINATED", "last_update": "2013-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00253422", "title": "Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors", "status": "COMPLETED", "last_update": "2025-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00256698", "title": "Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy", "status": "COMPLETED", "last_update": "2012-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313170", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg", "status": "COMPLETED", "last_update": "2020-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00324259", "title": "Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00327769", "title": "Faslodex Advanced Breast Cancer Local Chinese Study", "status": "COMPLETED", "last_update": "2011-01-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00357110", "title": "Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2010-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372996", "title": "Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2015-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00423917", "title": "Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00522262", "title": "Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial", "status": "COMPLETED", "last_update": "2015-01-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00570258", "title": "Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy", "status": "TERMINATED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00629616", "title": "Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer", "status": "COMPLETED", "last_update": "2021-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00661531", "title": "Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy", "status": "TERMINATED", "last_update": "2017-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00698035", "title": "Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients", "status": "COMPLETED", "last_update": "2014-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00728949", "title": "A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer", "status": "COMPLETED", "last_update": "2018-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00871858", "title": "Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01142401", "title": "Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01219699", "title": "A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene", "status": "COMPLETED", "last_update": "2020-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01296555", "title": "A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01344031", "title": "MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01528345", "title": "Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer", "status": "TERMINATED", "last_update": "2016-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01560416", "title": "Fulvestrant With or Without Ganetespib in HR+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597193", "title": "Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer", "status": "COMPLETED", "last_update": "2019-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597388", "title": "AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602380", "title": "A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01797120", "title": "Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI", "status": "COMPLETED", "last_update": "2018-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01923298", "title": "Estradiol Levels in Patients Treated With Estring", "status": "COMPLETED", "last_update": "2022-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01942135", "title": "Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01984138", "title": "REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02107703", "title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02115594", "title": "Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2014-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02137083", "title": "A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02188745", "title": "ER Reactivation Therapy for Breast Cancer", "status": "COMPLETED", "last_update": "2024-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02206984", "title": "Endocrine Response in Women With Invasive Lobular Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02238808", "title": "A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02291913", "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02447328", "title": "A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex\u00ae ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-09-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02455453", "title": "Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography", "status": "COMPLETED", "last_update": "2020-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530411", "title": "Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer", "status": "UNKNOWN", "last_update": "2015-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530424", "title": "\"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment \"", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02540330", "title": "A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant", "status": "TERMINATED", "last_update": "2024-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632045", "title": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02690480", "title": "Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02694809", "title": "The PROMISE Study: Duavee in Women With DCIS", "status": "COMPLETED", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02729701", "title": "Pilot Study of the Effect of Duavee\u00ae on Benign Breast Tissue Proliferation", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756364", "title": "Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02792465", "title": "A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02894398", "title": "Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02913430", "title": "Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib", "status": "COMPLETED", "last_update": "2024-09-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02922127", "title": "Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02953860", "title": "Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2021-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02955394", "title": "Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02958852", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02964507", "title": "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983071", "title": "G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-02-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983604", "title": "GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer", "status": "TERMINATED", "last_update": "2019-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056755", "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments", "status": "COMPLETED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03134638", "title": "A Study of SY-1365 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2021-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03147287", "title": "Palbociclib After CDK and Endocrine Therapy (PACE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03179904", "title": "TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03202862", "title": "The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2017-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280563", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289039", "title": "Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03355157", "title": "A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386162", "title": "SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03442504", "title": "Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03447132", "title": "Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03481998", "title": "A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544762", "title": "Correlation of 16\u03b1-[18F]Fluoro-17\u03b2-estradiol PET Imaging With ESR1 Mutation", "status": "UNKNOWN", "last_update": "2019-05-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03554044", "title": "T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03555877", "title": "Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03633331", "title": "Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685331", "title": "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03772353", "title": "Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2023-03-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03778931", "title": "Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809988", "title": "PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)", "status": "COMPLETED", "last_update": "2023-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854903", "title": "WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor", "status": "COMPLETED", "last_update": "2025-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03873428", "title": "Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES", "status": "UNKNOWN", "last_update": "2024-02-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04024436", "title": "A Study of TAS-120 in Patients With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04031885", "title": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-08-24", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04033172", "title": "Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )", "status": "UNKNOWN", "last_update": "2019-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04034589", "title": "Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive\uff0cHR-Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2020-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04053322", "title": "Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224272", "title": "A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04247126", "title": "A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305236", "title": "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer", "status": "TERMINATED", "last_update": "2023-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334330", "title": "Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China", "status": "UNKNOWN", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379024", "title": "Pilot Study of Effects of Duavee\u00ae on Imaging and Blood Biomarkers In Women With Menopausal Symptoms", "status": "TERMINATED", "last_update": "2021-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04524000", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04544189", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04567420", "title": "DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04726332", "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)", "status": "TERMINATED", "last_update": "2024-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04738292", "title": "Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)", "status": "TERMINATED", "last_update": "2024-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762979", "title": "Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796623", "title": "A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821375", "title": "Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers", "status": "COMPLETED", "last_update": "2025-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04856371", "title": "Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862663", "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04901299", "title": "Fulvestrant + Neratinib In Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04975308", "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05047848", "title": "Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-09-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05054374", "title": "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05075512", "title": "The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05076695", "title": "Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05191004", "title": "Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC", "status": "WITHDRAWN", "last_update": "2023-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05251714", "title": "CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05252416", "title": "(VELA) Study of BLU-222 in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05328440", "title": "Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)", "status": "UNKNOWN", "last_update": "2023-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05392608", "title": "SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05411380", "title": "Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.", "status": "UNKNOWN", "last_update": "2022-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05433480", "title": "A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554354", "title": "Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)", "status": "TERMINATED", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05574881", "title": "Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05625087", "title": "Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05654623", "title": "A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05792410", "title": "A Phase \u2160b/\u2161 Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.", "status": "UNKNOWN", "last_update": "2023-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806047", "title": "Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806671", "title": "Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05870579", "title": "[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05905341", "title": "Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.", "status": "WITHDRAWN", "last_update": "2023-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05932667", "title": "Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2023-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05966584", "title": "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer", "status": "TERMINATED", "last_update": "2024-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05986071", "title": "I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047184", "title": "Phase I Study of BEBT-209 in Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06074757", "title": "Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06375707", "title": "First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06506955", "title": "Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561022", "title": "Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping", "status": "UNKNOWN", "last_update": "2024-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06635447", "title": "Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680921", "title": "A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764186", "title": "A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06941142", "title": "A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957379", "title": "Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07038369", "title": "A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340619", "title": "Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07393321", "title": "A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07408089", "title": "Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07679269", "title": "Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07729046", "title": "Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07748208", "title": "A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07767474", "title": "A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07784036", "title": "JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07802626", "title": "Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ESTRADIOL VALERATE": { "n": 189, "n_observational": 11, "n_active": 71, "n_withdrawn": 5, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04263298", "title": "Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2022-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05181033", "title": "Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05307705", "title": "A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467891", "title": "Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05524584", "title": "Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05573126", "title": "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05594095", "title": "SNF Platform Study of HR+/ HER2-advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05601440", "title": "Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05608252", "title": "VS-6766+Abema+Fulv in Met HR+/HER- BC", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05683418", "title": "A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05816655", "title": "Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05933395", "title": "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06202261", "title": "A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2024-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06607757", "title": "Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06726148", "title": "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06756932", "title": "BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06954961", "title": "A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06982521", "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998407", "title": "ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024173", "title": "A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07062965", "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07117630", "title": "An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07207070", "title": "A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07405801", "title": "A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07498478", "title": "Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07540572", "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07558733", "title": "Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07604571", "title": "Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07666555", "title": "A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003066", "title": "Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2014-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012025", "title": "ICI 182780 in Treating Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00057941", "title": "Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00065325", "title": "The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2015-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00075764", "title": "S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00099437", "title": "Comparison of Fulvestrant (FASLODEX\u2122) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00146601", "title": "Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2007-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193726", "title": "Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer", "status": "TERMINATED", "last_update": "2018-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00206414", "title": "Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer", "status": "TERMINATED", "last_update": "2013-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00253422", "title": "Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors", "status": "COMPLETED", "last_update": "2025-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00256698", "title": "Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy", "status": "COMPLETED", "last_update": "2012-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313170", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg", "status": "COMPLETED", "last_update": "2020-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00324259", "title": "Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00327769", "title": "Faslodex Advanced Breast Cancer Local Chinese Study", "status": "COMPLETED", "last_update": "2011-01-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00357110", "title": "Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2010-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372996", "title": "Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2015-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00423917", "title": "Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00522262", "title": "Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial", "status": "COMPLETED", "last_update": "2015-01-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00570258", "title": "Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy", "status": "TERMINATED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00629616", "title": "Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer", "status": "COMPLETED", "last_update": "2021-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00661531", "title": "Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy", "status": "TERMINATED", "last_update": "2017-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00698035", "title": "Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients", "status": "COMPLETED", "last_update": "2014-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00728949", "title": "A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer", "status": "COMPLETED", "last_update": "2018-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00871858", "title": "Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01142401", "title": "Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01219699", "title": "A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene", "status": "COMPLETED", "last_update": "2020-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01296555", "title": "A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01344031", "title": "MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01528345", "title": "Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer", "status": "TERMINATED", "last_update": "2016-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01560416", "title": "Fulvestrant With or Without Ganetespib in HR+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597193", "title": "Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer", "status": "COMPLETED", "last_update": "2019-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597388", "title": "AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602380", "title": "A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01797120", "title": "Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI", "status": "COMPLETED", "last_update": "2018-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01923298", "title": "Estradiol Levels in Patients Treated With Estring", "status": "COMPLETED", "last_update": "2022-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01942135", "title": "Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01984138", "title": "REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02107703", "title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02115594", "title": "Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2014-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02137083", "title": "A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02188745", "title": "ER Reactivation Therapy for Breast Cancer", "status": "COMPLETED", "last_update": "2024-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02206984", "title": "Endocrine Response in Women With Invasive Lobular Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02238808", "title": "A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02291913", "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02447328", "title": "A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex\u00ae ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-09-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02455453", "title": "Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography", "status": "COMPLETED", "last_update": "2020-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530411", "title": "Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer", "status": "UNKNOWN", "last_update": "2015-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530424", "title": "\"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment \"", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02540330", "title": "A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant", "status": "TERMINATED", "last_update": "2024-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632045", "title": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02690480", "title": "Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02694809", "title": "The PROMISE Study: Duavee in Women With DCIS", "status": "COMPLETED", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02729701", "title": "Pilot Study of the Effect of Duavee\u00ae on Benign Breast Tissue Proliferation", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756364", "title": "Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02792465", "title": "A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02894398", "title": "Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02913430", "title": "Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib", "status": "COMPLETED", "last_update": "2024-09-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02922127", "title": "Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02953860", "title": "Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2021-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02955394", "title": "Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02958852", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02964507", "title": "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983071", "title": "G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-02-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983604", "title": "GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer", "status": "TERMINATED", "last_update": "2019-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056755", "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments", "status": "COMPLETED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03134638", "title": "A Study of SY-1365 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2021-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03147287", "title": "Palbociclib After CDK and Endocrine Therapy (PACE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03179904", "title": "TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03202862", "title": "The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2017-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280563", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289039", "title": "Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03355157", "title": "A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386162", "title": "SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03442504", "title": "Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03447132", "title": "Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03481998", "title": "A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544762", "title": "Correlation of 16\u03b1-[18F]Fluoro-17\u03b2-estradiol PET Imaging With ESR1 Mutation", "status": "UNKNOWN", "last_update": "2019-05-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03554044", "title": "T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03555877", "title": "Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03633331", "title": "Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685331", "title": "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03772353", "title": "Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2023-03-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03778931", "title": "Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809988", "title": "PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)", "status": "COMPLETED", "last_update": "2023-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854903", "title": "WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor", "status": "COMPLETED", "last_update": "2025-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03873428", "title": "Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES", "status": "UNKNOWN", "last_update": "2024-02-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04024436", "title": "A Study of TAS-120 in Patients With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04031885", "title": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-08-24", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04033172", "title": "Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )", "status": "UNKNOWN", "last_update": "2019-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04034589", "title": "Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive\uff0cHR-Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2020-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04053322", "title": "Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224272", "title": "A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04247126", "title": "A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305236", "title": "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer", "status": "TERMINATED", "last_update": "2023-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334330", "title": "Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China", "status": "UNKNOWN", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379024", "title": "Pilot Study of Effects of Duavee\u00ae on Imaging and Blood Biomarkers In Women With Menopausal Symptoms", "status": "TERMINATED", "last_update": "2021-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04524000", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04544189", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04567420", "title": "DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04726332", "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)", "status": "TERMINATED", "last_update": "2024-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04738292", "title": "Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)", "status": "TERMINATED", "last_update": "2024-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762979", "title": "Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796623", "title": "A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821375", "title": "Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers", "status": "COMPLETED", "last_update": "2025-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04856371", "title": "Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862663", "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04901299", "title": "Fulvestrant + Neratinib In Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04975308", "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05047848", "title": "Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-09-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05054374", "title": "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05075512", "title": "The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05076695", "title": "Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05191004", "title": "Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC", "status": "WITHDRAWN", "last_update": "2023-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05251714", "title": "CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05252416", "title": "(VELA) Study of BLU-222 in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05328440", "title": "Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)", "status": "UNKNOWN", "last_update": "2023-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05392608", "title": "SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05411380", "title": "Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.", "status": "UNKNOWN", "last_update": "2022-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05433480", "title": "A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554354", "title": "Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)", "status": "TERMINATED", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05574881", "title": "Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05625087", "title": "Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05654623", "title": "A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05792410", "title": "A Phase \u2160b/\u2161 Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.", "status": "UNKNOWN", "last_update": "2023-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806047", "title": "Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806671", "title": "Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05870579", "title": "[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05905341", "title": "Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.", "status": "WITHDRAWN", "last_update": "2023-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05932667", "title": "Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2023-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05966584", "title": "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer", "status": "TERMINATED", "last_update": "2024-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05986071", "title": "I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047184", "title": "Phase I Study of BEBT-209 in Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06074757", "title": "Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06375707", "title": "First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06506955", "title": "Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561022", "title": "Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping", "status": "UNKNOWN", "last_update": "2024-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06635447", "title": "Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680921", "title": "A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764186", "title": "A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06941142", "title": "A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957379", "title": "Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07038369", "title": "A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340619", "title": "Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07393321", "title": "A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07408089", "title": "Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07679269", "title": "Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07729046", "title": "Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07748208", "title": "A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07767474", "title": "A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07784036", "title": "JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07802626", "title": "Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ESTRIOL": { "n": 6, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00464516", "title": "Preoperative Estetrol in Breast Cancer", "status": "COMPLETED", "last_update": "2012-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01370551", "title": "Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor\u00ae) for Atrophic Vaginitis in Breast Cancer Patients", "status": "COMPLETED", "last_update": "2024-10-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02413008", "title": "A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting", "status": "COMPLETED", "last_update": "2019-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02718144", "title": "Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer", "status": "COMPLETED", "last_update": "2021-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04081805", "title": "LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05562518", "title": "GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.", "status": "COMPLETED", "last_update": "2026-08-13", "phase": "PHASE4", "study_type": "INTERVENTIONAL" } ] }, "ESTROGENS, CONJUGATED": { "n": 15, "n_observational": 3, "n_active": 6, "n_withdrawn": 1, "trials": [ { "nct": "NCT04965766", "title": "Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06176261", "title": "DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06439693", "title": "The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07198724", "title": "ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00026286", "title": "Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00079248", "title": "Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer", "status": "UNKNOWN", "last_update": "2009-05-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193726", "title": "Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer", "status": "TERMINATED", "last_update": "2018-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01997333", "title": "Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2019-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02694809", "title": "The PROMISE Study: Duavee in Women With DCIS", "status": "COMPLETED", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02729701", "title": "Pilot Study of the Effect of Duavee\u00ae on Benign Breast Tissue Proliferation", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379024", "title": "Pilot Study of Effects of Duavee\u00ae on Imaging and Blood Biomarkers In Women With Menopausal Symptoms", "status": "TERMINATED", "last_update": "2021-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04606550", "title": "MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study", "status": "WITHDRAWN", "last_update": "2022-10-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821141", "title": "Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821375", "title": "Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers", "status": "COMPLETED", "last_update": "2025-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07618923", "title": "Neoadjuvant Dalpiciclib + AI \u2192 SHR-A1811 for HR+/HER2-Low Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ESTROGENS, CONJUGATED SYNTHETIC A": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07618923", "title": "Neoadjuvant Dalpiciclib + AI \u2192 SHR-A1811 for HR+/HER2-Low Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ESTROGENS, ESTERIFIED": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00131924", "title": "High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy", "status": "TERMINATED", "last_update": "2012-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ESTRONE": { "n": 6, "n_observational": 2, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00193726", "title": "Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer", "status": "TERMINATED", "last_update": "2018-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00522262", "title": "Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial", "status": "COMPLETED", "last_update": "2015-01-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01089049", "title": "Effect of a Natural Health Product on Urinary Estrogen Metabolites", "status": "COMPLETED", "last_update": "2012-03-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02922127", "title": "Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03684096", "title": "Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes", "status": "COMPLETED", "last_update": "2024-02-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05762042", "title": "Comparison of the Efficacy and Tolerability of Femal Versus Placebo", "status": "COMPLETED", "last_update": "2023-03-09", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "ESTROPIPATE": { "n": 6, "n_observational": 2, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00193726", "title": "Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer", "status": "TERMINATED", "last_update": "2018-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00522262", "title": "Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial", "status": "COMPLETED", "last_update": "2015-01-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01089049", "title": "Effect of a Natural Health Product on Urinary Estrogen Metabolites", "status": "COMPLETED", "last_update": "2012-03-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02922127", "title": "Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03684096", "title": "Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes", "status": "COMPLETED", "last_update": "2024-02-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05762042", "title": "Comparison of the Efficacy and Tolerability of Femal Versus Placebo", "status": "COMPLETED", "last_update": "2023-03-09", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "ETHINYL ESTRADIOL": { "n": 2, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00193726", "title": "Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer", "status": "TERMINATED", "last_update": "2018-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02922127", "title": "Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "FULVESTRANT": { "n": 179, "n_observational": 21, "n_active": 77, "n_withdrawn": 7, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04263298", "title": "Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2022-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04646759", "title": "Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2020-11-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04923542", "title": "SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05181033", "title": "Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05307705", "title": "A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467891", "title": "Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05524584", "title": "Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05594095", "title": "SNF Platform Study of HR+/ HER2-advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05601440", "title": "Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05608252", "title": "VS-6766+Abema+Fulv in Met HR+/HER- BC", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05683418", "title": "A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05816655", "title": "Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05872347", "title": "Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05894239", "title": "A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05933395", "title": "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05949541", "title": "Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05985655", "title": "Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06176534", "title": "Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase \u2161 Clinical Trial", "status": "RECRUITING", "last_update": "2024-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06202261", "title": "A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2024-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06369285", "title": "A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06726148", "title": "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06756932", "title": "BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06837792", "title": "Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06954961", "title": "A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998407", "title": "ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024173", "title": "A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07062965", "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07117630", "title": "An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07354022", "title": "A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.", "status": "RECRUITING", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07405801", "title": "A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07498478", "title": "Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07540572", "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07604571", "title": "Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012025", "title": "ICI 182780 in Treating Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00057941", "title": "Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00065325", "title": "The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2015-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00075764", "title": "S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00099437", "title": "Comparison of Fulvestrant (FASLODEX\u2122) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00146601", "title": "Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2007-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00253422", "title": "Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors", "status": "COMPLETED", "last_update": "2025-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00256698", "title": "Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy", "status": "COMPLETED", "last_update": "2012-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313170", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg", "status": "COMPLETED", "last_update": "2020-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00327769", "title": "Faslodex Advanced Breast Cancer Local Chinese Study", "status": "COMPLETED", "last_update": "2011-01-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00357110", "title": "Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2010-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372996", "title": "Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2015-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00423917", "title": "Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00570258", "title": "Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy", "status": "TERMINATED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00626106", "title": "QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00629616", "title": "Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer", "status": "COMPLETED", "last_update": "2021-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00728949", "title": "A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer", "status": "COMPLETED", "last_update": "2018-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01142401", "title": "Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01219699", "title": "A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene", "status": "COMPLETED", "last_update": "2020-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01226316", "title": "Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules", "status": "COMPLETED", "last_update": "2025-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01296555", "title": "A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01344031", "title": "MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01528345", "title": "Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer", "status": "TERMINATED", "last_update": "2016-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01560416", "title": "Fulvestrant With or Without Ganetespib in HR+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597193", "title": "Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer", "status": "COMPLETED", "last_update": "2019-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602380", "title": "A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01797120", "title": "Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI", "status": "COMPLETED", "last_update": "2018-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01942135", "title": "Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02107703", "title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02115594", "title": "Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2014-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02206984", "title": "Endocrine Response in Women With Invasive Lobular Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02238509", "title": "Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies", "status": "UNKNOWN", "last_update": "2016-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02291913", "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02447328", "title": "A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex\u00ae ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-09-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632045", "title": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02690480", "title": "Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02734615", "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers", "status": "TERMINATED", "last_update": "2022-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756364", "title": "Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02792465", "title": "A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02894398", "title": "Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02913430", "title": "Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib", "status": "COMPLETED", "last_update": "2024-09-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02953860", "title": "Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2021-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02955394", "title": "Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02958852", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02964507", "title": "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983071", "title": "G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-02-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983604", "title": "GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer", "status": "TERMINATED", "last_update": "2019-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056755", "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments", "status": "COMPLETED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03079011", "title": "PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03147287", "title": "Palbociclib After CDK and Endocrine Therapy (PACE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03179904", "title": "TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03202862", "title": "The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2017-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03204734", "title": "Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2017-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03227328", "title": "CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280563", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289039", "title": "Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03355157", "title": "A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386162", "title": "SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430466", "title": "Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2020-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03481998", "title": "A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03554044", "title": "T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03555877", "title": "Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03633331", "title": "Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685331", "title": "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03750396", "title": "Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2019-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03772353", "title": "Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2023-03-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03778931", "title": "Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809988", "title": "PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)", "status": "COMPLETED", "last_update": "2023-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854903", "title": "WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor", "status": "COMPLETED", "last_update": "2025-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04024436", "title": "A Study of TAS-120 in Patients With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04031885", "title": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-08-24", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04033172", "title": "Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )", "status": "UNKNOWN", "last_update": "2019-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04034589", "title": "Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive\uff0cHR-Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2020-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04053322", "title": "Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224272", "title": "A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04247126", "title": "A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305236", "title": "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer", "status": "TERMINATED", "last_update": "2023-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04318223", "title": "Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy", "status": "UNKNOWN", "last_update": "2020-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334330", "title": "Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China", "status": "UNKNOWN", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460430", "title": "Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2022-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04524000", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04544189", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04567420", "title": "DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04726332", "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)", "status": "TERMINATED", "last_update": "2024-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762979", "title": "Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796623", "title": "A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04901299", "title": "Fulvestrant + Neratinib In Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04975308", "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05004142", "title": "Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin", "status": "UNKNOWN", "last_update": "2021-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05041842", "title": "Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05047848", "title": "Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-09-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05054374", "title": "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05075512", "title": "The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05076695", "title": "Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05079360", "title": "Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05191004", "title": "Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC", "status": "WITHDRAWN", "last_update": "2023-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05205200", "title": "Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02", "status": "UNKNOWN", "last_update": "2024-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05251714", "title": "CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05262400", "title": "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05392608", "title": "SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05433480", "title": "A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05438810", "title": "This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant \u00b1 Goseraline Versus Placebo Combined With Fulvestrant \u00b1 Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.", "status": "UNKNOWN", "last_update": "2022-07-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05546268", "title": "Study of Oral MRT-2359 in Selected Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554354", "title": "Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)", "status": "TERMINATED", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05574881", "title": "Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05625087", "title": "Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05654623", "title": "A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05670054", "title": "Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients", "status": "UNKNOWN", "last_update": "2023-01-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806047", "title": "Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806671", "title": "Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05808582", "title": "Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2023-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05905341", "title": "Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.", "status": "WITHDRAWN", "last_update": "2023-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05986071", "title": "I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047184", "title": "Phase I Study of BEBT-209 in Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06074757", "title": "Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06375707", "title": "First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06506955", "title": "Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561022", "title": "Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping", "status": "UNKNOWN", "last_update": "2024-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585969", "title": "A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06612814", "title": "PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-09-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06635447", "title": "Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680921", "title": "A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06702618", "title": "Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06750848", "title": "Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764186", "title": "A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06788197", "title": "A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06941142", "title": "A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957379", "title": "Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07038369", "title": "A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340619", "title": "Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07408089", "title": "Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07679269", "title": "Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07683754", "title": "T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07729046", "title": "Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07767474", "title": "A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07784036", "title": "JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07802626", "title": "Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "GANCOTAMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01304797", "title": "Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2017-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213744", "title": "MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients", "status": "TERMINATED", "last_update": "2017-01-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "GEDATOLISIB": { "n": 10, "n_observational": 1, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT06757634", "title": "Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01920061", "title": "A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)", "status": "COMPLETED", "last_update": "2022-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02069158", "title": "Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor", "status": "COMPLETED", "last_update": "2019-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02626507", "title": "Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer", "status": "UNKNOWN", "last_update": "2022-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02684032", "title": "A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2022-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03243331", "title": "An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer", "status": "COMPLETED", "last_update": "2021-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03400254", "title": "Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (\"GLACIER\")", "status": "WITHDRAWN", "last_update": "2020-04-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03698383", "title": "Phase II Study of Herzuma\u00ae Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2021-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03911973", "title": "Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-06-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05501886", "title": "Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "GIREDESTRANT": { "n": 19, "n_observational": 1, "n_active": 14, "n_withdrawn": 0, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802759", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05708235", "title": "A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06065748", "title": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259929", "title": "NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer", "status": "RECRUITING", "last_update": "2025-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07054190", "title": "A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07100106", "title": "A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07541079", "title": "A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03332797", "title": "A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03916744", "title": "A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04436744", "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)", "status": "COMPLETED", "last_update": "2023-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04546009", "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04576455", "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04961996", "title": "A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05296798", "title": "A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05306340", "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05659563", "title": "Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67\u226510%", "status": "COMPLETED", "last_update": "2026-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05896566", "title": "A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer", "status": "COMPLETED", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07214662", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer", "status": "TERMINATED", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "HEMAY-022": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06313983", "title": "A Phase \u2162 Study of Hemay022 in Combination With AI In Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02476539", "title": "Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2024-03-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03308201", "title": "Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2024-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "HYDROXYPROGESTERONE CAPROATE": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00577122", "title": "Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IDASANUTLIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03566485", "title": "Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer", "status": "TERMINATED", "last_update": "2021-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "INAVOLISIB": { "n": 19, "n_observational": 2, "n_active": 18, "n_withdrawn": 0, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802759", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05306041", "title": "Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332561", "title": "Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05646862", "title": "A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05708235", "title": "A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05894239", "title": "A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06790693", "title": "A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07054190", "title": "A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07368998", "title": "To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07405801", "title": "A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03006172", "title": "To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04191499", "title": "A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04849364", "title": "Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07245797", "title": "A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07441512", "title": "A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07618390", "title": "A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07748208", "title": "A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IPATASERTIB": { "n": 24, "n_observational": 0, "n_active": 10, "n_withdrawn": 0, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802759", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332561", "title": "Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564377", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02162719", "title": "A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors", "status": "COMPLETED", "last_update": "2021-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02301988", "title": "A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2018-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280563", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03337724", "title": "A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-03-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03395899", "title": "Pre-operative Immunotherapy Combination Strategies in Breast Cancer", "status": "COMPLETED", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03800836", "title": "A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03840200", "title": "A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.", "status": "COMPLETED", "last_update": "2023-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03853707", "title": "Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-02-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03959891", "title": "AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04060862", "title": "A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04177108", "title": "A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04253561", "title": "Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients", "status": "COMPLETED", "last_update": "2026-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464174", "title": "Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04650581", "title": "Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04920708", "title": "Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05180006", "title": "Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy", "status": "TERMINATED", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05498896", "title": "Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554380", "title": "Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "KN-026": { "n": 8, "n_observational": 1, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05838066", "title": "Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.", "status": "RECRUITING", "last_update": "2025-05-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07441460", "title": "A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07597629", "title": "A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03619681", "title": "Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer", "status": "COMPLETED", "last_update": "2024-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03847168", "title": "KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04165993", "title": "Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04881929", "title": "Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2022-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06747338", "title": "A Phase III Study of KN026 in Combination With HB1801 \u00b1 Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB": { "n": 183, "n_observational": 17, "n_active": 5, "n_withdrawn": 9, "trials": [ { "nct": "NCT06313983", "title": "A Phase \u2162 Study of Hemay022 in Combination With AI In Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00051103", "title": "Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.", "status": "COMPLETED", "last_update": "2015-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00062686", "title": "GW572016 For Treatment Of Refractory Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00073528", "title": "Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00075270", "title": "Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00078572", "title": "Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2010-12-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085020", "title": "GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00089999", "title": "Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00098605", "title": "Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases", "status": "COMPLETED", "last_update": "2013-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00105950", "title": "Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer", "status": "COMPLETED", "last_update": "2015-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00111787", "title": "Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer", "status": "COMPLETED", "last_update": "2017-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00118157", "title": "Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen", "status": "COMPLETED", "last_update": "2017-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00148902", "title": "Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)", "status": "COMPLETED", "last_update": "2017-12-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00169533", "title": "Rollover Study Of Lapatinib In Cancer Patients", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00206427", "title": "Neoadjuvant GW572016 to Treat Breast Cancer", "status": "COMPLETED", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00225758", "title": "Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy", "status": "TERMINATED", "last_update": "2018-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00251433", "title": "GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2023-03-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00263588", "title": "Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2019-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00272987", "title": "ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib", "status": "TERMINATED", "last_update": "2023-04-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281658", "title": "Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2", "status": "COMPLETED", "last_update": "2023-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00299286", "title": "Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer", "status": "COMPLETED", "last_update": "2012-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00316407", "title": "Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients", "status": "COMPLETED", "last_update": "2011-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00316875", "title": "Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00320385", "title": "Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00320411", "title": "GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2019-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00331630", "title": "Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer", "status": "COMPLETED", "last_update": "2020-03-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00343759", "title": "Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy", "status": "WITHDRAWN", "last_update": "2015-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00347919", "title": "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00356811", "title": "Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00359190", "title": "Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00371488", "title": "GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00374322", "title": "Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer", "status": "COMPLETED", "last_update": "2014-08-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00379509", "title": "Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-03-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00388076", "title": "Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00390455", "title": "Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive", "status": "COMPLETED", "last_update": "2019-12-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00404066", "title": "Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer", "status": "COMPLETED", "last_update": "2017-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00422903", "title": "Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer", "status": "COMPLETED", "last_update": "2016-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00424164", "title": "Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00437073", "title": "Brain Metastases In ErbB2-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2015-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00444535", "title": "Lapatinib and Bevacizumab for Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00450892", "title": "Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00455039", "title": "INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients", "status": "WITHDRAWN", "last_update": "2023-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00462956", "title": "GW572016 In Patients With Advanced Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00470704", "title": "Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00470847", "title": "Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2014-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00477464", "title": "Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00479856", "title": "Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer", "status": "TERMINATED", "last_update": "2012-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00482391", "title": "Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer", "status": "COMPLETED", "last_update": "2017-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00486668", "title": "A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer", "status": "UNKNOWN", "last_update": "2016-06-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00496366", "title": "Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer", "status": "TERMINATED", "last_update": "2017-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00499681", "title": "PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE", "status": "TERMINATED", "last_update": "2012-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00508274", "title": "Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China", "status": "TERMINATED", "last_update": "2021-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00513058", "title": "Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00524303", "title": "Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.", "status": "COMPLETED", "last_update": "2016-11-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00544804", "title": "Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00548184", "title": "Lapatinib and Trastuzumab With or Without Endocrine Therapy", "status": "COMPLETED", "last_update": "2019-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553358", "title": "Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study", "status": "COMPLETED", "last_update": "2021-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00555152", "title": "Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ", "status": "COMPLETED", "last_update": "2018-04-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00558103", "title": "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer", "status": "COMPLETED", "last_update": "2013-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00567554", "title": "Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer", "status": "COMPLETED", "last_update": "2016-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00614978", "title": "Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2012-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00632489", "title": "LBH589 in Combination With Capecitabine Plus/Minus (\u00b1) Lapatinib in Breast Cancer Patients", "status": "COMPLETED", "last_update": "2015-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00634088", "title": "Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2016-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00650910", "title": "Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00657137", "title": "APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)", "status": "TERMINATED", "last_update": "2012-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00667251", "title": "Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2025-03-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00684983", "title": "Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer", "status": "COMPLETED", "last_update": "2020-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00688194", "title": "Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy", "status": "UNKNOWN", "last_update": "2013-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00694252", "title": "Lapatinib and Circulating Tumor Cells in Breast Cancer", "status": "COMPLETED", "last_update": "2015-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00706030", "title": "Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00709618", "title": "Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects", "status": "TERMINATED", "last_update": "2014-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00709761", "title": "Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC", "status": "COMPLETED", "last_update": "2019-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00721630", "title": "Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00741260", "title": "Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00753207", "title": "Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30", "status": "COMPLETED", "last_update": "2016-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00754702", "title": "Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2015-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00756470", "title": "Phase II Neoadjuvant in Inflammatory Breast Cancer", "status": "TERMINATED", "last_update": "2014-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00759642", "title": "Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy", "status": "TERMINATED", "last_update": "2019-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00769470", "title": "Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2016-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00770809", "title": "Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00777101", "title": "Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00790816", "title": "Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents", "status": "COMPLETED", "last_update": "2018-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00807859", "title": "Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2022-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820222", "title": "Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2019-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820872", "title": "Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2019-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820924", "title": "Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells", "status": "TERMINATED", "last_update": "2012-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00821054", "title": "A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00826267", "title": "6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab", "status": "COMPLETED", "last_update": "2013-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00829166", "title": "A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00841828", "title": "Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients", "status": "COMPLETED", "last_update": "2023-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00842998", "title": "Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer", "status": "UNKNOWN", "last_update": "2009-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00849329", "title": "A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00857714", "title": "Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast", "status": "TERMINATED", "last_update": "2015-07-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00903656", "title": "Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy", "status": "TERMINATED", "last_update": "2013-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00912275", "title": "Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2019-05-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00952692", "title": "Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00963547", "title": "A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)", "status": "TERMINATED", "last_update": "2024-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00967031", "title": "Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases", "status": "COMPLETED", "last_update": "2013-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968968", "title": "Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone", "status": "TERMINATED", "last_update": "2019-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00996762", "title": "A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00999804", "title": "Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01005641", "title": "ELBA: Exemestane and Lapatinib in Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2012-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01013740", "title": "Lapatinib in Combination With Vinorelbine", "status": "COMPLETED", "last_update": "2017-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01044485", "title": "Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2012-09-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01050322", "title": "Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.", "status": "COMPLETED", "last_update": "2013-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01068704", "title": "Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01104571", "title": "Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer", "status": "UNKNOWN", "last_update": "2018-09-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01118975", "title": "GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers", "status": "TERMINATED", "last_update": "2019-11-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01128543", "title": "Lapatinib in Combination With Vinorelbine", "status": "COMPLETED", "last_update": "2012-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01133912", "title": "Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb\u00ae) (PGT)", "status": "COMPLETED", "last_update": "2012-01-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01137994", "title": "A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01138046", "title": "Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC", "status": "COMPLETED", "last_update": "2014-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01138384", "title": "Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01160211", "title": "A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2025-03-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01161368", "title": "A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients", "status": "TERMINATED", "last_update": "2015-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01199367", "title": "Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01205217", "title": "Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer", "status": "WITHDRAWN", "last_update": "2017-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01218529", "title": "Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors", "status": "COMPLETED", "last_update": "2014-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01238029", "title": "Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2014-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01245205", "title": "Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer", "status": "COMPLETED", "last_update": "2014-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01262469", "title": "Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.", "status": "COMPLETED", "last_update": "2014-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01272141", "title": "A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2014-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01273610", "title": "Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01275859", "title": "Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01281163", "title": "Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2015-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01283789", "title": "Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2017-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01290354", "title": "Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01300962", "title": "Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-12-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01309607", "title": "Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb\u00ae) in Patients With ErbB2-Positive Stage I-III Breast Cancer", "status": "UNKNOWN", "last_update": "2014-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01361945", "title": "AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2017-05-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01419197", "title": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy", "status": "COMPLETED", "last_update": "2016-10-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01426880", "title": "Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer", "status": "COMPLETED", "last_update": "2016-02-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01434303", "title": "Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only", "status": "COMPLETED", "last_update": "2019-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01471847", "title": "A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01477060", "title": "Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2014-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01479179", "title": "Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab", "status": "WITHDRAWN", "last_update": "2016-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01485926", "title": "A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.", "status": "COMPLETED", "last_update": "2018-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01494662", "title": "HKI-272 for HER2-Positive Breast Cancer and Brain Metastases", "status": "COMPLETED", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01495884", "title": "The Myocet/Lapatinib Study. ICORG 10-03, V5", "status": "TERMINATED", "last_update": "2015-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01499160", "title": "Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2022-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01526369", "title": "A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2025-05-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01534455", "title": "Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)", "status": "TERMINATED", "last_update": "2016-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01557764", "title": "Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-07-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01589861", "title": "Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2026-04-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01619111", "title": "DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01622868", "title": "Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01688609", "title": "Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2017-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01730677", "title": "Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab", "status": "UNKNOWN", "last_update": "2014-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01783756", "title": "Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis", "status": "COMPLETED", "last_update": "2019-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01808573", "title": "A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting", "status": "COMPLETED", "last_update": "2021-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01827163", "title": "Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2019-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01847599", "title": "Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib", "status": "TERMINATED", "last_update": "2017-07-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01868503", "title": "Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer", "status": "TERMINATED", "last_update": "2017-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01873833", "title": "Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2023-10-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01875666", "title": "Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib", "status": "COMPLETED", "last_update": "2020-09-04", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01891357", "title": "Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer", "status": "TERMINATED", "last_update": "2019-09-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01934894", "title": "Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases", "status": "TERMINATED", "last_update": "2017-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01973660", "title": "PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01985893", "title": "Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2016-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02073487", "title": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel", "status": "COMPLETED", "last_update": "2021-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02131506", "title": "A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer", "status": "TERMINATED", "last_update": "2016-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02158507", "title": "Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213042", "title": "Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02238509", "title": "Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies", "status": "UNKNOWN", "last_update": "2016-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02294786", "title": "Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2019-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02362958", "title": "A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02394496", "title": "Overcoming Endocrine Resistance in Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2016-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02422199", "title": "A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab", "status": "UNKNOWN", "last_update": "2018-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02650752", "title": "Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases", "status": "COMPLETED", "last_update": "2021-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02768415", "title": "Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer", "status": "UNKNOWN", "last_update": "2019-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03075995", "title": "To Discuss the Best Mode for Taking Lapatinib Under the Influence of the Diet", "status": "UNKNOWN", "last_update": "2017-04-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03080805", "title": "Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)", "status": "UNKNOWN", "last_update": "2020-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03084939", "title": "Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03262935", "title": "SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-10-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03273595", "title": "Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2017-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03500380", "title": "A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases", "status": "UNKNOWN", "last_update": "2024-02-20", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03523585", "title": "DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04185649", "title": "The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-12-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07152782", "title": "T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB DITOSYLATE": { "n": 184, "n_observational": 16, "n_active": 5, "n_withdrawn": 9, "trials": [ { "nct": "NCT06313983", "title": "A Phase \u2162 Study of Hemay022 in Combination With AI In Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00062686", "title": "GW572016 For Treatment Of Refractory Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00073528", "title": "Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00075270", "title": "Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00078572", "title": "Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2010-12-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085020", "title": "GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00089999", "title": "Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00098605", "title": "Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases", "status": "COMPLETED", "last_update": "2013-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00105950", "title": "Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer", "status": "COMPLETED", "last_update": "2015-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00111787", "title": "Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer", "status": "COMPLETED", "last_update": "2017-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00118157", "title": "Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen", "status": "COMPLETED", "last_update": "2017-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00148902", "title": "Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)", "status": "COMPLETED", "last_update": "2017-12-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00169533", "title": "Rollover Study Of Lapatinib In Cancer Patients", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00206427", "title": "Neoadjuvant GW572016 to Treat Breast Cancer", "status": "COMPLETED", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00225758", "title": "Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy", "status": "TERMINATED", "last_update": "2018-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00251433", "title": "GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2023-03-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00258050", "title": "To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients", "status": "COMPLETED", "last_update": "2017-12-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00263588", "title": "Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2019-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00272987", "title": "ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib", "status": "TERMINATED", "last_update": "2023-04-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281658", "title": "Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2", "status": "COMPLETED", "last_update": "2023-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00299286", "title": "Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer", "status": "COMPLETED", "last_update": "2012-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00316407", "title": "Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients", "status": "COMPLETED", "last_update": "2011-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00316875", "title": "Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00320385", "title": "Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00320411", "title": "GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2019-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00331630", "title": "Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer", "status": "COMPLETED", "last_update": "2020-03-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00343759", "title": "Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy", "status": "WITHDRAWN", "last_update": "2015-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00347919", "title": "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00356811", "title": "Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00359190", "title": "Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00371488", "title": "GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00374322", "title": "Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer", "status": "COMPLETED", "last_update": "2014-08-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00379509", "title": "Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-03-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00388076", "title": "Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00390455", "title": "Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive", "status": "COMPLETED", "last_update": "2019-12-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00404066", "title": "Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer", "status": "COMPLETED", "last_update": "2017-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00422903", "title": "Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer", "status": "COMPLETED", "last_update": "2016-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00424164", "title": "Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00437073", "title": "Brain Metastases In ErbB2-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2015-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00444535", "title": "Lapatinib and Bevacizumab for Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00450892", "title": "Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00455039", "title": "INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients", "status": "WITHDRAWN", "last_update": "2023-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00462956", "title": "GW572016 In Patients With Advanced Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00470704", "title": "Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00470847", "title": "Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2014-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00477464", "title": "Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00479856", "title": "Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer", "status": "TERMINATED", "last_update": "2012-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00482391", "title": "Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer", "status": "COMPLETED", "last_update": "2017-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00486668", "title": "A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer", "status": "UNKNOWN", "last_update": "2016-06-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00496366", "title": "Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer", "status": "TERMINATED", "last_update": "2017-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00499681", "title": "PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE", "status": "TERMINATED", "last_update": "2012-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00508274", "title": "Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China", "status": "TERMINATED", "last_update": "2021-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00513058", "title": "Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00524303", "title": "Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.", "status": "COMPLETED", "last_update": "2016-11-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00544804", "title": "Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00548184", "title": "Lapatinib and Trastuzumab With or Without Endocrine Therapy", "status": "COMPLETED", "last_update": "2019-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553358", "title": "Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study", "status": "COMPLETED", "last_update": "2021-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00555152", "title": "Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ", "status": "COMPLETED", "last_update": "2018-04-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00558103", "title": "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer", "status": "COMPLETED", "last_update": "2013-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00567554", "title": "Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer", "status": "COMPLETED", "last_update": "2016-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00614978", "title": "Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2012-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00632489", "title": "LBH589 in Combination With Capecitabine Plus/Minus (\u00b1) Lapatinib in Breast Cancer Patients", "status": "COMPLETED", "last_update": "2015-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00634088", "title": "Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2016-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00650910", "title": "Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00657137", "title": "APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)", "status": "TERMINATED", "last_update": "2012-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00667251", "title": "Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2025-03-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00684983", "title": "Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer", "status": "COMPLETED", "last_update": "2020-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00688194", "title": "Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy", "status": "UNKNOWN", "last_update": "2013-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00694252", "title": "Lapatinib and Circulating Tumor Cells in Breast Cancer", "status": "COMPLETED", "last_update": "2015-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00706030", "title": "Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00709618", "title": "Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects", "status": "TERMINATED", "last_update": "2014-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00709761", "title": "Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC", "status": "COMPLETED", "last_update": "2019-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00721630", "title": "Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00741260", "title": "Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00753207", "title": "Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30", "status": "COMPLETED", "last_update": "2016-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00754702", "title": "Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2015-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00756470", "title": "Phase II Neoadjuvant in Inflammatory Breast Cancer", "status": "TERMINATED", "last_update": "2014-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00759642", "title": "Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy", "status": "TERMINATED", "last_update": "2019-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00769470", "title": "Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2016-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00770809", "title": "Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00777101", "title": "Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00790816", "title": "Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents", "status": "COMPLETED", "last_update": "2018-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00807859", "title": "Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2022-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820222", "title": "Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2019-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820872", "title": "Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2019-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820924", "title": "Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells", "status": "TERMINATED", "last_update": "2012-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00821054", "title": "A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00826267", "title": "6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab", "status": "COMPLETED", "last_update": "2013-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00829166", "title": "A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00841828", "title": "Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients", "status": "COMPLETED", "last_update": "2023-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00842998", "title": "Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer", "status": "UNKNOWN", "last_update": "2009-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00849329", "title": "A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00857714", "title": "Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast", "status": "TERMINATED", "last_update": "2015-07-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00903656", "title": "Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy", "status": "TERMINATED", "last_update": "2013-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00912275", "title": "Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2019-05-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00952692", "title": "Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00963547", "title": "A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)", "status": "TERMINATED", "last_update": "2024-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00967031", "title": "Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases", "status": "COMPLETED", "last_update": "2013-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968968", "title": "Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone", "status": "TERMINATED", "last_update": "2019-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00996762", "title": "A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00999804", "title": "Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01005641", "title": "ELBA: Exemestane and Lapatinib in Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2012-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01013740", "title": "Lapatinib in Combination With Vinorelbine", "status": "COMPLETED", "last_update": "2017-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01044485", "title": "Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2012-09-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01050322", "title": "Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.", "status": "COMPLETED", "last_update": "2013-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01068704", "title": "Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01104571", "title": "Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer", "status": "UNKNOWN", "last_update": "2018-09-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01118975", "title": "GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers", "status": "TERMINATED", "last_update": "2019-11-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01128543", "title": "Lapatinib in Combination With Vinorelbine", "status": "COMPLETED", "last_update": "2012-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01133912", "title": "Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb\u00ae) (PGT)", "status": "COMPLETED", "last_update": "2012-01-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01137994", "title": "A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01138046", "title": "Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC", "status": "COMPLETED", "last_update": "2014-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01138384", "title": "Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01160211", "title": "A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2025-03-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01161368", "title": "A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients", "status": "TERMINATED", "last_update": "2015-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01199367", "title": "Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01205217", "title": "Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer", "status": "WITHDRAWN", "last_update": "2017-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01218529", "title": "Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors", "status": "COMPLETED", "last_update": "2014-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01238029", "title": "Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2014-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01245205", "title": "Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer", "status": "COMPLETED", "last_update": "2014-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01262469", "title": "Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.", "status": "COMPLETED", "last_update": "2014-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01272141", "title": "A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2014-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01273610", "title": "Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01275859", "title": "Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01281163", "title": "Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2015-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01283789", "title": "Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2017-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01290354", "title": "Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01300962", "title": "Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-12-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01309607", "title": "Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb\u00ae) in Patients With ErbB2-Positive Stage I-III Breast Cancer", "status": "UNKNOWN", "last_update": "2014-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01361945", "title": "AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2017-05-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01419197", "title": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy", "status": "COMPLETED", "last_update": "2016-10-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01426880", "title": "Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer", "status": "COMPLETED", "last_update": "2016-02-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01434303", "title": "Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only", "status": "COMPLETED", "last_update": "2019-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01471847", "title": "A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01477060", "title": "Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2014-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01479179", "title": "Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab", "status": "WITHDRAWN", "last_update": "2016-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01485926", "title": "A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.", "status": "COMPLETED", "last_update": "2018-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01494662", "title": "HKI-272 for HER2-Positive Breast Cancer and Brain Metastases", "status": "COMPLETED", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01495884", "title": "The Myocet/Lapatinib Study. ICORG 10-03, V5", "status": "TERMINATED", "last_update": "2015-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01499160", "title": "Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2022-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01526369", "title": "A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2025-05-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01534455", "title": "Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)", "status": "TERMINATED", "last_update": "2016-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01557764", "title": "Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-07-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01589861", "title": "Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2026-04-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01619111", "title": "DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01622868", "title": "Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01688609", "title": "Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2017-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01730677", "title": "Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab", "status": "UNKNOWN", "last_update": "2014-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01783756", "title": "Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis", "status": "COMPLETED", "last_update": "2019-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01808573", "title": "A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting", "status": "COMPLETED", "last_update": "2021-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01827163", "title": "Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2019-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01847599", "title": "Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib", "status": "TERMINATED", "last_update": "2017-07-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01868503", "title": "Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer", "status": "TERMINATED", "last_update": "2017-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01873833", "title": "Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2023-10-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01875666", "title": "Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib", "status": "COMPLETED", "last_update": "2020-09-04", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01891357", "title": "Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer", "status": "TERMINATED", "last_update": "2019-09-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01934894", "title": "Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases", "status": "TERMINATED", "last_update": "2017-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01973660", "title": "PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01985893", "title": "Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2016-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02073487", "title": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel", "status": "COMPLETED", "last_update": "2021-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02131506", "title": "A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer", "status": "TERMINATED", "last_update": "2016-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02158507", "title": "Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213042", "title": "Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02238509", "title": "Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies", "status": "UNKNOWN", "last_update": "2016-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02294786", "title": "Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2019-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02362958", "title": "A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02394496", "title": "Overcoming Endocrine Resistance in Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2016-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02422199", "title": "A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab", "status": "UNKNOWN", "last_update": "2018-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02650752", "title": "Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases", "status": "COMPLETED", "last_update": "2021-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02768415", "title": "Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer", "status": "UNKNOWN", "last_update": "2019-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03075995", "title": "To Discuss the Best Mode for Taking Lapatinib Under the Influence of the Diet", "status": "UNKNOWN", "last_update": "2017-04-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03080805", "title": "Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)", "status": "UNKNOWN", "last_update": "2020-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03084939", "title": "Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03085368", "title": "A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin", "status": "UNKNOWN", "last_update": "2017-07-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03262935", "title": "SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-10-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03273595", "title": "Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2017-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03500380", "title": "A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases", "status": "UNKNOWN", "last_update": "2024-02-20", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03523585", "title": "DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04185649", "title": "The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-12-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07152782", "title": "T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LASOFOXIFENE": { "n": 4, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05696626", "title": "Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03781063", "title": "Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432454", "title": "Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation", "status": "COMPLETED", "last_update": "2025-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LEVONORGESTREL": { "n": 0, "n_observational": 2, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "LONAPRISAN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00555919", "title": "ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LY-2780301": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01980277", "title": "Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-04-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MARGETUXIMAB": { "n": 9, "n_observational": 1, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01148849", "title": "Safety Study of MGAH22 in HER2-positive Carcinomas", "status": "COMPLETED", "last_update": "2025-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01828021", "title": "Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02492711", "title": "Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03219268", "title": "A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms", "status": "COMPLETED", "last_update": "2023-12-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04262804", "title": "A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC", "status": "UNKNOWN", "last_update": "2023-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398108", "title": "A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC", "status": "COMPLETED", "last_update": "2021-06-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04425018", "title": "MARGetuximab Or Trastuzumab (MARGOT)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05227131", "title": "Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MEDROXYPROGESTERONE": { "n": 4, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00002920", "title": "S9630, Medroxyprogesterone in Treating Women With Breast Cancer", "status": "COMPLETED", "last_update": "2012-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00026286", "title": "Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00577122", "title": "Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01698164", "title": "Multi-centre Clinical Trial on Hormone Replacement Treatment in China", "status": "UNKNOWN", "last_update": "2012-10-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" } ] }, "MEGESTROL": { "n": 9, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT07543536", "title": "Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002465", "title": "High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma", "status": "UNKNOWN", "last_update": "2013-11-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002680", "title": "Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005975", "title": "S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer", "status": "COMPLETED", "last_update": "2015-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01237327", "title": "Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2011-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02269670", "title": "Phase II Study of Everolimus Beyond Progression", "status": "TERMINATED", "last_update": "2022-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03024580", "title": "A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03306472", "title": "A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer", "status": "COMPLETED", "last_update": "2024-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07254416", "title": "A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" } ] }, "MIFEPRISTONE": { "n": 11, "n_observational": 1, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT06099769", "title": "A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00579475", "title": "The Effect of Mifepristone on Uterine Fibroids and Breast Tissue", "status": "COMPLETED", "last_update": "2015-05-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01138553", "title": "Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer", "status": "TERMINATED", "last_update": "2019-07-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01493310", "title": "Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01898312", "title": "BRCA1/2 and Effect of Mifepristone on the Breast", "status": "COMPLETED", "last_update": "2022-01-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02014337", "title": "Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors", "status": "COMPLETED", "last_update": "2018-01-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02046421", "title": "Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer", "status": "COMPLETED", "last_update": "2018-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02651844", "title": "Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.", "status": "COMPLETED", "last_update": "2022-05-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02788981", "title": "Abraxane\u00ae With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03225547", "title": "Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05016349", "title": "Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "MIRANSERTIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02476955", "title": "Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole", "status": "TERMINATED", "last_update": "2020-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MK-2206": { "n": 14, "n_observational": 0, "n_active": 1, "n_withdrawn": 3, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00963547", "title": "A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)", "status": "TERMINATED", "last_update": "2024-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01240928", "title": "MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01240941", "title": "Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01245205", "title": "Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer", "status": "COMPLETED", "last_update": "2014-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01263145", "title": "MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01277757", "title": "Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2018-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01281163", "title": "Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2015-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01295632", "title": "Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)", "status": "COMPLETED", "last_update": "2015-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01319539", "title": "MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer", "status": "TERMINATED", "last_update": "2017-08-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01344031", "title": "MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01714128", "title": "FES-PET for Patients Treated on NCI Protocol 8762", "status": "WITHDRAWN", "last_update": "2021-10-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01776008", "title": "Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer", "status": "TERMINATED", "last_update": "2018-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MM-111": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00911898", "title": "A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers", "status": "COMPLETED", "last_update": "2015-01-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01097460", "title": "MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer", "status": "COMPLETED", "last_update": "2015-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MUBRITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00034281", "title": "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2", "status": "COMPLETED", "last_update": "2012-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NERATINIB": { "n": 52, "n_observational": 7, "n_active": 18, "n_withdrawn": 2, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04886531", "title": "Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04965064", "title": "Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05388149", "title": "Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease", "status": "RECRUITING", "last_update": "2025-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564377", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05760612", "title": "Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab", "status": "RECRUITING", "last_update": "2025-09-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05919108", "title": "Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05933395", "title": "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008275", "title": "Neratinib in Combination With Ruxolitinib in Patients With mTNBC", "status": "RECRUITING", "last_update": "2025-11-10", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06643585", "title": "A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse", "status": "RECRUITING", "last_update": "2025-05-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06892093", "title": "Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00146172", "title": "Study Evaluating HKI-272 in Tumors", "status": "COMPLETED", "last_update": "2018-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00300781", "title": "Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00366600", "title": "Study Evaluating HKI-272 Administered to Healthy Subjects", "status": "COMPLETED", "last_update": "2017-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00398567", "title": "A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2018-07-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00445458", "title": "A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer", "status": "COMPLETED", "last_update": "2018-07-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00706030", "title": "Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00708903", "title": "Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)", "status": "COMPLETED", "last_update": "2012-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00741260", "title": "Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00777101", "title": "Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00878709", "title": "Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2021-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00915018", "title": "Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2018-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01008150", "title": "Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2021-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01111825", "title": "Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01423123", "title": "Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2014-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01494662", "title": "HKI-272 for HER2-Positive Breast Cancer and Brain Metastases", "status": "COMPLETED", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01670877", "title": "Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer", "status": "COMPLETED", "last_update": "2022-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01808573", "title": "A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting", "status": "COMPLETED", "last_update": "2021-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953926", "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations", "status": "TERMINATED", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02236000", "title": "A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-01-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02400476", "title": "An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide", "status": "COMPLETED", "last_update": "2022-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02673398", "title": "Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03094052", "title": "Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib", "status": "COMPLETED", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03101748", "title": "Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2026-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03182634", "title": "The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial", "status": "UNKNOWN", "last_update": "2019-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289039", "title": "Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03377387", "title": "Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03812393", "title": "Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast", "status": "UNKNOWN", "last_update": "2023-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04366713", "title": "A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib", "status": "COMPLETED", "last_update": "2023-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460430", "title": "Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2022-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04760431", "title": "TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)", "status": "UNKNOWN", "last_update": "2021-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04856475", "title": "Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04901299", "title": "Fulvestrant + Neratinib In Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05154396", "title": "Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer", "status": "UNKNOWN", "last_update": "2021-12-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05243641", "title": "Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test", "status": "TERMINATED", "last_update": "2025-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05252988", "title": "Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06015113", "title": "Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2023-08-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07152782", "title": "T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07333937", "title": "Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07729046", "title": "Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NORETHINDRONE": { "n": 1, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003771", "title": "Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2013-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "NORGESTREL": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02922127", "title": "Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "OMIPALISIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ONAPRISTONE": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT02052128", "title": "Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers", "status": "UNKNOWN", "last_update": "2015-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04142892", "title": "Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer", "status": "COMPLETED", "last_update": "2022-04-01", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04738292", "title": "Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)", "status": "TERMINATED", "last_update": "2024-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04872608", "title": "A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05618613", "title": "Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-07-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06938711", "title": "A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2025-04-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PALBOCICLIB": { "n": 152, "n_observational": 48, "n_active": 71, "n_withdrawn": 5, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802759", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04819243", "title": "PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study", "status": "RECRUITING", "last_update": "2025-01-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04841148", "title": "Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925856", "title": "Immunomonitoring of Breast Cancer Patients During Systemic Treatment", "status": "RECRUITING", "last_update": "2023-10-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05190094", "title": "Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.", "status": "RECRUITING", "last_update": "2025-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05683418", "title": "A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05696626", "title": "Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05766410", "title": "A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC", "status": "RECRUITING", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05953350", "title": "A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i", "status": "RECRUITING", "last_update": "2024-12-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06044623", "title": "Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients", "status": "RECRUITING", "last_update": "2024-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06176534", "title": "Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase \u2161 Clinical Trial", "status": "RECRUITING", "last_update": "2024-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06207734", "title": "Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer", "status": "RECRUITING", "last_update": "2025-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06377852", "title": "The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06380751", "title": "Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06486883", "title": "Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06757634", "title": "Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06856200", "title": "A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06997029", "title": "A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07180160", "title": "Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07491380", "title": "Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07492641", "title": "BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07558733", "title": "Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00721409", "title": "Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2019-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01037790", "title": "Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer", "status": "COMPLETED", "last_update": "2021-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602887", "title": "Relative Bioavailability Study", "status": "COMPLETED", "last_update": "2012-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01709370", "title": "Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women", "status": "UNKNOWN", "last_update": "2013-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01723774", "title": "PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01740427", "title": "A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)", "status": "COMPLETED", "last_update": "2024-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01823835", "title": "A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "status": "TERMINATED", "last_update": "2021-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01942135", "title": "Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01976169", "title": "Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02040857", "title": "Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02296801", "title": "A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer", "status": "COMPLETED", "last_update": "2022-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02297438", "title": "A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]", "status": "COMPLETED", "last_update": "2026-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02389842", "title": "PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib", "status": "COMPLETED", "last_update": "2024-09-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02448420", "title": "Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02448771", "title": "A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer", "status": "COMPLETED", "last_update": "2022-10-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02499146", "title": "Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530424", "title": "\"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment \"", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02549430", "title": "To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy", "status": "COMPLETED", "last_update": "2017-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02592083", "title": "Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2020-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02592746", "title": "A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC", "status": "UNKNOWN", "last_update": "2019-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02603679", "title": "Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2021-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02605486", "title": "Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02624973", "title": "PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02626507", "title": "Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer", "status": "UNKNOWN", "last_update": "2022-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02630693", "title": "Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02690480", "title": "Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02692755", "title": "Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer", "status": "COMPLETED", "last_update": "2021-09-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02738866", "title": "Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02764541", "title": "Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02871791", "title": "Palbociclib With Everolimus + Exemestane In BC", "status": "COMPLETED", "last_update": "2022-08-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02894398", "title": "Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02907918", "title": "Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer", "status": "TERMINATED", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02913430", "title": "Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib", "status": "COMPLETED", "last_update": "2024-09-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03054363", "title": "Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03065621", "title": "Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)", "status": "COMPLETED", "last_update": "2023-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03079011", "title": "PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03147287", "title": "Palbociclib After CDK and Endocrine Therapy (PACE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03184090", "title": "Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC", "status": "COMPLETED", "last_update": "2022-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03220178", "title": "Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy", "status": "TERMINATED", "last_update": "2022-01-06", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03227328", "title": "CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03284957", "title": "Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03304080", "title": "Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03322215", "title": "HR+/HER2- Advanced Breast Cancer and Endocrine Resistance", "status": "TERMINATED", "last_update": "2024-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03332797", "title": "A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03355157", "title": "A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03401359", "title": "The Resistance and Immune Response to Palbociclib in Breast Cancer", "status": "UNKNOWN", "last_update": "2018-01-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03425838", "title": "Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03439735", "title": "Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03447132", "title": "Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03455270", "title": "G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2022-12-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03530696", "title": "T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer", "status": "COMPLETED", "last_update": "2024-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03535506", "title": "Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery", "status": "TERMINATED", "last_update": "2025-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03560531", "title": "A Study of ZN-c5 in Subjects With Breast Cancer", "status": "COMPLETED", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03560856", "title": "A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2018-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03573648", "title": "Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03609047", "title": "Adjuvant Palbociclib in Elderly Patients With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03616587", "title": "Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03628066", "title": "Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer", "status": "COMPLETED", "last_update": "2022-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03633331", "title": "Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03644186", "title": "To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)", "status": "COMPLETED", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685331", "title": "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03774472", "title": "Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809988", "title": "PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)", "status": "COMPLETED", "last_update": "2023-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854903", "title": "WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor", "status": "COMPLETED", "last_update": "2025-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03900884", "title": "Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04047758", "title": "Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer", "status": "UNKNOWN", "last_update": "2021-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04060862", "title": "A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04072952", "title": "A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE\u00ae) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04130152", "title": "Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy", "status": "COMPLETED", "last_update": "2022-10-25", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04137640", "title": "Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy", "status": "UNKNOWN", "last_update": "2021-07-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04191499", "title": "A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04216576", "title": "A Study of the Use of Text Message Reminders to Take Palbociclib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04220476", "title": "CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer", "status": "WITHDRAWN", "last_update": "2020-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224272", "title": "A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04288089", "title": "A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04318223", "title": "Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy", "status": "UNKNOWN", "last_update": "2020-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334330", "title": "Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China", "status": "UNKNOWN", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04436744", "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)", "status": "COMPLETED", "last_update": "2023-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04478266", "title": "Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2025-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04483505", "title": "Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.", "status": "COMPLETED", "last_update": "2023-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04494958", "title": "Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04546009", "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04553133", "title": "PF-07104091 as a Single Agent and in Combination Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04567420", "title": "DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585724", "title": "Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases", "status": "WITHDRAWN", "last_update": "2021-10-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04653740", "title": "Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04708860", "title": "Feasibility of Fasting & Exercise in Pts With HR+ MBC", "status": "COMPLETED", "last_update": "2024-08-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04818632", "title": "AZD9833 China PK Study", "status": "COMPLETED", "last_update": "2024-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04856371", "title": "Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04858516", "title": "Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2021-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04858997", "title": "Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients", "status": "UNKNOWN", "last_update": "2021-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862663", "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04872608", "title": "A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04946864", "title": "A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer", "status": "SUSPENDED", "last_update": "2024-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964934", "title": "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05067530", "title": "Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study", "status": "NOT_YET_RECRUITING", "last_update": "2021-10-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05076695", "title": "Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05207709", "title": "Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype", "status": "TERMINATED", "last_update": "2026-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05226871", "title": "Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05277935", "title": "Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib", "status": "UNKNOWN", "last_update": "2024-08-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05293964", "title": "Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05384119", "title": "Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-02-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429684", "title": "Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-06-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05501886", "title": "Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05563220", "title": "Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05655598", "title": "TAS-116 Plus Palbociclib in Breast and Rb-null Cancer", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05670054", "title": "Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients", "status": "UNKNOWN", "last_update": "2023-01-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05949424", "title": "OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults", "status": "UNKNOWN", "last_update": "2023-11-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06757335", "title": "A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760637", "title": "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06810492", "title": "The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06941142", "title": "A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07061717", "title": "Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130643", "title": "Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07300215", "title": "An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07487129", "title": "Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt", "status": "COMPLETED", "last_update": "2026-03-23", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07683754", "title": "T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07687225", "title": "Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07717450", "title": "Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07748208", "title": "A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07802626", "title": "Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "PERTUZUMAB": { "n": 180, "n_observational": 20, "n_active": 99, "n_withdrawn": 9, "trials": [ { "nct": "NCT04281641", "title": "Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2020-05-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04329065", "title": "Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04547907", "title": "A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2024-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04680442", "title": "Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction", "status": "RECRUITING", "last_update": "2025-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04750122", "title": "Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients", "status": "RECRUITING", "last_update": "2021-04-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802759", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04993014", "title": "Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2021-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020860", "title": "Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer", "status": "RECRUITING", "last_update": "2025-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05159193", "title": "Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2024-02-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05256745", "title": "RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05292742", "title": "Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2022-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05325632", "title": "Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab", "status": "RECRUITING", "last_update": "2026-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05420467", "title": "A Study for the Adjuvant Treatment of Breast Cancer", "status": "RECRUITING", "last_update": "2022-07-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582499", "title": "Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05760612", "title": "Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab", "status": "RECRUITING", "last_update": "2025-09-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05838066", "title": "Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.", "status": "RECRUITING", "last_update": "2025-05-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05891561", "title": "Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2024-11-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05900206", "title": "Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06162559", "title": "Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study", "status": "RECRUITING", "last_update": "2024-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06278870", "title": "Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial", "status": "RECRUITING", "last_update": "2024-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06414733", "title": "HER-2 B Cell Peptide Vaccine", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06439693", "title": "The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06441890", "title": "BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06927180", "title": "SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC", "status": "RECRUITING", "last_update": "2025-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06949410", "title": "HER2 Vaccine for Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07003074", "title": "A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07043725", "title": "A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07053085", "title": "A Study of Surgery and Radiotherapy in People With Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07057427", "title": "Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07095023", "title": "Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07220135", "title": "Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07294508", "title": "A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07335081", "title": "ctDNA in HER2+ EBC Neoadjuvant Treatment", "status": "RECRUITING", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340398", "title": "Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07393425", "title": "Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07441460", "title": "A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07600164", "title": "Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07612215", "title": "Elacestrant in Advanced Triple Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07616427", "title": "Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07695259", "title": "Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00301899", "title": "Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab", "status": "COMPLETED", "last_update": "2012-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00545688", "title": "A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.", "status": "COMPLETED", "last_update": "2017-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00943670", "title": "Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression", "status": "COMPLETED", "last_update": "2013-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00976989", "title": "A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01026142", "title": "A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)", "status": "COMPLETED", "last_update": "2018-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01048099", "title": "Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-01-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01276041", "title": "Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01376505", "title": "Vaccine Therapy in Treating Patients With Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01501487", "title": "MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I", "status": "COMPLETED", "last_update": "2018-06-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01565083", "title": "A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2016-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01583426", "title": "Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)", "status": "COMPLETED", "last_update": "2020-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597414", "title": "Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1", "status": "COMPLETED", "last_update": "2022-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01669239", "title": "Study of Neoadjuvant Myocet\u00ae, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01835236", "title": "Trastuzumab & Pertuzumab Followed by T-DM1 in MBC", "status": "COMPLETED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01875666", "title": "Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib", "status": "COMPLETED", "last_update": "2020-09-04", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01937117", "title": "Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01959490", "title": "Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer", "status": "COMPLETED", "last_update": "2019-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01996410", "title": "The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients", "status": "TERMINATED", "last_update": "2016-11-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02000596", "title": "1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.", "status": "TERMINATED", "last_update": "2022-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02019277", "title": "A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02073487", "title": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel", "status": "COMPLETED", "last_update": "2021-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02131064", "title": "A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2019-07-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02132949", "title": "A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer", "status": "COMPLETED", "last_update": "2021-09-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02139358", "title": "Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2021-02-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02336984", "title": "A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS", "status": "WITHDRAWN", "last_update": "2021-01-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02344472", "title": "Detect V / CHEVENDO (Chemo vs. Endo)", "status": "UNKNOWN", "last_update": "2024-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02390427", "title": "Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02402712", "title": "Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2019-09-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02445586", "title": "Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer", "status": "COMPLETED", "last_update": "2019-10-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530424", "title": "\"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment \"", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02586025", "title": "Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel", "status": "COMPLETED", "last_update": "2023-05-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02598427", "title": "Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer", "status": "TERMINATED", "last_update": "2018-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02624973", "title": "PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625441", "title": "Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02682693", "title": "Denosumab as an add-on Neoadjuvant Treatment (GeparX)", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02738970", "title": "A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)", "status": "COMPLETED", "last_update": "2018-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02789657", "title": "Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.", "status": "COMPLETED", "last_update": "2022-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02896855", "title": "A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02909751", "title": "Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer", "status": "COMPLETED", "last_update": "2021-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02993198", "title": "A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging", "status": "UNKNOWN", "last_update": "2024-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03058939", "title": "Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer", "status": "WITHDRAWN", "last_update": "2019-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03112590", "title": "Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-04-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03199885", "title": "Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03238495", "title": "Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer", "status": "UNKNOWN", "last_update": "2021-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03264547", "title": "A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab", "status": "COMPLETED", "last_update": "2025-09-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03304080", "title": "Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03329378", "title": "Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer", "status": "TERMINATED", "last_update": "2023-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03387553", "title": "HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer", "status": "COMPLETED", "last_update": "2026-05-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03414658", "title": "The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03460067", "title": "Omission of Radiation in Patients With Her-2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03619044", "title": "The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-\u03b1 Status in Patients With Metastatic Breast Cancer HER2 + and ER\u03b1 Neg Treated With Trastuzumab + Pertuzumab + Taxane.", "status": "TERMINATED", "last_update": "2022-02-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03644186", "title": "To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)", "status": "COMPLETED", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03716180", "title": "DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03726879", "title": "A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03747120", "title": "Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811418", "title": "A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2019-11-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03964142", "title": "Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity", "status": "COMPLETED", "last_update": "2023-05-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04001829", "title": "Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04094896", "title": "TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2019-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04188548", "title": "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04193059", "title": "Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04197687", "title": "TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery", "status": "UNKNOWN", "last_update": "2023-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04208178", "title": "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04215003", "title": "A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC", "status": "UNKNOWN", "last_update": "2024-06-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04246502", "title": "Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04249622", "title": "Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer", "status": "TERMINATED", "last_update": "2025-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04266249", "title": "CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04301375", "title": "Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2020-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04351230", "title": "T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398914", "title": "Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419181", "title": "Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04425018", "title": "MARGetuximab Or Trastuzumab (MARGOT)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04514419", "title": "Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04538742", "title": "A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04569747", "title": "A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04578106", "title": "Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy", "status": "TERMINATED", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04588545", "title": "Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04629846", "title": "Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.", "status": "COMPLETED", "last_update": "2024-04-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665986", "title": "Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2020-12-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04675827", "title": "De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade", "status": "TERMINATED", "last_update": "2024-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04760431", "title": "TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)", "status": "UNKNOWN", "last_update": "2021-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04784715", "title": "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04858529", "title": "Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)", "status": "UNKNOWN", "last_update": "2023-11-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04900311", "title": "Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-05-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04957212", "title": "Comparing Efficacy and Safety Between Pertuzumab\u00ae and Perjeta\u00ae in Neoadjuvant Treatment of HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05041842", "title": "Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05113251", "title": "Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05132582", "title": "A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05180006", "title": "Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy", "status": "TERMINATED", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05255523", "title": "Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2022-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05296798", "title": "A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05323955", "title": "Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05346224", "title": "A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta\u00ae in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05353361", "title": "A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer", "status": "UNKNOWN", "last_update": "2023-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05385705", "title": "A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020", "status": "TERMINATED", "last_update": "2025-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05426486", "title": "A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429684", "title": "Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-06-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05474690", "title": "A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2024-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05574881", "title": "Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05656079", "title": "To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study", "status": "UNKNOWN", "last_update": "2022-12-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05721248", "title": "STOP-HER2: Stopping Trastuzumab in HER2+ MBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05744375", "title": "Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab", "status": "TERMINATED", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05802225", "title": "Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta\u00ae as Neoadjuvant Therapy of HER2-Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05954143", "title": "Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05985187", "title": "Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta\u00ae Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.", "status": "UNKNOWN", "last_update": "2023-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06038539", "title": "Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta\u00ae Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy na\u00efve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer", "status": "TERMINATED", "last_update": "2026-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06057610", "title": "A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06068985", "title": "Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06080620", "title": "The Choice of Treatment Methods and Efficacy of LABC", "status": "UNKNOWN", "last_update": "2023-10-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06136897", "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06435104", "title": "Aromatherapy in the Treatment of Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06510465", "title": "Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06548178", "title": "T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06578299", "title": "Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06884254", "title": "Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta\u00ae (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.", "status": "WITHDRAWN", "last_update": "2025-10-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06907082", "title": "Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma\u00ae) in Early HER2-positive Breast Cancer in Routine Clinical Practice", "status": "COMPLETED", "last_update": "2025-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06973525", "title": "This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07093931", "title": "Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07116824", "title": "HB1801 Combined Treatment of HER2-positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07136974", "title": "Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07150767", "title": "A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2025-12-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07187752", "title": "Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07239271", "title": "A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07245797", "title": "A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07246317", "title": "Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07386938", "title": "A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta\u00ae in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07528898", "title": "Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07533526", "title": "Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07565324", "title": "Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07578116", "title": "Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07589972", "title": "Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07679269", "title": "Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07683754", "title": "T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07687225", "title": "Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07748260", "title": "De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07772245", "title": "Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PF-04691502": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01430585", "title": "Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer", "status": "TERMINATED", "last_update": "2014-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01658176", "title": "Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2012-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PICTILISIB": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00928330", "title": "Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00960960", "title": "A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-12-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01437566", "title": "Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01740336", "title": "A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01918306", "title": "GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2017-06-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02389842", "title": "PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib", "status": "COMPLETED", "last_update": "2024-09-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PILARALISIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00704392", "title": "Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors", "status": "WITHDRAWN", "last_update": "2015-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01042925", "title": "Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen", "status": "COMPLETED", "last_update": "2016-06-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01082068", "title": "Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer", "status": "COMPLETED", "last_update": "2016-06-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "POLYESTRADIOL": { "n": 189, "n_observational": 11, "n_active": 71, "n_withdrawn": 5, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04263298", "title": "Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2022-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05181033", "title": "Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05307705", "title": "A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467891", "title": "Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05524584", "title": "Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05573126", "title": "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05594095", "title": "SNF Platform Study of HR+/ HER2-advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05601440", "title": "Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05608252", "title": "VS-6766+Abema+Fulv in Met HR+/HER- BC", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05683418", "title": "A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05816655", "title": "Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05933395", "title": "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor", "status": "RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06202261", "title": "A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2024-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06607757", "title": "Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06726148", "title": "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06756932", "title": "BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06954961", "title": "A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06982521", "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998407", "title": "ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024173", "title": "A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07062965", "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07117630", "title": "An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07207070", "title": "A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07405801", "title": "A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07498478", "title": "Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07540572", "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07558733", "title": "Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07604571", "title": "Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07666555", "title": "A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003066", "title": "Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2014-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012025", "title": "ICI 182780 in Treating Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00057941", "title": "Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00065325", "title": "The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2015-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00075764", "title": "S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00099437", "title": "Comparison of Fulvestrant (FASLODEX\u2122) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00146601", "title": "Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2007-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193726", "title": "Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer", "status": "TERMINATED", "last_update": "2018-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00206414", "title": "Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer", "status": "TERMINATED", "last_update": "2013-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00253422", "title": "Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors", "status": "COMPLETED", "last_update": "2025-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00256698", "title": "Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy", "status": "COMPLETED", "last_update": "2012-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313170", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg", "status": "COMPLETED", "last_update": "2020-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00324259", "title": "Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00327769", "title": "Faslodex Advanced Breast Cancer Local Chinese Study", "status": "COMPLETED", "last_update": "2011-01-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00357110", "title": "Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2010-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372996", "title": "Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2015-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00423917", "title": "Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00522262", "title": "Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial", "status": "COMPLETED", "last_update": "2015-01-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00570258", "title": "Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy", "status": "TERMINATED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00629616", "title": "Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer", "status": "COMPLETED", "last_update": "2021-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00661531", "title": "Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy", "status": "TERMINATED", "last_update": "2017-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00698035", "title": "Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients", "status": "COMPLETED", "last_update": "2014-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00728949", "title": "A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer", "status": "COMPLETED", "last_update": "2018-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00871858", "title": "Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01142401", "title": "Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01219699", "title": "A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene", "status": "COMPLETED", "last_update": "2020-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01296555", "title": "A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01344031", "title": "MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01528345", "title": "Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer", "status": "TERMINATED", "last_update": "2016-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01560416", "title": "Fulvestrant With or Without Ganetespib in HR+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597193", "title": "Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer", "status": "COMPLETED", "last_update": "2019-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597388", "title": "AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602380", "title": "A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01797120", "title": "Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI", "status": "COMPLETED", "last_update": "2018-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01923298", "title": "Estradiol Levels in Patients Treated With Estring", "status": "COMPLETED", "last_update": "2022-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01942135", "title": "Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01984138", "title": "REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02107703", "title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02115594", "title": "Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer", "status": "WITHDRAWN", "last_update": "2014-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02137083", "title": "A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02188745", "title": "ER Reactivation Therapy for Breast Cancer", "status": "COMPLETED", "last_update": "2024-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02206984", "title": "Endocrine Response in Women With Invasive Lobular Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02238808", "title": "A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02291913", "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02447328", "title": "A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex\u00ae ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-09-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02455453", "title": "Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography", "status": "COMPLETED", "last_update": "2020-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530411", "title": "Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer", "status": "UNKNOWN", "last_update": "2015-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530424", "title": "\"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment \"", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02540330", "title": "A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant", "status": "TERMINATED", "last_update": "2024-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632045", "title": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02690480", "title": "Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02694809", "title": "The PROMISE Study: Duavee in Women With DCIS", "status": "COMPLETED", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02729701", "title": "Pilot Study of the Effect of Duavee\u00ae on Benign Breast Tissue Proliferation", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756364", "title": "Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02792465", "title": "A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02894398", "title": "Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02913430", "title": "Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib", "status": "COMPLETED", "last_update": "2024-09-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02922127", "title": "Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02953860", "title": "Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2021-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02955394", "title": "Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02958852", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02964507", "title": "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983071", "title": "G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-02-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983604", "title": "GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer", "status": "TERMINATED", "last_update": "2019-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03056755", "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments", "status": "COMPLETED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03134638", "title": "A Study of SY-1365 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2021-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03147287", "title": "Palbociclib After CDK and Endocrine Therapy (PACE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03179904", "title": "TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03202862", "title": "The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2017-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280563", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289039", "title": "Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03355157", "title": "A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386162", "title": "SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03442504", "title": "Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03447132", "title": "Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03481998", "title": "A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544762", "title": "Correlation of 16\u03b1-[18F]Fluoro-17\u03b2-estradiol PET Imaging With ESR1 Mutation", "status": "UNKNOWN", "last_update": "2019-05-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03554044", "title": "T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03555877", "title": "Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03633331", "title": "Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685331", "title": "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03772353", "title": "Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2023-03-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03778931", "title": "Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809988", "title": "PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)", "status": "COMPLETED", "last_update": "2023-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854903", "title": "WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor", "status": "COMPLETED", "last_update": "2025-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03873428", "title": "Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES", "status": "UNKNOWN", "last_update": "2024-02-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04024436", "title": "A Study of TAS-120 in Patients With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04031885", "title": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-08-24", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04033172", "title": "Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )", "status": "UNKNOWN", "last_update": "2019-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04034589", "title": "Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive\uff0cHR-Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2020-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04053322", "title": "Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224272", "title": "A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04247126", "title": "A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305236", "title": "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer", "status": "TERMINATED", "last_update": "2023-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334330", "title": "Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China", "status": "UNKNOWN", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379024", "title": "Pilot Study of Effects of Duavee\u00ae on Imaging and Blood Biomarkers In Women With Menopausal Symptoms", "status": "TERMINATED", "last_update": "2021-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04524000", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04544189", "title": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04567420", "title": "DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04726332", "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)", "status": "TERMINATED", "last_update": "2024-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04738292", "title": "Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)", "status": "TERMINATED", "last_update": "2024-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762979", "title": "Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796623", "title": "A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821375", "title": "Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers", "status": "COMPLETED", "last_update": "2025-10-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04856371", "title": "Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862663", "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04901299", "title": "Fulvestrant + Neratinib In Breast Cancer", "status": "WITHDRAWN", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04975308", "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05047848", "title": "Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-09-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05054374", "title": "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05075512", "title": "The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05076695", "title": "Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05191004", "title": "Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC", "status": "WITHDRAWN", "last_update": "2023-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05251714", "title": "CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05252416", "title": "(VELA) Study of BLU-222 in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05328440", "title": "Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)", "status": "UNKNOWN", "last_update": "2023-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05392608", "title": "SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05411380", "title": "Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.", "status": "UNKNOWN", "last_update": "2022-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05433480", "title": "A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554354", "title": "Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)", "status": "TERMINATED", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05574881", "title": "Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05625087", "title": "Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05654623", "title": "A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05792410", "title": "A Phase \u2160b/\u2161 Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.", "status": "UNKNOWN", "last_update": "2023-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806047", "title": "Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806671", "title": "Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05870579", "title": "[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05905341", "title": "Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.", "status": "WITHDRAWN", "last_update": "2023-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05932667", "title": "Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2023-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05966584", "title": "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer", "status": "TERMINATED", "last_update": "2024-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05986071", "title": "I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047184", "title": "Phase I Study of BEBT-209 in Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06074757", "title": "Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06375707", "title": "First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06506955", "title": "Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561022", "title": "Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping", "status": "UNKNOWN", "last_update": "2024-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06635447", "title": "Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680921", "title": "A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764186", "title": "A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06941142", "title": "A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957379", "title": "Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07038369", "title": "A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340619", "title": "Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07393321", "title": "A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07408089", "title": "Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07679269", "title": "Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07729046", "title": "Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07748208", "title": "A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07767474", "title": "A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07784036", "title": "JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07802626", "title": "Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "POZIOTINIB": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02418689", "title": "Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens", "status": "COMPLETED", "last_update": "2022-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02544997", "title": "A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway", "status": "COMPLETED", "last_update": "2020-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02659514", "title": "Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2022-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03429101", "title": "A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2021-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03744715", "title": "A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib", "status": "TERMINATED", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04172597", "title": "A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies", "status": "TERMINATED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PROGESTERONE": { "n": 142, "n_observational": 27, "n_active": 16, "n_withdrawn": 7, "trials": [ { "nct": "NCT04965766", "title": "Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05989347", "title": "Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06974604", "title": "Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM", "status": "RECRUITING", "last_update": "2025-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07062965", "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340541", "title": "Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002920", "title": "S9630, Medroxyprogesterone in Treating Women With Breast Cancer", "status": "COMPLETED", "last_update": "2012-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003953", "title": "Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer", "status": "COMPLETED", "last_update": "2013-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003992", "title": "Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2", "status": "COMPLETED", "last_update": "2013-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005822", "title": "SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer", "status": "COMPLETED", "last_update": "2010-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00022516", "title": "Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer", "status": "COMPLETED", "last_update": "2016-09-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00026286", "title": "Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00026962", "title": "Effects of Raloxifene on Hormone Levels", "status": "COMPLETED", "last_update": "2008-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00046371", "title": "Safety and Immunological Response Rate Study of THERATOPE\u00ae Vaccine in Metastatic Breast Cancer Patients", "status": "COMPLETED", "last_update": "2008-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00050011", "title": "Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy", "status": "COMPLETED", "last_update": "2014-03-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00050141", "title": "Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2013-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00053339", "title": "Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer", "status": "WITHDRAWN", "last_update": "2016-07-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00066703", "title": "Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer", "status": "COMPLETED", "last_update": "2026-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00068601", "title": "S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer", "status": "COMPLETED", "last_update": "2019-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00070564", "title": "S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00072293", "title": "Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases", "status": "COMPLETED", "last_update": "2018-01-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00073528", "title": "Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00077025", "title": "Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00077168", "title": "Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole", "status": "UNKNOWN", "last_update": "2009-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00079248", "title": "Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer", "status": "UNKNOWN", "last_update": "2009-05-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00084396", "title": "Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer", "status": "COMPLETED", "last_update": "2016-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00123669", "title": "Primary Progesterone Therapy for Operable Breast Cancer", "status": "COMPLETED", "last_update": "2020-07-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00134680", "title": "Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC", "status": "COMPLETED", "last_update": "2014-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00171340", "title": "Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.", "status": "COMPLETED", "last_update": "2012-04-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00210028", "title": "Study Assessing Efficacy of ZARNESTRA\u2122 Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2006-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00229697", "title": "Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study", "status": "COMPLETED", "last_update": "2015-10-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00232505", "title": "Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00252811", "title": "A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer", "status": "WITHDRAWN", "last_update": "2011-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00255463", "title": "Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study", "status": "COMPLETED", "last_update": "2009-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00303615", "title": "Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2008-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00305825", "title": "Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery", "status": "COMPLETED", "last_update": "2017-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00338728", "title": "Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2020-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00365599", "title": "Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2014-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00371345", "title": "Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer", "status": "COMPLETED", "last_update": "2011-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00417885", "title": "A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer", "status": "TERMINATED", "last_update": "2010-09-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00424203", "title": "Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery", "status": "COMPLETED", "last_update": "2013-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00427245", "title": "Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer", "status": "COMPLETED", "last_update": "2013-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00433589", "title": "Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes", "status": "COMPLETED", "last_update": "2022-11-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00446030", "title": "Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer", "status": "COMPLETED", "last_update": "2012-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00463489", "title": "Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00463788", "title": "Cetuximab and Cisplatin in the Treatment of \"Triple Negative\" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00468715", "title": "Bicalutamide in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2022-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00479674", "title": "Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00499083", "title": "Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)", "status": "COMPLETED", "last_update": "2023-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00541086", "title": "Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery", "status": "UNKNOWN", "last_update": "2020-02-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00556374", "title": "Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy", "status": "COMPLETED", "last_update": "2023-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00573755", "title": "Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2016-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00577122", "title": "Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00580112", "title": "An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2014-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00580333", "title": "Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2021-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00608972", "title": "Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00674557", "title": "Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2013-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00680667", "title": "Clinical Trial of Trametes Versicolor in Women With Breast Cancer", "status": "COMPLETED", "last_update": "2017-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00687648", "title": "Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2009-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00755885", "title": "Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-01-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00759642", "title": "Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy", "status": "TERMINATED", "last_update": "2019-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00834678", "title": "Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer", "status": "COMPLETED", "last_update": "2018-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00847366", "title": "Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma", "status": "COMPLETED", "last_update": "2018-03-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00856492", "title": "S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2017-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00870168", "title": "Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2011-05-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00871858", "title": "Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00892268", "title": "Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain", "status": "TERMINATED", "last_update": "2010-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00893061", "title": "Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00912548", "title": "Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women", "status": "UNKNOWN", "last_update": "2009-06-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00925548", "title": "STRIDE - STimulating Immune Response In aDvanced brEast Cancer", "status": "TERMINATED", "last_update": "2014-07-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00963417", "title": "Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02", "status": "COMPLETED", "last_update": "2025-07-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968409", "title": "Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)", "status": "COMPLETED", "last_update": "2015-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00975676", "title": "Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02", "status": "COMPLETED", "last_update": "2021-10-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00999804", "title": "Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01004744", "title": "Pre-Surgical Intervention for Targeted Therapies for Breast Cancer", "status": "COMPLETED", "last_update": "2021-01-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01013506", "title": "Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01016665", "title": "Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy", "status": "COMPLETED", "last_update": "2009-11-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01093235", "title": "Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2010-03-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01101438", "title": "A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2023-09-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01105312", "title": "Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-06-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01124695", "title": "Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01138553", "title": "Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer", "status": "TERMINATED", "last_update": "2019-07-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01147016", "title": "Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery", "status": "TERMINATED", "last_update": "2023-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01147484", "title": "A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01151046", "title": "Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer", "status": "COMPLETED", "last_update": "2016-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01160718", "title": "Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy", "status": "COMPLETED", "last_update": "2019-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01207102", "title": "Study Of Abraxane\u00ae And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2014-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01216176", "title": "A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer", "status": "COMPLETED", "last_update": "2025-01-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01272141", "title": "A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2014-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01293032", "title": "Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01320787", "title": "18-F-Fluoroacetate as PET Imaging Agent", "status": "WITHDRAWN", "last_update": "2014-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01349322", "title": "Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01385137", "title": "S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy", "status": "COMPLETED", "last_update": "2017-04-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01515800", "title": "S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer", "status": "COMPLETED", "last_update": "2018-03-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01535066", "title": "S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer", "status": "COMPLETED", "last_update": "2022-12-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01547741", "title": "Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01573442", "title": "Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment", "status": "COMPLETED", "last_update": "2025-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01598298", "title": "S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy", "status": "COMPLETED", "last_update": "2022-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01608451", "title": "Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2022-05-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01612910", "title": "Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery", "status": "WITHDRAWN", "last_update": "2014-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01674140", "title": "S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01698164", "title": "Multi-centre Clinical Trial on Hormone Replacement Treatment in China", "status": "UNKNOWN", "last_update": "2012-10-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01800422", "title": "Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer", "status": "UNKNOWN", "last_update": "2020-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01831076", "title": "Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors", "status": "COMPLETED", "last_update": "2022-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01881230", "title": "Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)", "status": "COMPLETED", "last_update": "2019-02-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01898312", "title": "BRCA1/2 and Effect of Mifepristone on the Breast", "status": "COMPLETED", "last_update": "2022-01-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01997333", "title": "Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2019-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02007512", "title": "Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02052128", "title": "Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers", "status": "UNKNOWN", "last_update": "2015-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02132000", "title": "Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients", "status": "UNKNOWN", "last_update": "2014-05-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02137837", "title": "S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer", "status": "TERMINATED", "last_update": "2021-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02158507", "title": "Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02244580", "title": "Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit \"MammaTyperTM\"", "status": "COMPLETED", "last_update": "2016-11-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02353988", "title": "AR-inhibitor Bicalutamide in Treating Patients With TNBC", "status": "UNKNOWN", "last_update": "2015-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02408770", "title": "Breast Cancer - Anti-Progestin Prevention Study 1", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02515110", "title": "Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02651844", "title": "Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.", "status": "COMPLETED", "last_update": "2022-05-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02654119", "title": "Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery", "status": "COMPLETED", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02734290", "title": "Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02779855", "title": "Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03078751", "title": "Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer", "status": "COMPLETED", "last_update": "2021-10-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03081234", "title": "Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer", "status": "WITHDRAWN", "last_update": "2018-03-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03137693", "title": "Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer", "status": "TERMINATED", "last_update": "2023-02-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212170", "title": "FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer", "status": "COMPLETED", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03219476", "title": "Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03306472", "title": "A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer", "status": "COMPLETED", "last_update": "2024-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03519178", "title": "A Study of PF-06873600 in People With Cancer", "status": "TERMINATED", "last_update": "2025-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809988", "title": "PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)", "status": "COMPLETED", "last_update": "2023-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03875313", "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2022-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03906669", "title": "A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.", "status": "UNKNOWN", "last_update": "2023-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04052555", "title": "Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152057", "title": "Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2019-11-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04296942", "title": "BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)", "status": "TERMINATED", "last_update": "2022-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04420598", "title": "DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease", "status": "COMPLETED", "last_update": "2025-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04629846", "title": "Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.", "status": "COMPLETED", "last_update": "2024-04-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895358", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069038", "title": "Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05177432", "title": "Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05560685", "title": "SMART-ER: Symptom Monitoring With Patient-reported Outcomes", "status": "TERMINATED", "last_update": "2025-08-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05618613", "title": "Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2026-07-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760637", "title": "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06938711", "title": "A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2025-04-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PYROTINIB": { "n": 151, "n_observational": 29, "n_active": 74, "n_withdrawn": 0, "trials": [ { "nct": "NCT04254263", "title": "Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04481932", "title": "Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2020-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04646759", "title": "Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2020-11-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04983121", "title": "Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients", "status": "RECRUITING", "last_update": "2022-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05228951", "title": "Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC", "status": "RECRUITING", "last_update": "2022-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05292742", "title": "Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2022-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05575804", "title": "GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582499", "title": "Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05635487", "title": "A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients", "status": "RECRUITING", "last_update": "2024-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05638594", "title": "Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer", "status": "RECRUITING", "last_update": "2023-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05769010", "title": "Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases", "status": "RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05834764", "title": "Pyrotinib in Women With High-risk in Early Stage Breast Cancer", "status": "RECRUITING", "last_update": "2023-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05861271", "title": "Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer", "status": "RECRUITING", "last_update": "2024-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05910398", "title": "Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06000917", "title": "A Study of Neoadjuvant TCHpy\uff08Pyrotinib \uff0cTrastuzumab\uff0cCarboplatin and Paclitaxel\uff09for ER+/HER2+ Breast Cancer", "status": "RECRUITING", "last_update": "2023-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06001086", "title": "A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2023-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06035679", "title": "Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06217185", "title": "The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).", "status": "RECRUITING", "last_update": "2024-02-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06234137", "title": "A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2024-01-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06254690", "title": "The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study", "status": "RECRUITING", "last_update": "2024-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06278870", "title": "Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial", "status": "RECRUITING", "last_update": "2024-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06641544", "title": "The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2024-10-15", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06718933", "title": "Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis", "status": "RECRUITING", "last_update": "2025-02-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06770296", "title": "The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study", "status": "RECRUITING", "last_update": "2025-01-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06832904", "title": "Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)", "status": "RECRUITING", "last_update": "2025-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06958627", "title": "The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study", "status": "RECRUITING", "last_update": "2025-05-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07014410", "title": "Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07065435", "title": "RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study", "status": "RECRUITING", "last_update": "2025-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07180082", "title": "Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07335081", "title": "ctDNA in HER2+ EBC Neoadjuvant Treatment", "status": "RECRUITING", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340398", "title": "Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07393425", "title": "Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07528716", "title": "Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07600164", "title": "Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07610720", "title": "Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07615751", "title": "Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07616453", "title": "Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07635342", "title": "Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07708194", "title": "Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07797218", "title": "Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01937689", "title": "Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2018-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02361112", "title": "Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2018-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02422199", "title": "A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab", "status": "UNKNOWN", "last_update": "2018-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02500199", "title": "Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors", "status": "UNKNOWN", "last_update": "2021-02-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02973737", "title": "A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2022-10-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03080805", "title": "Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)", "status": "UNKNOWN", "last_update": "2020-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03412383", "title": "Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer", "status": "UNKNOWN", "last_update": "2018-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03588091", "title": "Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2025-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03691051", "title": "A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735966", "title": "Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.", "status": "COMPLETED", "last_update": "2022-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03756064", "title": "Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2019-08-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03772353", "title": "Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2023-03-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03805399", "title": "FUSCC Refractory TNBC Umbrella (FUTURE)", "status": "UNKNOWN", "last_update": "2022-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03847818", "title": "Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2019-03-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03863223", "title": "A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2022-11-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03876587", "title": "Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC", "status": "UNKNOWN", "last_update": "2019-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03910712", "title": "Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC", "status": "UNKNOWN", "last_update": "2019-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03919253", "title": "Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study", "status": "UNKNOWN", "last_update": "2019-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03923166", "title": "Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03923179", "title": "Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03933982", "title": "A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2019-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03947242", "title": "Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.", "status": "UNKNOWN", "last_update": "2019-05-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03980054", "title": "A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03993964", "title": "Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03997539", "title": "A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2019-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04001621", "title": "Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-12-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04033172", "title": "Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )", "status": "UNKNOWN", "last_update": "2019-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04034589", "title": "Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive\uff0cHR-Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2020-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04066790", "title": "Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer", "status": "TERMINATED", "last_update": "2020-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04088110", "title": "Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer", "status": "UNKNOWN", "last_update": "2019-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04095390", "title": "A Phase \u2161 Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2019-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04126525", "title": "Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152057", "title": "Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2019-11-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04158856", "title": "Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2019-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04236310", "title": "A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.", "status": "UNKNOWN", "last_update": "2020-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04246502", "title": "Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04255056", "title": "Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab", "status": "UNKNOWN", "last_update": "2020-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04290793", "title": "Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04293276", "title": "Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2023-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334330", "title": "Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China", "status": "UNKNOWN", "last_update": "2022-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04355858", "title": "Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04367090", "title": "Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-09-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04395989", "title": "An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.", "status": "UNKNOWN", "last_update": "2023-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398914", "title": "Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04407988", "title": "Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04486911", "title": "Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04582968", "title": "Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases", "status": "UNKNOWN", "last_update": "2023-01-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04605575", "title": "Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2022-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639271", "title": "Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis", "status": "UNKNOWN", "last_update": "2020-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659499", "title": "Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2020-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04681911", "title": "Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2020-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04717531", "title": "Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer", "status": "UNKNOWN", "last_update": "2021-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04736589", "title": "Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway", "status": "NOT_YET_RECRUITING", "last_update": "2021-02-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04760431", "title": "TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)", "status": "UNKNOWN", "last_update": "2021-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04858516", "title": "Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2021-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04872985", "title": "Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04900311", "title": "Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-05-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04903652", "title": "Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2022-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04917900", "title": "Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04929548", "title": "Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP", "status": "NOT_YET_RECRUITING", "last_update": "2022-01-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04963595", "title": "Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04973319", "title": "Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2021-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04997798", "title": "Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020964", "title": "Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib", "status": "UNKNOWN", "last_update": "2021-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05042791", "title": "A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases", "status": "UNKNOWN", "last_update": "2024-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05076695", "title": "Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2021-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05165225", "title": "Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05252546", "title": "Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects", "status": "COMPLETED", "last_update": "2022-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05255523", "title": "Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2022-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05328440", "title": "Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)", "status": "UNKNOWN", "last_update": "2023-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05346861", "title": "Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab", "status": "UNKNOWN", "last_update": "2022-04-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05353361", "title": "A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer", "status": "UNKNOWN", "last_update": "2023-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05357417", "title": "Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases", "status": "UNKNOWN", "last_update": "2022-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05424835", "title": "A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05426486", "title": "A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429294", "title": "Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038", "status": "UNKNOWN", "last_update": "2022-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429684", "title": "Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-06-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05430347", "title": "Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05444998", "title": "Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer", "status": "COMPLETED", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05560308", "title": "Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy", "status": "UNKNOWN", "last_update": "2022-10-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05577442", "title": "Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05577923", "title": "Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)", "status": "UNKNOWN", "last_update": "2022-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05621434", "title": "A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2022-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05659056", "title": "Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer", "status": "UNKNOWN", "last_update": "2024-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05800756", "title": "Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer", "status": "UNKNOWN", "last_update": "2023-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05806671", "title": "Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05823623", "title": "Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05841381", "title": "Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-05-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05880927", "title": "Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer", "status": "UNKNOWN", "last_update": "2023-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06015113", "title": "Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2023-08-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06144944", "title": "Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06152822", "title": "Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases", "status": "UNKNOWN", "last_update": "2023-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06245824", "title": "Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-07", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06362096", "title": "A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2024-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475443", "title": "Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06483386", "title": "Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06495541", "title": "The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06718335", "title": "Pyrotinib in HER2-positive Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06973525", "title": "This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06975475", "title": "SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07019337", "title": "Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07132242", "title": "SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07179939", "title": "Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07189884", "title": "Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07239271", "title": "A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07290166", "title": "A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07307287", "title": "SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07417241", "title": "SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07589699", "title": "Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07766772", "title": "Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07787338", "title": "SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "RALOXIFENE": { "n": 12, "n_observational": 4, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003906", "title": "Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women", "status": "COMPLETED", "last_update": "2015-10-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00019500", "title": "Raloxifene in Preventing Breast Cancer in Premenopausal Women", "status": "COMPLETED", "last_update": "2013-06-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00026962", "title": "Effects of Raloxifene on Hormone Levels", "status": "COMPLETED", "last_update": "2008-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031811", "title": "Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer", "status": "COMPLETED", "last_update": "2012-05-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031850", "title": "Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer", "status": "COMPLETED", "last_update": "2013-06-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00190593", "title": "Raloxifene Use for The Heart", "status": "COMPLETED", "last_update": "2007-01-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00200174", "title": "Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease", "status": "COMPLETED", "last_update": "2023-07-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00687102", "title": "Cognition in the Study of Tamoxifen and Raloxifene", "status": "COMPLETED", "last_update": "2018-09-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00723398", "title": "Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention", "status": "COMPLETED", "last_update": "2018-11-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02188745", "title": "ER Reactivation Therapy for Breast Cancer", "status": "COMPLETED", "last_update": "2024-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02517593", "title": "Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake", "status": "COMPLETED", "last_update": "2020-12-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06062810", "title": "Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "RIBOCICLIB": { "n": 144, "n_observational": 45, "n_active": 94, "n_withdrawn": 5, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04025541", "title": "Analysis of Circulating Tumor Markers in Blood", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802759", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925856", "title": "Immunomonitoring of Breast Cancer Patients During Systemic Treatment", "status": "RECRUITING", "last_update": "2023-10-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05216432", "title": "First-in-Human Study of Mutant-selective PI3K\u03b1 Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05452213", "title": "Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients", "status": "RECRUITING", "last_update": "2023-04-18", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467891", "title": "Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05508906", "title": "Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2025-10-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05683418", "title": "A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05696626", "title": "Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05766410", "title": "A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC", "status": "RECRUITING", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05816655", "title": "Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05827081", "title": "Phase IIIb Study of Ribociclib + ET in Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05900206", "title": "Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05977036", "title": "BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05996107", "title": "Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06044623", "title": "Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients", "status": "RECRUITING", "last_update": "2024-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06062498", "title": "Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06065748", "title": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06188520", "title": "A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06197581", "title": "Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer", "status": "RECRUITING", "last_update": "2024-08-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06377852", "title": "The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06380751", "title": "Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06409390", "title": "Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06486883", "title": "Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06656624", "title": "Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)", "status": "RECRUITING", "last_update": "2024-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06726148", "title": "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06757634", "title": "Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06953882", "title": "Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07002177", "title": "A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07037199", "title": "Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07054190", "title": "A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07085767", "title": "Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07164976", "title": "Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07174336", "title": "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07180160", "title": "Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07195227", "title": "Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07214532", "title": "Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07237256", "title": "Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07242352", "title": "Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07380646", "title": "the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07391774", "title": "Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07400523", "title": "Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy", "status": "RECRUITING", "last_update": "2026-04-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07405801", "title": "A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07491380", "title": "Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07492641", "title": "BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07647328", "title": "A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07708571", "title": "Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy Management", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01857193", "title": "Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2021-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01872260", "title": "Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01919229", "title": "A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)", "status": "TERMINATED", "last_update": "2016-01-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01958021", "title": "Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-03-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02035813", "title": "DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02088684", "title": "Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02154776", "title": "Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02187783", "title": "LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)", "status": "COMPLETED", "last_update": "2019-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02278120", "title": "Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2024-03-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02333370", "title": "A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02344472", "title": "Detect V / CHEVENDO (Chemo vs. Endo)", "status": "UNKNOWN", "last_update": "2024-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02422615", "title": "Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.", "status": "COMPLETED", "last_update": "2023-11-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02586675", "title": "TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer", "status": "COMPLETED", "last_update": "2022-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02599363", "title": "A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02608216", "title": "[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632045", "title": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657343", "title": "An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.", "status": "COMPLETED", "last_update": "2022-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02712723", "title": "Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02732119", "title": "Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.", "status": "COMPLETED", "last_update": "2021-05-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02734615", "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers", "status": "TERMINATED", "last_update": "2022-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02754011", "title": "Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative", "status": "COMPLETED", "last_update": "2023-12-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02941926", "title": "Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC", "status": "COMPLETED", "last_update": "2023-10-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050398", "title": "A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib", "status": "TERMINATED", "last_update": "2020-05-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03078751", "title": "Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer", "status": "COMPLETED", "last_update": "2021-10-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03081234", "title": "Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer", "status": "WITHDRAWN", "last_update": "2018-03-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03090165", "title": "Ribociclib and Bicalutamide in AR+ TNBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03096847", "title": "Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2021-10-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03227328", "title": "CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03248427", "title": "Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.", "status": "COMPLETED", "last_update": "2021-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03283384", "title": "Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03285412", "title": "CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03294694", "title": "Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer", "status": "TERMINATED", "last_update": "2025-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03425838", "title": "Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03439046", "title": "Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant", "status": "TERMINATED", "last_update": "2026-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03462251", "title": "Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line", "status": "COMPLETED", "last_update": "2023-01-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03477396", "title": "Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03555877", "title": "Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03616587", "title": "Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03671330", "title": "Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.", "status": "COMPLETED", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03701334", "title": "A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03822468", "title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03839823", "title": "Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03905343", "title": "Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC", "status": "TERMINATED", "last_update": "2021-06-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03913234", "title": "Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients", "status": "UNKNOWN", "last_update": "2022-05-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944434", "title": "FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04055493", "title": "Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04256941", "title": "Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study", "status": "TERMINATED", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04315233", "title": "Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics", "status": "TERMINATED", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585724", "title": "Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases", "status": "WITHDRAWN", "last_update": "2021-10-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04657679", "title": "Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts", "status": "TERMINATED", "last_update": "2024-11-26", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862663", "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04920708", "title": "Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964934", "title": "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05161195", "title": "Roll-over Study to Allow Continued Access to Ribociclib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05163106", "title": "Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole", "status": "COMPLETED", "last_update": "2024-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05207709", "title": "Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype", "status": "TERMINATED", "last_update": "2026-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05244434", "title": "Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-06-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05252416", "title": "(VELA) Study of BLU-222 in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05296746", "title": "Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05319873", "title": "Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05384119", "title": "Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-02-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05529862", "title": "Trans-RosaLEE Study: a Biomarker-directed, Translational Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05563220", "title": "Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05573555", "title": "TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05625087", "title": "Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05664893", "title": "Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)", "status": "WITHDRAWN", "last_update": "2026-04-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05670054", "title": "Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients", "status": "UNKNOWN", "last_update": "2023-01-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05759949", "title": "First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors", "status": "COMPLETED", "last_update": "2025-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05870579", "title": "[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06239467", "title": "First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06375707", "title": "First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06481956", "title": "T-DM1 Combined With CDK4/6 Inhibitor Ribociclib", "status": "ENROLLING_BY_INVITATION", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585969", "title": "A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760637", "title": "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06810492", "title": "The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06849947", "title": "Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06996093", "title": "Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07005557", "title": "Chemo-free in Older (\u226565) Node-Positive ER+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130643", "title": "Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07173556", "title": "A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340658", "title": "A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara\u00ae (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07423611", "title": "ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07487129", "title": "Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt", "status": "COMPLETED", "last_update": "2026-03-23", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07527806", "title": "Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07618390", "title": "A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07630948", "title": "Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07706933", "title": "Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07717450", "title": "Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07767474", "title": "A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07782840", "title": "QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07802626", "title": "Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "SACITUZUMAB GOVITECAN": { "n": 81, "n_observational": 15, "n_active": 64, "n_withdrawn": 4, "trials": [ { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03606967", "title": "Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230109", "title": "Sacituzumab Govitecan In TNBC", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04434040", "title": "Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04468061", "title": "Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04986579", "title": "Scalp Cooling in MBC", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332561", "title": "Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05601440", "title": "Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05627960", "title": "First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2022-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633654", "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05770531", "title": "Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06081244", "title": "NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06102824", "title": "Organoid-based Functional Precision Therapy for Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06230055", "title": "Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06236269", "title": "HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan", "status": "RECRUITING", "last_update": "2024-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06238921", "title": "Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases", "status": "RECRUITING", "last_update": "2025-12-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06263543", "title": "Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06409390", "title": "Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06462092", "title": "Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer", "status": "RECRUITING", "last_update": "2025-09-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06616987", "title": "Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer", "status": "RECRUITING", "last_update": "2025-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06665178", "title": "Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06793332", "title": "BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC", "status": "RECRUITING", "last_update": "2025-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06827613", "title": "A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06878625", "title": "A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06889610", "title": "A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06926920", "title": "A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06963905", "title": "Saci Nivo Rela for TNBC", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07011654", "title": "Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07046455", "title": "Trop-2 Targeted PET Probes in Advanced TNBC", "status": "RECRUITING", "last_update": "2025-07-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07394218", "title": "ctDNA-guided Treatment Decision-making", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07461454", "title": "YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07471776", "title": "Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07533123", "title": "A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07657130", "title": "Optimal Application Timing of ADC Drugs for Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01631552", "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer", "status": "COMPLETED", "last_update": "2021-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02161679", "title": "Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer", "status": "WITHDRAWN", "last_update": "2021-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02574455", "title": "Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)", "status": "COMPLETED", "last_update": "2022-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03901339", "title": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03971409", "title": "Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03992131", "title": "A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)", "status": "TERMINATED", "last_update": "2024-01-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03995706", "title": "Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0", "status": "COMPLETED", "last_update": "2024-09-04", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04039230", "title": "Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04143711", "title": "Study of DF1001 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04448886", "title": "Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04454437", "title": "Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04595565", "title": "Sacituzumab Govitecan in Primary HER2-negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639986", "title": "Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04647916", "title": "Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04927884", "title": "A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies", "status": "TERMINATED", "last_update": "2024-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04958785", "title": "Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05008510", "title": "P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .", "status": "WITHDRAWN", "last_update": "2022-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05101096", "title": "Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05113966", "title": "Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05143229", "title": "Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05382286", "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05382299", "title": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05520723", "title": "Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05552001", "title": "Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05675579", "title": "A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05708144", "title": "NIR Fluorescent Molecular Probe for the Identification of Breast Tissue", "status": "COMPLETED", "last_update": "2024-01-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05774886", "title": "Implantable Microdevice for TNBC - Pilot Study", "status": "WITHDRAWN", "last_update": "2023-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05840211", "title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06100874", "title": "A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06328387", "title": "HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06462079", "title": "Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06612203", "title": "Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07040644", "title": "A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07134556", "title": "Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC", "status": "WITHDRAWN", "last_update": "2026-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07151586", "title": "Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07163481", "title": "A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07178730", "title": "NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07271992", "title": "TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07299409", "title": "First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07359404", "title": "Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07367178", "title": "Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07368543", "title": "Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07371910", "title": "Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07788222", "title": "Sacituzumab Govitecan and Q901 in Advanced TNBC", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SAPITINIB": { "n": 5, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00900627", "title": "Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)", "status": "COMPLETED", "last_update": "2016-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01003158", "title": "Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.", "status": "COMPLETED", "last_update": "2014-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01151215", "title": "Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer", "status": "TERMINATED", "last_update": "2014-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01596530", "title": "Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment", "status": "TERMINATED", "last_update": "2012-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02299999", "title": "SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SERABELISIB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07558733", "title": "Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03193853", "title": "TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2023-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04073680", "title": "A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2020-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SIREMADLIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02890069", "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat", "status": "COMPLETED", "last_update": "2023-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TAMOXIFEN": { "n": 163, "n_observational": 37, "n_active": 38, "n_withdrawn": 3, "trials": [ { "nct": "NCT03011684", "title": "Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04666961", "title": "Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ", "status": "RECRUITING", "last_update": "2022-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04852887", "title": "De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05035836", "title": "A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467891", "title": "Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05501704", "title": "ETHAN - ET for Male BC", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05512364", "title": "Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05861271", "title": "Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer", "status": "RECRUITING", "last_update": "2024-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05894239", "title": "A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941520", "title": "Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06218303", "title": "Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06369285", "title": "A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06434064", "title": "Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06507618", "title": "Pre-Operative Window of ET to Inform RT Decisions (POWER II)", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06837792", "title": "Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07071038", "title": "Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients", "status": "RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07671885", "title": "Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002460", "title": "Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer", "status": "UNKNOWN", "last_update": "2013-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002580", "title": "Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer", "status": "COMPLETED", "last_update": "2013-11-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002581", "title": "Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer", "status": "COMPLETED", "last_update": "2013-11-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002720", "title": "Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer", "status": "COMPLETED", "last_update": "2013-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002967", "title": "Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer", "status": "COMPLETED", "last_update": "2013-06-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003016", "title": "Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer", "status": "UNKNOWN", "last_update": "2009-02-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003035", "title": "Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2011-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003140", "title": "Letrozole After Tamoxifen in Treating Women With Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003199", "title": "Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer", "status": "COMPLETED", "last_update": "2017-07-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003418", "title": "Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer", "status": "UNKNOWN", "last_update": "2013-12-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003679", "title": "Combination Chemotherapy in Treating Women With Breast Cancer", "status": "UNKNOWN", "last_update": "2013-11-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003972", "title": "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer", "status": "COMPLETED", "last_update": "2010-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005908", "title": "Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer", "status": "COMPLETED", "last_update": "2013-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005970", "title": "Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2020-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00010140", "title": "Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer", "status": "UNKNOWN", "last_update": "2013-12-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00010322", "title": "Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2014-03-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00016276", "title": "Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer", "status": "TERMINATED", "last_update": "2013-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031720", "title": "Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease", "status": "COMPLETED", "last_update": "2016-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00040014", "title": "Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women", "status": "TERMINATED", "last_update": "2012-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00044291", "title": "Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2015-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00047099", "title": "Combination Chemotherapy in Treating Women With Breast Cancer", "status": "COMPLETED", "last_update": "2013-05-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00096369", "title": "Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer", "status": "TERMINATED", "last_update": "2019-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00097344", "title": "The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2007-08-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00107263", "title": "Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer", "status": "COMPLETED", "last_update": "2016-12-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00118157", "title": "Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen", "status": "COMPLETED", "last_update": "2017-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00152178", "title": "The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)", "status": "COMPLETED", "last_update": "2011-07-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00206492", "title": "Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients", "status": "TERMINATED", "last_update": "2017-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00210028", "title": "Study Assessing Efficacy of ZARNESTRA\u2122 Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2006-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00232661", "title": "PROACT - Pre-Operative Arimidex Compared To Tamoxifen", "status": "COMPLETED", "last_update": "2010-02-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00267553", "title": "Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2007-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00279448", "title": "Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2011-12-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00286117", "title": "ITA - Clinical Study Comparing ARIMIDEX\u2122 With NOLVADEX\u2122 in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years", "status": "COMPLETED", "last_update": "2009-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00287534", "title": "Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.", "status": "COMPLETED", "last_update": "2009-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00293540", "title": "Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer", "status": "COMPLETED", "last_update": "2016-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00309478", "title": "Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00365599", "title": "Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2014-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00382070", "title": "Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00412022", "title": "HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.", "status": "UNKNOWN", "last_update": "2023-03-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00499083", "title": "Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)", "status": "COMPLETED", "last_update": "2023-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00538330", "title": "Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer", "status": "UNKNOWN", "last_update": "2011-12-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00590785", "title": "Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)", "status": "COMPLETED", "last_update": "2017-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00629278", "title": "Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2013-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00632723", "title": "IRESSA\u2122 (Gefitinib) in Breast Cancer Patients", "status": "COMPLETED", "last_update": "2009-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00637871", "title": "Casodex - Nolvadex Combination", "status": "COMPLETED", "last_update": "2011-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00728949", "title": "A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer", "status": "COMPLETED", "last_update": "2018-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00784680", "title": "ATAC - Quality of Life Sub-Protocol", "status": "COMPLETED", "last_update": "2009-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00793377", "title": "Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer", "status": "COMPLETED", "last_update": "2008-11-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00808522", "title": "Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women", "status": "UNKNOWN", "last_update": "2008-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00827307", "title": "Zoladex Plus Tamoxifen in Breast Cancer", "status": "COMPLETED", "last_update": "2011-08-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00849030", "title": "ATAC - Arimidex, Tamoxifen Alone or in Combination", "status": "COMPLETED", "last_update": "2012-06-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00887380", "title": "STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)", "status": "UNKNOWN", "last_update": "2022-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00896155", "title": "Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients", "status": "UNKNOWN", "last_update": "2011-08-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00899288", "title": "Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98", "status": "TERMINATED", "last_update": "2012-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00903162", "title": "Extended Endocrine Therapy for Premenopausal Women With Breast Cancer", "status": "COMPLETED", "last_update": "2016-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00912548", "title": "Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women", "status": "UNKNOWN", "last_update": "2009-06-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00929591", "title": "SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer", "status": "COMPLETED", "last_update": "2013-01-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00949598", "title": "Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer", "status": "COMPLETED", "last_update": "2025-02-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00952731", "title": "4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ", "status": "COMPLETED", "last_update": "2015-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00963417", "title": "Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02", "status": "COMPLETED", "last_update": "2025-07-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00967824", "title": "Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer", "status": "COMPLETED", "last_update": "2011-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01027416", "title": "Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients", "status": "COMPLETED", "last_update": "2026-04-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01073865", "title": "Study to Compare Zoladex\u2122 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer", "status": "COMPLETED", "last_update": "2018-12-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01127295", "title": "Pharmacology of Adjuvant Hormonotherapy in Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01157026", "title": "A Pilot Clinical Trial With Tocotrienol on Breast Cancer", "status": "COMPLETED", "last_update": "2010-07-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01192308", "title": "PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)", "status": "COMPLETED", "last_update": "2020-12-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01196936", "title": "Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01220076", "title": "Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+", "status": "COMPLETED", "last_update": "2021-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01272037", "title": "Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01273168", "title": "Endoxifen in Adults With Hormone Receptor Positive Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01298713", "title": "Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer", "status": "COMPLETED", "last_update": "2023-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01357772", "title": "Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01419197", "title": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy", "status": "COMPLETED", "last_update": "2016-10-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01579734", "title": "Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users", "status": "UNKNOWN", "last_update": "2023-06-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01612728", "title": "Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01612871", "title": "Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01622361", "title": "Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2013-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01674140", "title": "S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01712893", "title": "Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer", "status": "COMPLETED", "last_update": "2017-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01950182", "title": "Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01973660", "title": "PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02040857", "title": "Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02089854", "title": "Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer", "status": "UNKNOWN", "last_update": "2016-12-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02188745", "title": "ER Reactivation Therapy for Breast Cancer", "status": "COMPLETED", "last_update": "2024-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02206984", "title": "Endocrine Response in Women With Invasive Lobular Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02278120", "title": "Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2024-03-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02285179", "title": "Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen", "status": "COMPLETED", "last_update": "2022-10-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02291913", "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02344550", "title": "Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2020-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02395627", "title": "Reversing Therapy Resistance With Epigenetic-Immune Modification", "status": "TERMINATED", "last_update": "2020-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02404844", "title": "Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer", "status": "COMPLETED", "last_update": "2018-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02488603", "title": "Decision Aids for Tamoxifen Treatment in Breast Cancer Patients", "status": "UNKNOWN", "last_update": "2015-07-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02506790", "title": "Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02517593", "title": "Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake", "status": "COMPLETED", "last_update": "2020-12-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02586675", "title": "TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer", "status": "COMPLETED", "last_update": "2022-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02592083", "title": "Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2020-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02603679", "title": "Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2021-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02624973", "title": "PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02734615", "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers", "status": "TERMINATED", "last_update": "2022-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02764541", "title": "Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02806544", "title": "Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country", "status": "COMPLETED", "last_update": "2017-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02913430", "title": "Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib", "status": "COMPLETED", "last_update": "2024-09-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02914158", "title": "Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women", "status": "UNKNOWN", "last_update": "2023-01-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02988986", "title": "TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer", "status": "COMPLETED", "last_update": "2021-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02993159", "title": "Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast", "status": "COMPLETED", "last_update": "2024-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02995772", "title": "Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients", "status": "COMPLETED", "last_update": "2019-06-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03045653", "title": "Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer", "status": "COMPLETED", "last_update": "2022-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03078751", "title": "Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer", "status": "COMPLETED", "last_update": "2021-10-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03137368", "title": "A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations \uff08STEP\uff09", "status": "UNKNOWN", "last_update": "2018-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03204734", "title": "Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2017-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03238703", "title": "Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer", "status": "WITHDRAWN", "last_update": "2018-12-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280563", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03346200", "title": "Low Dose Tamoxifen for Mammographic Density Reduction", "status": "COMPLETED", "last_update": "2025-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03351062", "title": "Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer", "status": "UNKNOWN", "last_update": "2017-11-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03355157", "title": "A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03554044", "title": "T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer", "status": "COMPLETED", "last_update": "2025-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03707340", "title": "A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03715413", "title": "Analgesic Efficacy of Pulsed Radiofrequency in Non-cyclic Mastalgia", "status": "COMPLETED", "last_update": "2019-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03750396", "title": "Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2019-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03879577", "title": "Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03906669", "title": "A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.", "status": "UNKNOWN", "last_update": "2023-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03948568", "title": "Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)", "status": "COMPLETED", "last_update": "2022-09-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03997539", "title": "A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2019-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04023292", "title": "Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer", "status": "UNKNOWN", "last_update": "2019-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04080297", "title": "Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen", "status": "COMPLETED", "last_update": "2020-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460430", "title": "Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2022-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04504331", "title": "Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2026-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04570956", "title": "Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk", "status": "TERMINATED", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05150652", "title": "Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05156606", "title": "Testosterone & Tamoxifen Trial", "status": "TERMINATED", "last_update": "2024-08-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05296798", "title": "A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05645536", "title": "Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05690295", "title": "Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer", "status": "COMPLETED", "last_update": "2024-05-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05780567", "title": "Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06001762", "title": "TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06120595", "title": "Intervention Study Based on Real-world Data to Improve Quality of Life After Breast Cancer Treatment, the REBECCA-2 Study", "status": "UNKNOWN", "last_update": "2024-06-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06164119", "title": "Effects of Diet and Osteopathy on Quality of Life and Inflammation in Breast Cancer Patients Under Hormonal Therapy", "status": "UNKNOWN", "last_update": "2024-03-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06440967", "title": "A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585969", "title": "A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06630325", "title": "A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer", "status": "TERMINATED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06671912", "title": "Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial", "status": "SUSPENDED", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153757", "title": "De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07213206", "title": "CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07729046", "title": "Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07806630", "title": "SHORTened Duration of TAMoxifen", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TAS-108": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00166543", "title": "Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer", "status": "COMPLETED", "last_update": "2015-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TASELISIB": { "n": 7, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT02273973", "title": "A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)", "status": "COMPLETED", "last_update": "2018-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02340221", "title": "A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy", "status": "TERMINATED", "last_update": "2022-07-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02389842", "title": "PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib", "status": "COMPLETED", "last_update": "2024-09-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02390427", "title": "Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02457910", "title": "Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2022-08-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439175", "title": "Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TELAPRISTONE": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01800422", "title": "Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer", "status": "UNKNOWN", "last_update": "2020-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314156", "title": "Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy", "status": "COMPLETED", "last_update": "2023-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TESEVATINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02154529", "title": "Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2022-04-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TOREMIFENE": { "n": 25, "n_observational": 3, "n_active": 7, "n_withdrawn": 1, "trials": [ { "nct": "NCT05472792", "title": "Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05861271", "title": "Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer", "status": "RECRUITING", "last_update": "2024-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05891093", "title": "Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)", "status": "RECRUITING", "last_update": "2024-02-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07581834", "title": "Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study", "status": "RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002529", "title": "Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2013-04-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00010322", "title": "Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2014-03-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00044291", "title": "Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2015-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00097344", "title": "The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2007-08-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00267553", "title": "Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer", "status": "TERMINATED", "last_update": "2007-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00437359", "title": "Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer", "status": "TERMINATED", "last_update": "2012-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01072318", "title": "Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene", "status": "UNKNOWN", "last_update": "2010-02-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01352091", "title": "Adjuvant AI Combined With Zoladex", "status": "UNKNOWN", "last_update": "2011-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02089854", "title": "Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer", "status": "UNKNOWN", "last_update": "2016-12-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02097459", "title": "Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer", "status": "UNKNOWN", "last_update": "2016-05-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02132000", "title": "Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients", "status": "UNKNOWN", "last_update": "2014-05-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02132390", "title": "Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea", "status": "UNKNOWN", "last_update": "2014-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02344940", "title": "Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer", "status": "COMPLETED", "last_update": "2019-09-24", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02506790", "title": "Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03204734", "title": "Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2017-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03238703", "title": "Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer", "status": "WITHDRAWN", "last_update": "2018-12-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03351062", "title": "Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer", "status": "UNKNOWN", "last_update": "2017-11-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04383275", "title": "Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06495515", "title": "Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study", "status": "UNKNOWN", "last_update": "2024-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153757", "title": "De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07706933", "title": "Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB": { "n": 178, "n_observational": 22, "n_active": 62, "n_withdrawn": 12, "trials": [ { "nct": "NCT04254263", "title": "Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04281641", "title": "Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2020-05-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04893109", "title": "ATEMPT 2.0: Adjuvant T-DM1 vs TH", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04993014", "title": "Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2021-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05159193", "title": "Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer", "status": "RECRUITING", "last_update": "2024-02-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05232916", "title": "Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05288777", "title": "Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582499", "title": "Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05868226", "title": "PRE-ISPY Phase I/II Oncology Platform Program", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05982678", "title": "Basket Study for Oligo-metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06035679", "title": "Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06217185", "title": "The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).", "status": "RECRUITING", "last_update": "2024-02-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06278870", "title": "Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial", "status": "RECRUITING", "last_update": "2024-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06435429", "title": "A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06837792", "title": "Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06949410", "title": "HER2 Vaccine for Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06992882", "title": "A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)", "status": "RECRUITING", "last_update": "2025-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07003074", "title": "A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07053085", "title": "A Study of Surgery and Radiotherapy in People With Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07136428", "title": "Asciminib in HER2+ Breast Cancer Brain Metastases", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07216105", "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07263425", "title": "Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis", "status": "RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07281001", "title": "A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07294508", "title": "A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340398", "title": "Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07383818", "title": "Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)", "status": "RECRUITING", "last_update": "2026-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07612215", "title": "Elacestrant in Advanced Triple Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07616427", "title": "Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07630402", "title": "Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07647016", "title": "Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07657130", "title": "Optimal Application Timing of ADC Drugs for Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07694986", "title": "Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005970", "title": "Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2020-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00038402", "title": "Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer", "status": "COMPLETED", "last_update": "2012-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00068757", "title": "Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer", "status": "COMPLETED", "last_update": "2012-09-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00103233", "title": "Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00129896", "title": "Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients", "status": "COMPLETED", "last_update": "2023-03-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00134680", "title": "Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC", "status": "COMPLETED", "last_update": "2014-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00146042", "title": "UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2012-10-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00194714", "title": "Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab", "status": "COMPLETED", "last_update": "2024-06-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00243503", "title": "Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2011-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00258349", "title": "Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer", "status": "COMPLETED", "last_update": "2014-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00301730", "title": "Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung", "status": "COMPLETED", "last_update": "2015-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00381901", "title": "Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery", "status": "COMPLETED", "last_update": "2011-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00404066", "title": "Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer", "status": "COMPLETED", "last_update": "2017-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00433407", "title": "T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2012-10-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00434031", "title": "CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2012-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00440622", "title": "Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients", "status": "TERMINATED", "last_update": "2013-02-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00470704", "title": "Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509769", "title": "A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00567554", "title": "Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer", "status": "COMPLETED", "last_update": "2016-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00605397", "title": "PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00625898", "title": "BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab", "status": "TERMINATED", "last_update": "2020-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00741260", "title": "Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer", "status": "COMPLETED", "last_update": "2018-09-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00768859", "title": "Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study", "status": "COMPLETED", "last_update": "2012-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00770809", "title": "Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00796978", "title": "Trastuzumab in Treating Older Women With Early-Stage Breast Cancer", "status": "COMPLETED", "last_update": "2024-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00803556", "title": "Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy", "status": "COMPLETED", "last_update": "2011-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820222", "title": "Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2019-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00841828", "title": "Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients", "status": "COMPLETED", "last_update": "2023-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00842998", "title": "Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer", "status": "UNKNOWN", "last_update": "2009-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00932373", "title": "A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen", "status": "COMPLETED", "last_update": "2015-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00943670", "title": "Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression", "status": "COMPLETED", "last_update": "2013-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00944047", "title": "Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression", "status": "COMPLETED", "last_update": "2018-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00949247", "title": "Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases", "status": "COMPLETED", "last_update": "2020-07-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00963547", "title": "A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)", "status": "TERMINATED", "last_update": "2024-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00971737", "title": "Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2019-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01137994", "title": "A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01142778", "title": "A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2018-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01196052", "title": "A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2014-10-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01205217", "title": "Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer", "status": "WITHDRAWN", "last_update": "2017-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01242449", "title": "Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2015-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01271920", "title": "Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01276041", "title": "Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01321775", "title": "Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer", "status": "UNKNOWN", "last_update": "2011-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01340430", "title": "Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2024-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01373710", "title": "Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis", "status": "COMPLETED", "last_update": "2025-11-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01387373", "title": "Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer", "status": "COMPLETED", "last_update": "2020-10-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01401166", "title": "Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer", "status": "COMPLETED", "last_update": "2017-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01419197", "title": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy", "status": "COMPLETED", "last_update": "2016-10-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01436604", "title": "Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin \u00ae) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging", "status": "TERMINATED", "last_update": "2017-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01479179", "title": "Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab", "status": "WITHDRAWN", "last_update": "2016-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01495884", "title": "The Myocet/Lapatinib Study. ICORG 10-03, V5", "status": "TERMINATED", "last_update": "2015-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01557764", "title": "Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2013-07-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01565200", "title": "HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1", "status": "COMPLETED", "last_update": "2025-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01596530", "title": "Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment", "status": "TERMINATED", "last_update": "2012-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597414", "title": "Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1", "status": "COMPLETED", "last_update": "2022-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01688609", "title": "Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2017-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01730677", "title": "Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab", "status": "UNKNOWN", "last_update": "2014-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01827163", "title": "Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2019-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01828021", "title": "Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01835236", "title": "Trastuzumab & Pertuzumab Followed by T-DM1 in MBC", "status": "COMPLETED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01853748", "title": "T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)", "status": "COMPLETED", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01921335", "title": "ARRY-380 + Trastuzuamab for Breast w/ Brain Mets", "status": "COMPLETED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01937117", "title": "Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01950182", "title": "Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer", "status": "COMPLETED", "last_update": "2020-07-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02038010", "title": "BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx", "status": "COMPLETED", "last_update": "2020-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02059876", "title": "Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer", "status": "UNKNOWN", "last_update": "2014-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02102438", "title": "Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2016-08-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02238509", "title": "Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies", "status": "UNKNOWN", "last_update": "2016-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02297230", "title": "Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics", "status": "TERMINATED", "last_update": "2018-10-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02297698", "title": "Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients", "status": "COMPLETED", "last_update": "2023-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02336984", "title": "A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS", "status": "WITHDRAWN", "last_update": "2021-01-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02422199", "title": "A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab", "status": "UNKNOWN", "last_update": "2018-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02433067", "title": "Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer", "status": "TERMINATED", "last_update": "2020-10-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02563925", "title": "Brain Irradiation and Tremelimumab in Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2022-08-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02598427", "title": "Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer", "status": "TERMINATED", "last_update": "2018-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625441", "title": "Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02627274", "title": "A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)", "status": "COMPLETED", "last_update": "2022-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02654119", "title": "Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery", "status": "COMPLETED", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02696707", "title": "An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer", "status": "COMPLETED", "last_update": "2025-12-18", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02789657", "title": "Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.", "status": "COMPLETED", "last_update": "2022-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02843126", "title": "Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer", "status": "COMPLETED", "last_update": "2019-09-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02993198", "title": "A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging", "status": "UNKNOWN", "last_update": "2024-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03140553", "title": "TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2020-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03190967", "title": "T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery", "status": "TERMINATED", "last_update": "2023-10-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03213925", "title": "Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer", "status": "UNKNOWN", "last_update": "2017-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03238495", "title": "Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer", "status": "UNKNOWN", "last_update": "2021-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03366428", "title": "Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer", "status": "COMPLETED", "last_update": "2022-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03425656", "title": "Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin\u00ae in Breast Cancer", "status": "COMPLETED", "last_update": "2024-06-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03460067", "title": "Omission of Radiation in Patients With Her-2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03765983", "title": "GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases", "status": "TERMINATED", "last_update": "2026-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03913234", "title": "Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients", "status": "UNKNOWN", "last_update": "2022-05-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04001621", "title": "Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-12-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04001829", "title": "Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04066790", "title": "Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer", "status": "TERMINATED", "last_update": "2020-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04094896", "title": "TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer", "status": "UNKNOWN", "last_update": "2019-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04185649", "title": "The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-12-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04246502", "title": "Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04266249", "title": "CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04298918", "title": "A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419181", "title": "Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508803", "title": "Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04514419", "title": "Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04588545", "title": "Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04917900", "title": "Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04957212", "title": "Comparing Efficacy and Safety Between Pertuzumab\u00ae and Perjeta\u00ae in Neoadjuvant Treatment of HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04963595", "title": "Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2021-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05041842", "title": "Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05081609", "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05378464", "title": "Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer", "status": "SUSPENDED", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05426486", "title": "A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429684", "title": "Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-06-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05474690", "title": "A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2024-02-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05574881", "title": "Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05577442", "title": "Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05721248", "title": "STOP-HER2: Stopping Trastuzumab in HER2+ MBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05774886", "title": "Implantable Microdevice for TNBC - Pilot Study", "status": "WITHDRAWN", "last_update": "2023-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05802225", "title": "Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta\u00ae as Neoadjuvant Therapy of HER2-Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05885776", "title": "Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research", "status": "UNKNOWN", "last_update": "2023-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05954143", "title": "Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05985187", "title": "Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta\u00ae Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.", "status": "UNKNOWN", "last_update": "2023-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06038539", "title": "Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta\u00ae Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy na\u00efve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer", "status": "TERMINATED", "last_update": "2026-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06057610", "title": "A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06125834", "title": "Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy", "status": "UNKNOWN", "last_update": "2024-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06136897", "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06299852", "title": "Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06328387", "title": "HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06429761", "title": "Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06435104", "title": "Aromatherapy in the Treatment of Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06884254", "title": "Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta\u00ae (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.", "status": "WITHDRAWN", "last_update": "2025-10-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06968585", "title": "A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07093931", "title": "Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07187752", "title": "Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07300215", "title": "An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07368543", "title": "Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07528898", "title": "Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07553390", "title": "Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07589972", "title": "Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07619365", "title": "Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07679269", "title": "Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB DERUXTECAN": { "n": 120, "n_observational": 30, "n_active": 101, "n_withdrawn": 3, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04553770", "title": "Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04986579", "title": "Scalp Cooling in MBC", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05376878", "title": "An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05417594", "title": "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05704829", "title": "NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05795101", "title": "TRUDI: TDXD+Durva in HER2+/Low IBC", "status": "RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05824975", "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)", "status": "RECRUITING", "last_update": "2024-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05868226", "title": "PRE-ISPY Phase I/II Oncology Platform Program", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05900206", "title": "Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05950945", "title": "Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05982678", "title": "Basket Study for Oligo-metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06102824", "title": "Organoid-based Functional Precision Therapy for Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06331169", "title": "Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-08-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06409390", "title": "Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06435429", "title": "A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06439693", "title": "The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06450314", "title": "Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06486883", "title": "Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06533826", "title": "TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06643585", "title": "A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse", "status": "RECRUITING", "last_update": "2025-05-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06665178", "title": "Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2025-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06686394", "title": "Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06750484", "title": "Trial of Trastuzumab Deruxtecan in Previously Treated HER2", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06832202", "title": "A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients", "status": "RECRUITING", "last_update": "2025-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06837792", "title": "Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07007559", "title": "ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07060807", "title": "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07065435", "title": "RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study", "status": "RECRUITING", "last_update": "2025-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07134153", "title": "Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases", "status": "RECRUITING", "last_update": "2025-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07137416", "title": "Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07195344", "title": "Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07198724", "title": "ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07281001", "title": "A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07294508", "title": "A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07371585", "title": "Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07393425", "title": "Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07394218", "title": "ctDNA-guided Treatment Decision-making", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07446452", "title": "Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07459673", "title": "HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07497386", "title": "A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07537673", "title": "Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan", "status": "RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07543536", "title": "Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07647016", "title": "Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07657130", "title": "Optimal Application Timing of ADC Drugs for Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07716189", "title": "Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03248492", "title": "A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)", "status": "TERMINATED", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03366428", "title": "Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer", "status": "COMPLETED", "last_update": "2022-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03368196", "title": "DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein", "status": "COMPLETED", "last_update": "2022-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03523572", "title": "Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer", "status": "COMPLETED", "last_update": "2025-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03523585", "title": "DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03529110", "title": "DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03734029", "title": "Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03742102", "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042701", "title": "DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04132960", "title": "Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04420598", "title": "DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease", "status": "COMPLETED", "last_update": "2025-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04494425", "title": "Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04538742", "title": "A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04539938", "title": "A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04622319", "title": "A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639219", "title": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04739761", "title": "A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752059", "title": "Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases", "status": "COMPLETED", "last_update": "2023-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04784715", "title": "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05113251", "title": "Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633979", "title": "Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650879", "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05678205", "title": "A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors", "status": "WITHDRAWN", "last_update": "2025-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05710666", "title": "Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05744375", "title": "Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab", "status": "TERMINATED", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05774886", "title": "Implantable Microdevice for TNBC - Pilot Study", "status": "WITHDRAWN", "last_update": "2023-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05919212", "title": "Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05953168", "title": "T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients", "status": "UNKNOWN", "last_update": "2023-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05954143", "title": "Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2025-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06048718", "title": "T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06100874", "title": "A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06172127", "title": "PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06245824", "title": "Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-07", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06271837", "title": "A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06328387", "title": "HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06429761", "title": "Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06548178", "title": "T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585969", "title": "A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680596", "title": "Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06797622", "title": "Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130344", "title": "PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07150208", "title": "T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07151586", "title": "Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07152782", "title": "T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07294430", "title": "Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07294534", "title": "A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07333937", "title": "Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07368543", "title": "Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07371910", "title": "Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07416253", "title": "Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07454668", "title": "Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07465172", "title": "GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07466303", "title": "Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07527806", "title": "Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07553390", "title": "Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07578116", "title": "Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07619365", "title": "Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07630103", "title": "Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07678957", "title": "A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07683754", "title": "T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07701941", "title": "A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07726342", "title": "SMP-656 for HER2-Positive Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07782086", "title": "A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07785856", "title": "Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB DUOCARMAZINE": { "n": 4, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03262935", "title": "SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-10-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "status": "WITHDRAWN", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04983238", "title": "Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985", "status": "COMPLETED", "last_update": "2024-01-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB EMTANSINE": { "n": 139, "n_observational": 23, "n_active": 53, "n_withdrawn": 6, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04680442", "title": "Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction", "status": "RECRUITING", "last_update": "2025-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04893109", "title": "ATEMPT 2.0: Adjuvant T-DM1 vs TH", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05288777", "title": "Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer", "status": "RECRUITING", "last_update": "2025-04-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05345860", "title": "Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer", "status": "RECRUITING", "last_update": "2022-04-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05388149", "title": "Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease", "status": "RECRUITING", "last_update": "2025-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05704829", "title": "NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05834764", "title": "Pyrotinib in Women With High-risk in Early Stage Breast Cancer", "status": "RECRUITING", "last_update": "2023-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313086", "title": "DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2024-05-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06348134", "title": "Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery", "status": "RECRUITING", "last_update": "2026-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06439693", "title": "The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06446882", "title": "Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06450314", "title": "Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06643585", "title": "A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse", "status": "RECRUITING", "last_update": "2025-05-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06830889", "title": "A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy", "status": "RECRUITING", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06846437", "title": "JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07008976", "title": "Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07257809", "title": "Herombopag Treated T-DM1 Induced Platelet Reduction", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07673029", "title": "A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509769", "title": "A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00679211", "title": "A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2017-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00679341", "title": "A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin\u00ae) and Docetaxel (Taxotere\u00ae) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease", "status": "COMPLETED", "last_update": "2014-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00829166", "title": "A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00875979", "title": "A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab", "status": "COMPLETED", "last_update": "2013-12-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00928330", "title": "Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00932373", "title": "A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen", "status": "COMPLETED", "last_update": "2015-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00934856", "title": "A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2017-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00943670", "title": "Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression", "status": "COMPLETED", "last_update": "2013-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00951665", "title": "A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01120184", "title": "A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)", "status": "COMPLETED", "last_update": "2024-03-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01196052", "title": "A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2014-10-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01419197", "title": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy", "status": "COMPLETED", "last_update": "2016-10-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01494662", "title": "HKI-272 for HER2-Positive Breast Cancer and Brain Metastases", "status": "COMPLETED", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01513083", "title": "A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01565200", "title": "HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1", "status": "COMPLETED", "last_update": "2025-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01597414", "title": "Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1", "status": "COMPLETED", "last_update": "2022-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01702558", "title": "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)", "status": "TERMINATED", "last_update": "2021-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01702571", "title": "A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01745965", "title": "A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.", "status": "COMPLETED", "last_update": "2025-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772472", "title": "A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)", "status": "COMPLETED", "last_update": "2025-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01816035", "title": "Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2017-05-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01835236", "title": "Trastuzumab & Pertuzumab Followed by T-DM1 in MBC", "status": "COMPLETED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01853748", "title": "T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)", "status": "COMPLETED", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01904903", "title": "Cardiac Safety Study in Patients With HER2 + Breast Cancer", "status": "COMPLETED", "last_update": "2022-05-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01966471", "title": "A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer", "status": "COMPLETED", "last_update": "2022-06-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01975142", "title": "Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.", "status": "COMPLETED", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01976169", "title": "Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01983501", "title": "A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2020-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02038010", "title": "BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx", "status": "COMPLETED", "last_update": "2020-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02073487", "title": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel", "status": "COMPLETED", "last_update": "2021-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02073916", "title": "T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2019-04-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02131064", "title": "A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2019-07-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02135159", "title": "Patients With Brain Metastases From HER2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2017-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02144012", "title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer", "status": "TERMINATED", "last_update": "2017-03-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213744", "title": "MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients", "status": "TERMINATED", "last_update": "2017-01-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02226276", "title": "Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02236000", "title": "A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-01-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02326974", "title": "T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02390427", "title": "Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02448420", "title": "Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2024-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02562378", "title": "T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2022-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02568839", "title": "Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2020-08-13", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02605915", "title": "Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer", "status": "COMPLETED", "last_update": "2020-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657343", "title": "An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.", "status": "COMPLETED", "last_update": "2022-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658084", "title": "Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2019-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658734", "title": "A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane", "status": "COMPLETED", "last_update": "2021-04-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02725541", "title": "Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer", "status": "WITHDRAWN", "last_update": "2016-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02924883", "title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy", "status": "COMPLETED", "last_update": "2021-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03032107", "title": "A Study Of Pembrolizumab In Combination With Trastuzumab-DM1", "status": "COMPLETED", "last_update": "2025-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03084939", "title": "Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03153163", "title": "Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2018-11-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03190967", "title": "T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery", "status": "TERMINATED", "last_update": "2023-10-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03203616", "title": "Kadcyla In pAtients With bRAin Metastasis", "status": "WITHDRAWN", "last_update": "2018-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03248492", "title": "A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)", "status": "TERMINATED", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03364348", "title": "4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2022-10-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03429101", "title": "A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2021-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03523572", "title": "Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer", "status": "COMPLETED", "last_update": "2025-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03523585", "title": "DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03529110", "title": "DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03530696", "title": "T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer", "status": "COMPLETED", "last_update": "2024-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03587740", "title": "ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03709082", "title": "Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2024-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03726879", "title": "A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03820063", "title": "Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03894007", "title": "Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer", "status": "TERMINATED", "last_update": "2021-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03975647", "title": "A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042051", "title": "Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer", "status": "TERMINATED", "last_update": "2025-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042701", "title": "DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04158947", "title": "A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone", "status": "UNKNOWN", "last_update": "2020-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04185649", "title": "The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2019-12-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04197687", "title": "TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery", "status": "UNKNOWN", "last_update": "2023-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04266249", "title": "CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04296942", "title": "BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)", "status": "TERMINATED", "last_update": "2022-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04298918", "title": "A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2021-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04351230", "title": "T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398914", "title": "Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419181", "title": "Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2025-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439110", "title": "Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04457596", "title": "T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04509596", "title": "DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer", "status": "COMPLETED", "last_update": "2025-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04578106", "title": "Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy", "status": "TERMINATED", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04622319", "title": "A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04675827", "title": "De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade", "status": "TERMINATED", "last_update": "2024-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04733118", "title": "Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04740918", "title": "A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)", "status": "TERMINATED", "last_update": "2025-08-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04856475", "title": "Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04873362", "title": "A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04924699", "title": "A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-03-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05081609", "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05323955", "title": "Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05388500", "title": "Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)", "status": "NOT_YET_RECRUITING", "last_update": "2022-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05415215", "title": "A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer", "status": "COMPLETED", "last_update": "2026-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429684", "title": "Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer", "status": "UNKNOWN", "last_update": "2022-06-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05560308", "title": "Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy", "status": "UNKNOWN", "last_update": "2022-10-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05593094", "title": "A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650879", "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05735392", "title": "Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)", "status": "COMPLETED", "last_update": "2023-02-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05755048", "title": "FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2023-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06068985", "title": "Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06125834", "title": "Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy", "status": "UNKNOWN", "last_update": "2024-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06126640", "title": "A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06265428", "title": "A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06299852", "title": "Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer", "status": "UNKNOWN", "last_update": "2024-03-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06316531", "title": "A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06481956", "title": "T-DM1 Combined With CDK4/6 Inhibitor Ribociclib", "status": "ENROLLING_BY_INVITATION", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06595563", "title": "HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer", "status": "TERMINATED", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06718335", "title": "Pyrotinib in HER2-positive Early Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06968585", "title": "A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07198672", "title": "Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07421141", "title": "De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07578116", "title": "Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "TRICIRIBINE": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01697293", "title": "PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer", "status": "TERMINATED", "last_update": "2020-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03326713", "title": "Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project", "status": "COMPLETED", "last_update": "2026-06-25", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "TRILACICLIB": { "n": 11, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05978648", "title": "Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy", "status": "RECRUITING", "last_update": "2023-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02978716", "title": "Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)", "status": "TERMINATED", "last_update": "2022-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04799249", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)", "status": "COMPLETED", "last_update": "2024-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05112536", "title": "Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05113966", "title": "Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2025-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05862610", "title": "The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC", "status": "NOT_YET_RECRUITING", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06027268", "title": "Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06297811", "title": "Myeloprotection With Trilaciclib in Pan-cancer Population", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06955156", "title": "Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC", "status": "UNKNOWN", "last_update": "2025-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07255612", "title": "Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TUCATINIB": { "n": 46, "n_observational": 6, "n_active": 30, "n_withdrawn": 4, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05748834", "title": "Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05800275", "title": "Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05868226", "title": "PRE-ISPY Phase I/II Oncology Platform Program", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05955170", "title": "Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer", "status": "RECRUITING", "last_update": "2025-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06016387", "title": "Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06162559", "title": "Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study", "status": "RECRUITING", "last_update": "2024-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06439693", "title": "The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06686394", "title": "Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06983691", "title": "Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07193394", "title": "Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07413939", "title": "RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01983501", "title": "A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2020-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02025192", "title": "A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2020-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02614794", "title": "A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2023-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03054363", "title": "Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer", "status": "COMPLETED", "last_update": "2023-11-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03501979", "title": "Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD", "status": "TERMINATED", "last_update": "2025-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03846583", "title": "Tucatinib + Abemaciclib + Herceptin for HER2+ MBC", "status": "WITHDRAWN", "last_update": "2020-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03975647", "title": "A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04457596", "title": "T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04512261", "title": "TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases", "status": "WITHDRAWN", "last_update": "2022-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04538742", "title": "A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04539938", "title": "A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer", "status": "COMPLETED", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579380", "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04721977", "title": "A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04760431", "title": "TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)", "status": "UNKNOWN", "last_update": "2021-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04789096", "title": "Tucatinib Together With Pembrolizumab and Trastuzumab", "status": "TERMINATED", "last_update": "2025-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04896320", "title": "Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.", "status": "WITHDRAWN", "last_update": "2023-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05041842", "title": "Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05132582", "title": "A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05227131", "title": "Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer", "status": "WITHDRAWN", "last_update": "2022-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05230810", "title": "Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05319873", "title": "Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05323955", "title": "Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05382364", "title": "Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05458674", "title": "Tucatinib+Trastuzumab+Eribulin in HER2+ MBC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05553522", "title": "Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer", "status": "TERMINATED", "last_update": "2025-12-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05583110", "title": "Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2025-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05892068", "title": "A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06157892", "title": "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06239467", "title": "First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07494448", "title": "Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07768358", "title": "Tucatinib Continuation Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" } ] }, "UCN-01": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00001444", "title": "A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms", "status": "COMPLETED", "last_update": "2008-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ULIPRISTAL": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02408770", "title": "Breast Cancer - Anti-Progestin Prevention Study 1", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02922127", "title": "Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "VANDETANIB": { "n": 10, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT00034918", "title": "This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2016-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00481845", "title": "Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer", "status": "TERMINATED", "last_update": "2017-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00494481", "title": "E3 Breast Cancer Taxotere Combination", "status": "COMPLETED", "last_update": "2016-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00496665", "title": "ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2013-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00752986", "title": "ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial", "status": "TERMINATED", "last_update": "2016-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00811369", "title": "Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2013-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00937417", "title": "S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2017-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01934335", "title": "Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer", "status": "TERMINATED", "last_update": "2021-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02299999", "title": "SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530411", "title": "Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer", "status": "UNKNOWN", "last_update": "2015-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VARLITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT07166367", "title": "Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer", "status": "TERMINATED", "last_update": "2025-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VOXTALISIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01082068", "title": "Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer", "status": "COMPLETED", "last_update": "2016-06-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01390818", "title": "Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2017-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ZANIDATAMAB": { "n": 12, "n_observational": 0, "n_active": 9, "n_withdrawn": 0, "trials": [ { "nct": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05035836", "title": "A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05868226", "title": "PRE-ISPY Phase I/II Oncology Platform Program", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06435429", "title": "A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07102381", "title": "A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224272", "title": "A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer", "status": "COMPLETED", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04276493", "title": "Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07494448", "title": "Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ZENOCUTUZUMAB": { "n": 1, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03321981", "title": "MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.", "status": "COMPLETED", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] } } } }